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Bipolar disorder (BD) is a common mood disorder, with an estimated prevalence of 
2.4 % in the Netherlands (1). According to the Trimbos institute and the most recent 
World Health Organization’s report “The world health report 2001 - Mental Health: New 
Understanding, New Hope”, in the Netherlands the burden of the disease is 30.000-
40.000 Disability-Adjusted Life Years (DALY’s), indicating a chronic disease disabling 
patients in normal functioning (2). Worldwide, BD  is estimated to stay in the top ten 
causes of Years Lived with Disability (YLDs), accounting for 2.5% of total global YLDs 
(3). BD was once considered an episodic illness with a favorable outcome, however, 
nowadays seems to be a disease with a more chronic course with cognitive deficits in 
between episodes, residual mood symptoms and impaired functioning in daily life roles 
(4). 
History
Bipolar disorder is characterized by mood episodes, with cycling patterns of both 
depression and mania or hypomania. Mania and hypomania are episodes of abnormal 
elevations of mood or irritability for at least 1 week (mania) or 4 days (hypomania), with 
raised activity level, inflated self-esteem, increased risk taking behavior, involvement 
in pleasant activities, and other features. Mania and hypomania differ with respect 
to severity of symptoms; when psychotic symptoms occur or admission is required, 
criteria for mania are met by definition. Furthermore, mania and hypomania can be 
distinguished in severity and duration of symptoms. Mania has a greater negative impact 
than hypomania in daily life with e.g. social and financial consequences. Depression is 
characterized by for at least 2 weeks of depressed mood or anhedonia for most of the 
time during the day. Several types of the disorder are distinguished according to the 
Diagnostic and Statistical Manual (DSM)-IV criteria: BD1 includes a history of at least 
one manic episode, though also depressive and hypo manic episodes are frequent, BD2 
is marked by at least one depressive episode and one hypo manic episode. In figure 
1, differences are shown. Furthermore, the DSM-IV includes cyclothymic disorder, 
consisting of a cycling pattern of hypomania and depressive symptoms, not fulfilling the 
criteria for full depressive episodes. Finally, BD not otherwise specified as rest category 
for patients with drastic mood changes regarded as mood disease, but not meeting 
enough criteria for hypomania and depressive episodes.
Manic and depressive episodes have already been described in ancient Greek 
Hippocrates. In his description of the Greek woman Thasos suffering from racing thoughts, 
sleeplessness, euphoria or irritable mood, and in severe cases hallucinations, he referred 
to this condition as a maniac state. The German doctor Emil Kraepelin (1856–1926), 








by depression or manic psychosis, with largely symptom-free intervals in between (5). 
Only until 1957 unipolar depressive and BD were distinguished into two different entities 
by K. Leonhard (6). In 1976, Goodwin and colleagues introduced hypomania and BD2 
as a separate diagnosis. BD as such was officially introduced as diagnosis in the DSM-III 
in 1980. Goodwin and Redfield note that a complicating factor in research is the poor 
reliability of BD2 diagnosis resulting from the difficulties of assessing the history of hypo 
manic symptoms, especially by depressed patients (6). It is under current debate in what 
respect BD2 and recurrent unipolar depression differ with respect to cycling patterns and 
polarity. Long-term studies to differentiate between and validate diagnostic boundaries 
are highly needed.   
Within this historical context, it is clear that the diagnosis and course of BD according to 
its modern criteria are only recently on their way to be further described and validated 
with respect to clinical course and treatment of the disease. Specifically validation of the 
“diagnostic” entity BD is subject to criticism (6), indicating the need for further research 
to the boundaries and criteria of this diagnosis. 
In addition to the diagnostic difficulties, one must to realize the clinical course of the 
disease as highly variable and unpredictable. The DSM-IV criteria for BD predominantly 
focus on mood, with characteristics of mood episodes. Number of mood episodes, and 
recovery in between episodes, are thus key features in evaluating course of disease. 
However, in the past years evidence is increasing that impaired daily life functioning 
in patients with BD is caused by for example mood disturbance, especially residual 
depressive symptoms, as well as cognitive deficits. 
Risk factors influencing clinical course
In identifying risk factors influencing clinical course, distal and proximal risk factors can 
be distinguished. Proximal factors are more immediately related to the actual episode 
of the disorder (preceding stress, interruptions daily rhythms, medication changes) 
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than distal factors which play a background role from conception and early childhood 
increasing imminent risk (maternal stress, childhood abuse). Several risk factors known 
to be associated with a worse long-term course of  BD are already identified. In a 
landmark retrospective study of almost 1,000 BD patients in the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD) (7), the following was found: early 
onset was identified as risk factor, predicting higher rates of co morbid anxiety disorders, 
substance abuse, more recurrences, shorter periods of euthymia, greater likelihood of 
suicide attempts and violence. In longitudinal studies a relation was found between 
number of episodes in the index year and prior course of illness (history of rapid cycling), 
family with substance abuse, and poor occupational functioning (8, 9). In other studies, 
early childhood trauma was repeatedly associated with earlier disease onset and more 
severe course (10, 11). It has been thought that alcohol use can cause vicious circles 
leading to depression and vice versa, influencing the course of illness. Alcohol use as 
“self medication” strategy during (bipolar) depression occurs frequently (41% of bipolar 
patients) (12), increasing the risk on developing alcohol dependence. However, in a 
recent longitudinal study, no relation was found between alcohol use and longitudinal 
course of BD (13). Other environmental factors known to influence BD are life events and 
daily life stress. Life events are found to be of major impact in the year before the first 
depressive or manic episode (14). There are several, though somewhat contradictory, 
studies underlining the influence of life events on course of BD in longitudinal studies 
(15). Stressful life events may trigger depressive episodes in BD by inducing changes 
in social “Zeitgebers”, circadian rhythms and the regulation of the stress response (15, 
16). Thus, illness history, early childhood trauma, alcohol abuse and stressful life events 
influence course of the illness. In this study, we included social support, life events, 
medication use as proximal factors, and childhood trauma as distal factor. However, in 
this dissertation we will step back towards a preceding level, namely the underpinnings 
of the disease. In order to be able to further improve the understanding of the disease, 
we will first focus on two endophenotypes, namely stress hormone exposure and 
cognitive performance, in relation with clinical course of the disease. 
Clinical course: endophenotypes as intermediate factors
Although clinical correlates associated with the course of the disease are known, the 
causes of the disease have still not been elucidated. Genetic risks seem to overlap with 
schizophrenia (17) in genome-wide association studies (GWAS), and currently, due to 
lack of convincing evidence, samples for a GWAS are now collected in 2,500 BD1 patients 
in the Dutch study named Bipolar Genetics. A major limitation of genetic association 








gene expression, RNA transcription and proteome function. Research to protein function 
in relation with mental diseases is promising by detailing pathophysiological processes, 
which could lead to understanding of the biochemical overlap and differences between 
for example schizophrenia and BD (18). However, core pathophysiological underpinnings 
of BD have to be elucidated to be able to understand genetic, epigenetic and proteomic 
findings. One of the possible entrances in finding pathophysiological processes is the 
introduction of endophenotypes as simpler clues to find genetic underpinnings than 
complex phenotypic diseases. Endophenotypes are known as sub clinical quantitative 
traits that exist in affected and unaffected relatives independent of the disorder (19). 
The traits can differ in their presentation as they can be neurophysiological, biochemical, 
endocrine, neuroanatomical, or cognitive in nature (20). 
Endophenotypes are generally less complex than their associated phenotype in a 
disorder as they have fewer genes, allowing easier linkage due to their higher signal-
to-noise ratio. They are therefore useful indicators of processes that mediate between 
genotype and phenotype (21). The concept of endophenotypes was originally introduced 
by Gottesman and Shields in the early 1970s. A renewed interest has emerged due to the 
limited success of genetic linkage and association studies.  For an endophenotype to be 
useful in genetically identifying a psychiatric disorder, it should meet a set of criteria as 
proposed by Gottesman and Gould (22): first, it must be associated with the disorder; 
second, it should be primarily independent of clinical state (i.e. it manifests whether 
or not illness is active); third, it should be heritable (i.e. more common in the non-
affected relatives than in the general population) and fourth, it must be associated with 
a candidate gene or gene region. A valid endophenotype should hence have trait-like 
properties (21); in contrast to a state variable, an endophenotype it is not only affected 
by mood phase. Because having a stable and permanent presentation, endophenotypes 
may be more reliable than mood symptoms in predicting the long-term course of BD. 
However, other concepts such as “biomarker” and “vulnerability trait” indicate the same 
need for better defined biological substrates for complex disease phenotypes. These 
terms refer to the search for biological underpinnings of diseases, while endophenotypes 
aim to serve as intermediate factors in finding genetic underpinnings of diseases. In BD, 
biological endophenotypes such as the status of the Hypothalamic- Pituitary- Adrenal 
(HPA-)-axis, could serve as endophenotype (23, 24). In addition, cognitive performance 
has been proposed to serve as a cognitive endophenotype (25-27) in BD, which also 
appears to be under influence of cortisol effects in the hippocampus (28, 29) and 
prefrontal cortex (30).
In the next paragraphs the HPA-axis as a biological endophenotype will be described in 
relation to BD. Furthermore, an overview will be provided with current assessments of 
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the HPA-axis, and new developments will be described. As a second endophenotype, 
cognition will be described in its relation both with the clinical course of BD and in its 
relation with the functioning of the HPA-axis. Although in this thesis the discussion of 
the role of endophenotypes will be limited, the introduction of this concept is needed to 
introduce the theoretical background and subsequently the choices made in our study 
design. The articles in this thesis focus mainly on  the results of the cross sectional data.
Endophenotype 1: the HPA-axis
The biological stress response consists of a precisely regulated cascade of release 
of hormones and neurotransmitters. The direct route is stimulating the adrenergic 
pathways, inducing the sympathetic response; the slower hormonal route is regulating 
the HPA-axis. To maintain stability in a continuously changing environment, the human 
Figure 2: Schematic overview of the HPA-axis, the major impacts on body processes, and 
the glucocorticoid (GC) feedback in the brain through Glucocorticoid Receptors (GRs) 
and Mineralocorticoid Receptors (MRs) (31) . GR and MR in the brain is included in this 
figure .Copied and adjusted with permission from Boonstra, 2004, in accordance with the 








body and mind are required to respond with flexibility, in which the HPA-axis plays an 
important role. The stress response is triggered by a stressor of any kind (psychological, 
physical). In figure 2 a schematic overview is provided.
Corticotropin Releasing Hormone (CRH) is a hormone that fulfils a central role in the 
stress response and is released by the hypothalamic paraventricular nucleus (PVN) 
under influence of a stressor. It is able to rapidly activate the sympathic response and 
plays an important role in orchestrating the so -called “fight, freeze or flight” reaction. In 
a second, slower way, CRH activates through ACTH- release in the pituitary, the release 
of cortisol in the adrenal glands. The combined system of CRH-ACTH-cortisol release is 
referred to as HPA-axis. Cortisol stimulates and regulates the mobilization of glucose in 
the liver, supporting the fight or flight reaction by stimulatory effects on the muscles, 
heart and blood pressure. Cortisol also affects cognitive processes such as memory of 
interpretation and decision-making in different situations. Furthermore, cortisol has 
suppressive effects on different organs and hormone systems not directly needed during 
Table 1: Cortisol effects in and outside the brain 
Cortisol Central/ Brain effects Systemic effects
Acute effects Negative feedback of cortisol pro-
duction by inhibition of CRH and 
ACTH production
Suppression of growth hormone and 
sex hormone production




Suppression of bone re-calcification 
and immunity/inflammation.
Chronic effects Affective dysregulation, depression, 
euphoria
Neurotoxic effects: cognitive deficits





Impaired immune defenses, in-




Based on PhD Thesis E. Van Rossum (2005) and “Stress, the brain and depression” – H.M. 
Van Praag, R. De Kloet and J.H. Van Os (2004).
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the stress response, such as the gastrointestinal system, the immune system, the gonadal 
hormones, growth hormone and bone calcification (32). In sum, cortisol acts at multiple 
sites within the body to maintain homeostasis. Because of the damaging effects of 
chronic exposure to cortisol, the HPA axis is tightly regulated through negative feedback 
on glucocorticoid receptors: cortisol inhibits its own release and thereby finalizes the 
stress response. Chronic raised cortisol levels could be very damaging. Long-term effects 
of increased cortisol levels are: osteoporosis, myopathy, fatigue, abdominal obesity, 
diabetes and dyslipidemia leading to increased risk of cardiovascular disease, impaired 
immune defenses, affective symptoms and neurotoxicity, especially in the hippocampus 
area associated with cognitive symptoms such as memory deficits and problems with 
concentration and executive functioning. In table 1, cortisol effects are summarized.
Dysregulation of the HPA-axis in BD as endophenotype
Dysregulation of the HPA-axis is known to occur in several psychiatric disorders such as 
anxiety disorders like post traumatic stress disorder (33) and mood disorders including BD 
(34-40), in patients as well as in healthy offspring of bipolar parents (24, 37). Activation of 
the HPA-axis during depressive episodes exists in more than 80% of the patients (41), this 
association seems at least partly state independent in bipolar patients (39), indicating a 
trait phenomenon: remitted patients have higher overall cortisol levels, reduced cortisol 
reactivity to negative daily events, and flatter diurnal slopes associate all with more 
episodes (42), reflecting subtle but on the long-term clinically relevant influence. Daban 
(43) and Watson (39), reviewed the abnormalities in HPA-axis functioning in patients with 
BD. Both conclude that the Dex/CRH test, the most sensitive challenge test provoking a 
stress response and measure HPA axis abnormalities, is abnormal in remitted and non-
remitted bipolar patients, indicating that this could serve as a trait marker in BD as well 
as in MDD (40). In chapter 1 and 2, this will be discussed in further detail. All mentioned 
arguments plead to the HPA-axis functioning as endophenotype in BD, following the 
aforementioned criteria according to Gottesman and Gould: it is associated with BD, it is 
at least partly independent of clinical state, it is found in healthy family members. In the 
next section we will focus on the final criteria, namely the genetic basis of the HPA axis 
regulation in relation with BD.
Dysregulation of the HPA-axis and the role of cortisol receptors: link to 
genetic underpinning.
There are two main cortisol receptors by which cortisol exerts its effect: the 








is predominantly localized in the hippocampus, the amygdala and the prefrontal cortex, 
and has a dominant function in controlling sensitivity of the stress response system, 
limiting disturbance of cellular homeostasis and for example acquisition and appraisal of 
information, and behavioral selection (prefrontal) (44).The GR is widespread throughout 
the brain, but has a high density in the hippocampus, the prefrontal cortex and the 
periventricular nucleus and is involved in facilitating recovery of cellular homeostasis, 
restraining stress induced responses and learning and memory processes promoting 
behavioral adaptation for future events (44). The affinity of the MR for cortisol is 10 
times higher than the affinity of the GR for cortisol. In normal circumstances cortisol 
predominantly binds to the MR, during the stress response cortisol also binds to the 
GR, whereas the GR is important for the negative feedback thereby determining the 
regulation of the HPA-axis (45-47). During periods of stress and elevated plasma cortisol, 
there is increased occupation of GR. 
The lipophilic cortisol is thought to enter the cell by passive diffusion through the cell 
membrane. In the cytoplasm it is binding with the GR or MR, after which the complex 
travels through the nuclear membrane into the nucleus. The MR and the GR function 
through several modes of action. An important route to affect gene transcription is the 
direct binding of GR or MR dimers to target genes. Metabolic effects and the feedback 
mechanism are exerted by stimulation of gene transcription, also transcription inhibition 
can occur through this mechanism. The second route is through to regulate gene 
expression by binding to gene regulating proteins like  AP-1 (activating protein-1) and 
NF-κB (nuclear factor- κB)  (48). These pathways influencing gene expression are time-
consuming, as it is clear that changing protein production by altered gene expression is 
a slow process, applicable in regulatory but not acute processes. In animal studies, the 
MR is also thought to be active as membrane MR in regulating the HPA-axis in a fast 
way, by regulating the threshold for stress induced surge and neuronal excitability (49). 
The effects of GR and MR dimers are complex and divers, and can modulate the signal 
transduction of for example serotonin and adrenaline. However, these hypotheses are 
based on animal studies, in which the predominant glucocorticoid is corticosterone; in 
humans it is cortisol; it is unclear to what extend these findings remain the same in 
humans. The therapeutic applications of these receptors is currently under debate in 
trials with GR-antagonists, such as mifepristone in treatment of depression with psychotic 
features (50), which is continued in a placebo controlled trial in depressed patients with 
psychotic symptoms (ClinicalTrials.gov: NCT00637494), planned until the end of 2013. 
In bipolar depressed patients it has been found to improve mood and neurocognitive 
functioning (51). However, it was not effective for treatment of major depressive 
episodes in previous trials. In the current treatment of BD, lithium en valproate take a 
central place. These drugs seem to have an effect through GR-co-chaperone proteins, 
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that attenuates GR translocation in the nucleus, and indirectly reduce hypercortisolemic 
effects at tissue level (52).
Several different MR gene and GR gene variants (polymorphisms), appear to alter 
glucocorticoid sensitivity, which are described in figure 3. These polymorphisms are 
known to result in clinically relevant consequences (53), and discussed in detail in 
chapter 1.  
Figure 3: Overview of the GR gene and MR gene, showing the single nucleotide 
polymorphisms (SNPs) and haplotypes 
In sum, these haplotypes have been known to lead to altered HPA-axis regulation with 
clinical consequences:
GR gene haplotypes:
 Haplotype 2 (BclI) and haplotype 3 (TthIIII+ BclI): both involving a C to G single 
nucleotide polymorphism (rs6189/rs6190) at a polymorphic BclI restriction site, 
were associated with hypersensitivity to GCs (54). Several previous studies reported 








mass index (BMI) (55), increased abdominal visceral fat(56, 57), hypertension(58), 
and lower amount of lean mass in the elderly (54).
 Haplotype 4 (TthIIII + 9β): The 9β polymorphism (rs6198) is a single nucleotide 
polymorphism (SNP) in exon 9β of the GR gene. An ATTTA sequence in the 3’ UTR 
is changed into GTTTA. This polymorphism is associated with an increased stability 
of the mRNA of the inactive GR-β isoform and may lead to a relative glucocorticoid 
resistance by increased inhibition of the active GR-α isoform (59). This polymorphism 
results in reduced transrepressional effects (by which, for example, genes important 
in the immune system are regulated), whereas the transactivational effects 
appeared to be normal(60). The 9β polymorphism has also been reported to be 
associated with rheumatoid arthritis (59), and a 68% reduced risk of carriage of 
nasal Staphylococcus aureus in carriers of this polymorphism (61).
 Haplotype 5 (TthIIII + 9β + ER22/23EK): is also associated with a relative resistance to 
GCs, but in contrast to haplotype 4, this resistance is linked to the transactivational 
effects of the GR, by which most of the adverse effects of GCs are being mediated. 
The ER22/23EK polymorphism (rs6189/rs6190) is located in the transactivation 
domain of the GR gene, and involves two nucleotide changes in codons 22 and 23 
(GAG AGG -> GAA AAG), which have been shown to be linked. This variant has been 
found to be associated with a healthy metabolic profile (lower C-reactive protein 
(CRP) levels, lower cholesterol levels and increased insulin sensitivity), longevity in 
the elderly and a beneficial body composition in young adults (48, 53).
 Haplotype 6 (N363S): this polymorphism (rs6195) is located in codon 363 of exon 
2 of the GR gene. The nucleotide change (AAT -> AGT) results in an asparagine to 
serine amino acid. It is associated with lower cortisol levels and higher insulin levels 
after DST, suggesting increased GC sensitivity (62).
MR gene haplotypes:
 Haplotype 2 (-2G/C): the C allele of this polymorphism (rs2070951) is in vitro 
resulting in more MR protein. These carriers have a more sensitive suppression of 
cortisol after low dose (0.25 mg) Dexamethasone, with a highest decrease in women 
(63). The Cortisol Awakening Rise was not affected (63). During the Trier Social Stress 
Test, these persons showed highest saliva cortisol and heart rate, indicating that 
more MR protein leads to a higher acute stress response (64). 
 Haplotype 3 (-2G/C and I180V): this haplotype is consisting of the C allele of the -2G/
C polymorphism  in combination with the A -> G allele of the I180V polymorphism 
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(rs5522). The G allele of the I180V polymorphism is associated with higher cortisol 
levels in men (63).
The genetic basis of HPA-axis functioning is fulfilling the final criteria to serve as 
endophenotype according to Gottesman and Gould. Recently, the GR polymorphisms 
BclI and ER22/23EK have been associated with unipolar depression in several studies (65, 
66). In addition, the ER22/23EK polymorphism seems to be associated with a decreased 
risk of dementia in healthy individuals. MR haplotype 2 has been found to correlate with 
optimism and a lower risk of depression, both in women (66b).
In this thesis we investigated the association between GR and MR polymorphisms 
and clinical characteristics of BD. The future plan is to study the possible associations 
between these genetic variations and cognitive performance.
Analyzing the HPA-axis: how to assess a system in continuous change?
Until now, there are several methods to investigate the HPA-axis functioning in vivo. 
Multiple consecutive saliva and serum cortisol levels can provide insight in cortisol 
curves, total daily cortisol production and the cortisol awakening response (CAR). 
Circulatory cortisol levels are known to depend on chronobiological rhythms (ultradian, 
circadian as well as seasonal rhythms) and daily life stress. 
Both the ultradian and circadian pacemakers reside in the hypothalamus (67), influencing 
hormonal release and hence cortisol level variability. First, ultradian rhythm is caused 
by oscillatory neurons in the hypothalamus, leading to CRH release and consequently, 
ACTH pulses and cortisol pulses, with a normal hourly rhythm (68). Contrary to GC 
binding to the MR (t1/2= 45 minutes), GR function is depending on this pulsatility, with 
a rapid dissociation of GCs after a rapid pulse (t1/2 = 5 min) (68). The timing of a stressor 
in a decreasing or increasing point of the pulse, has consequences for the magnitude 
of the stress response, which is absent in rats in the falling phase and vice versa in the 
increasing phase of GCs during the pulse. Second, circadian rhythms influence cortisol 
levels. Moreover, they are known to be disturbed during mood episodes, which in 
rats have been shown to be restored after fluoxetine (69). Third, seasonal variations 
influence HPA-axis activity, with higher cortisol levels in the morning and higher 
sensitivity of the stress response (increased feedback) during winter months, protecting 
against energy waste during winter sleeps in animals (70, 71). Therefore, it is crucial to 
be aware of the fact that the timing of an assessment during the day has limitations due 








Table 2: Methods to evaluate HPA-axis functioning – pros and cons










Robust impression of day 
rhythm
Mean cortisol level during 
the day
Low sensitivity for 
detecting psychopa-
thology in psychiatric 
patients
No evaluation of stress 
response















Comparison inter individual 
differences
Information on total cortisol 
production
No information on 
stress response, no in-
formation on ultradian 
or circadian changes
Increasingly unpopular 
due to low sensitivity 
as well as specificity 
in detecting Cushings’ 
syndrome, however 










over months to 
years (depend-
ing on length 
of hair)
Easy, non invasive, informa-
tion on long-term mean 
systemic cortisol levels.
Not affected by daily fluctua-
tions
Possibility to assess cortisol 
in retrospect
New method: clinical 
relevance?







activity as well 
as response to 
awakening.
Associated with mood dis-
orders
Non invasive, outpatients, 
home and non-stress situ-
ations
Highly dependent on 
time of awakening
Compliance







tisol levels as 






Induced “real” moderate to 
severe stress







ESM (77) Saliva sam-
pling after 
beeps (e.g. 
10 beeps per 
day) in daily 
life, simulta-
neous report 




ity in daily life 
experiences
No recall bias
Associated with reduced 
flexibility of stress response 
and higher overall cortisol 









To get insight in set point, negative feedback sensitivity and functioning of cortisol 
receptors, challenge tests are needed to evaluate HPA-axis functioning during the acute 
stress response. Mean cortisol levels during the day, and as a new method, mean cortisol 
levels over months may provide information concerning the long-term cortisol levels as 
result of HPA axis sensitivity in relation to psychopathology. The most sensitive way to 
establish sensitivity of the GR is to perform the earlier mentioned Dex/CRH tests (72). 
Other methods include the Trier Social Stress Test and the Dexamethasone Suppression 
Test. Alternative ways to assess the functioning of the HPA-axis in basal and daily life 
conditions are by measuring cortisol levels in saliva, morning awakening responses, or by 
the Experience Sampling Method. In table 2 these different assessments are summarized. 
DST (41) 0.25 mg, 0.5 








of the central 
GR 
Easy to perform
1-mg DST is valuable in diag-
nosing Cushing’s syndrome
0.25 mg DST is valuable in 
determining GR sensitivity in 
normal individuals.





1.5 mg Dex at 
11 pm fol-
lowed by 100 
µg CRH at 3 
pm next day, 
blood sam-




of the central 
GR 
High sensitivity in psychiatric 
inpatients (80-90%)
Higher cortisol levels predic-
tive for relapse depression 
(78)
Not suited for outpa-
tients due to frequent 
sampling












for testing the 
HPA-axis func-
tioning 
Widely used in endocrinol-
ogy to diagnose secondary 
adrenal insufficiency
Compensatory increasing 
ACTH levels indicate good 
functioning of HPA-axis on 
pituitary level
Not suited for subtle 















Risk for lethal hy-
poglycemia, should 
always be performed 
in clinical settings with 
closely monitoring of 
vital functions.
ACTH stimula-













High sensitivity and speci-
ficity 
Narrow indication, 
no information about 
feedback functioning.
Abbreviations: ESM: Experience Sampling Method; CAR: Cortisol Awakening Rise; DST: 
Dexamethasone Suppression Test; DEX/CRH test: Dexamethasone/ Cortisol Releasing 








Worldwide, we are the first to use scalp hairs to measure cortisol levels in patients with 
BD. This recently developed method is feasible to determine long-term cortisol levels 
and appears to yield a reliable estimate of long-term HPA-axis activity (80-82), with 
promising potential to inform about the consequences of increased long-term cortisol 
levels (83). A positive correlation has been found between cortisol levels in hair and 
waist circumference and Waist Hip Ratio (73), and higher cortisol levels have been found 
in patients with high endogenous cortisol levels (e.g. Cushings’ syndrome).  Since hair 
grows with an average rate of 1 cm per month, a hair segment of e.g. 3 cm would reflect 
mean cortisol levels over a period of approximately 3 months. This long-term cortisol 
measurement is therefore not influenced by the time of sample collection or acute stress 
due to daily circumstances or the research setting. Decreased cortisol levels are found 
in hair of patients with generalized anxiety disorder (GAD), but no differences in salivary 
cortisol levels between GAD patients and healthy controls (84). This suggests that hair 
cortisol levels may reflect the chronic cortisol secretion, whereas the results found with 
saliva or serum cortisol levels might also include acute responses to the measurement 
circumstances. Several other studies have shown that hair cortisol is indeed a marker 
of long-term cortisol exposure (80, 85-88). Previously, hair cortisol was used to provide 
a tool for doping control regarding chronic glucocorticoid use by top athletes (89). Van 
Uum et al used it to provide a technique to assess the cortisol levels due to chronic 
stress (88), which was confirmed one year later to be a reliable retrospective marker 
for cortisol levels for at least 6 months up to several years (90). This method proves 
promising in providing a retrospective calendar of cortisol production (73). Very recently, 
a relation has been found between higher cortisol levels over 6 months and depression 
(91), whereas lower hair cortisol levels relate to generalized anxiety disorder (92).  
In order to explore the possibilities and relevance of the new available long-term cortisol 
assessment in hairs in patients with BD, we decided to use this technique to assess cortisol 
levels in scalp hair in our cohort. Previous studies did not report on hair cortisol levels 
in BD patients yet, the results of the patients in our cohort are described in chapter 5. 
Furthermore, we collected saliva samples at two consecutive evenings at 22.00h. Several 
studies have shown that saliva samples taken in the late evening on different days show 
the lowest variation in cortisol levels compared to diurnal cortisol measurements and 
the cortisol awakening response (93-95). This suggests that late evening cortisol levels 
are not as much influenced by acute stressors and daily influences than e.g. the cortisol 
awakening response or other daytime cortisol measurements. Therefore, it is most likely 
that if there is a correlation between hair and saliva cortisol measurements, it may have 
been with evening salivary cortisol measurements. 
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Endophenotype 2: Cognitive functioning
The word cognition refers to mental functions or processes including attention, memory, 
language skills, planning and supervising behavior. It is a widely used term with different 
meanings depending of the field it is used in. Here, we use cognition to refer to mental 
processes in the prefrontal cortex (executive functions), and hippocampus (memory). 
Additionally, attention is necessary to select  information for further processing. 
This might be located in parietal lobes, where sensory information is selected to be 
transformed into “noticed” information. To avoid pollution of the meaning of these 3 
terms, the content is described in Box 1. Cognitive functions like attention, memory 
and executive functions are not stringent different, but show overlap: without focused 
information selection there is nothing to remember. Without working memory it is not 
possible to plan and coordinate information into behavioral selection. 
Box 1: Definitions of cognitive functions used in this thesis
Attention:
Attention is the spotlight on non selective sensory information, enabling 
persons to select and subsequently process selected information efficiently. 
This function is useful in preventing sensory overload.
Working memory:
Short term memory is useful for “holding” information (visual, phonological) 
in the present with direct past and direct future, with limited capacity. The 
information held is coordinated by executive skills like retrieving memories, 
selection and initiation of behaviour, etc. “This interaction between flexible 
executive functions and passive processing routines is an essential characteristic 
of working memory” .
Executive functions:
These functions act as the brain’s chairmen, coordinating information, silencing 
input, activating and synchronizing other brain regions. Prefrontal located; not 
one specific domain, but using for example attention, working memory and 
language. It is distinguished from “automatic” selection of behaviour; executive 
functions are needed when automatic behaviour appears to be insufficient. Five 








error correction and troubleshooting; 3) not well learned or novel sequences of 
actions; 4) dangerous or difficult actions; 5) need to overcome habitual actions 
or resisting temptation. 
Based on:”The Student’s Guide to cognitive neuroscience” – Jamie Ward; 2006; 
Psychology Press, Hove, East Sussex. 
Until recently, due to Kraepelin’s influence, BD was regarded as an episodic illness with 
the assumption that patients resumed complete recovery, cognitive function included, 
between episodes (96). Modern clinical neuropsychological batteries, have found that in 
BD there is a clear impact on cognitive function between episodes (21), with a clinically 
relevant relation between for example processing speed and a poorer outcome with 
respect to social and global functional (97), and verbal memory as a significant factor 
in determining functioning at work. This is in line with the finding that light depression 
and impairments in memory and executive functioning are predicting long-term (5 year) 
functional (negative) outcome of the disease (98). Poor outcome is highly associated 
with cognitive impairments, particularly executive dysfunction, persisting during 
euthymic phases, leading to impairment of psychosocial and occupational functioning 
(99). These studies underline that in addition to the clinical mood episodes (especially 
sub-threshold depression) also cognitive impairments should be taken into account to 
establish a functional prognosis of the clinical course of the disease. 
Several domains of cognitive function are recently recommended to focus on attention, 
processing speed, executive functioning, working memory and visual and verbal learning 
memory  (21, 100-102). These appear to influence daily life functioning significantly (98, 
99). In 2010 the International Society of Bipolar Disorders (ISBD) reached consensus 
about the preference of assessment of these cognitive functions in BD (102).  The ISBD 
Battery for Assessment of Neurocognition (ISBD-BANC) is proposed as still preliminary, 
still needing empirical validation towards a further delineation of a core set of cognitive 
tests. In 2005 however, we decided to use the Test for Attentional Performance(www.
psytest.net). This instrument is developed to assess attention performance, working 
memory and executive functions in adults and children with brain damage, and later 
applied in psychiatric patient populations. The development of these tests was based 
primarily on the needs of low complex, easy understandable neuropsychological 
diagnostics, which could be applied easily to patient groups and investigators (103). 
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Until now, cognitive domains which are found to be disturbed in BD differ somehow 
in different mood phases of the disease. During euthymia, mainly deficits in sustained 
attention, divided attention, verbal and working memory, processing speed,  and 
impairment of executive functioning appear to be most consistently observed according 
to a recent meta-analysis (100). However, these deficits are not limited to euthymic phases 
and seem to exacerbate by depressive and/or manic symptoms as well. Furthermore, 
depressive mood states are characterized by lack of concentration, deficits in working 
memory, and executive functioning (104). (Hypo)manic states are accompanied by lack 
of sustained and selective attention, and long-term working memory. However, with 
the aforementioned criteria of Gottesman and Gould (22) in mind, cognitive deficits 
are associated with BD, and seem at least partly state independent. Genetic factors 
are probably most important in explaining both cognitive impairments (105). The final 
criteria, namely the prevalence in unaffected family members, is met in some other 
studies (26), arguing that cognitive functioning could serve as an endophenotype in 
future research. However, this is still under debate, as cognitive functioning in unaffected 
family members is not convincingly found to be disturbed (106) and is still in need for 
future studies.
While cognitive abnormalities are recognized as an important feature of BD (107), the 
nature and extent of these are less clear in terms of their existence before onset of 
affective symptoms, their etiology, their relationship to underlying neuroanatomical 
abnormalities and how they are affected as illness progresses. Here we discuss the 
influence of medication on cognition, the hypothesis of cognitive damage due to HPA 
axis dysregulation and the scar hypothesis.
Cognition and medication
However, besides being a disease trait, cognitive performance is known to be influenced 
by other factors as well. Well known influences of better cognitive performance are 
younger age, higher level of education and euthymia. Furthermore, the influence of 
treatment and specifically medication on cognitive performance are other important 
factors. Effective medication became available in the early fifties of the twentieth 
century. Together with the development of more standardized diagnostic procedures, 
psychopharmacological treatment options were developed firstly to treat acute 
episodes and later to prevent new episodes. Lithium was first used in 1949 by John 
Cade for treatment of mania (108), and approved by the American Food and Drug 








the treatment of acute mood episodes as well as after recovery. Maintenance treatment 
preventing new episodes is a relative new phenomenon, influencing the long-term 
outcome of the disease. However, results have been contradictory; for example, in 2008 
it was convincingly argued that (long-term) antidepressant use is increasing the risk 
on developing a rapid cycling pattern of  BD on the long-term (109). In a naturalistic 
setting, patients with a history of psychotic episodes including 31 bipolar patients, were 
followed during 15 years and compared off and on medication use. On the long-term, 
it appeared that a subgroup of these patients did very well on symptom scores and 
global functioning (110). The influence of medication use on the long-term course of 
BD has to be further entangled, with respect to clinical observable mood episodes as 
well as cognitive functioning and physical health. It is already known that cognitive 
performance can be influenced by psychotropic medication. Although genetic factors 
are considered as most important influences on cognition in BD, the role of residual 
mood symptoms and of medication use is also topic of discussion (105). The impact 
of Lithium use on cognition concerns mainly a slight slowing of processing speed and 
subjective impairment of cognitive functioning; no other strong significant influences on 
cognitive performance have been found (111-113). Antipsychotic use seems associated 
with level of memory and executive functioning in a group of 40 BD patients compared 
with 40 healthy controls (112). Despite all the research, little attention has been given 
to the consequences for cognition of using polypharmacy, which is common practice in 
the treatment of BD.  
To be able to investigate cognitive performance as endophenotype in relation with 
clinical course and with cortisol exposure, the role of medication cannot be neglected. 
Therefore, in chapter 6 the association between medication and cognition is investigated. 
Cognition and impact of cortisol exposure: relation between two 
endophenotypes?
Recent studies suggest that abnormalities in the HPA-axis of BD patients may cause 
or exacerbate the cognitive impairments (114, 115). The negative influence of cortisol 
on neuroplasticity , which is disrupted in mood disorders, may well play a role in the 
development of cognitive deficits (116). In general, acute stress or the so called ‘fight or 
flight’ response improves cognitive functions such as attention and memory for the time 
the stressor is present. However chronic or excessive activation of the stress-system has 
disruptive effects on cognitive functioning (75).  Patients with Cushings’ syndrome with 
excess of ACTH as well as cortisol production, are known to suffer from cognitive deficits. 
Furthermore, cortisol excess causes hippocampal atrophy in these patients (117, 118), 
which is reversible after successful treatment (119). The cognitive deficits found in BD 
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patients might therefore be related to the dysregulation of the HPA-axis. Recently, a 
relationship between higher cortisol levels and hippocampal related cognitive functions 
such as verbal memory, and executive functioning in unipolar depressed patients (120). 
The proposed relationship between cognition and HPA-axis functioning as described 
above, is giving ground to the choice of assessing both HPA-axis functioning as well as 
cognitive functioning in this study. However, in this thesis, the relationship will not be 
further described.
Having responsibility for the onset and termination of the stress response, the GR and 
MR also seem to be important in cognitive functioning. The MR as well as the GR are 
involved in learning and working memory (121-123). In figure 3, different functions of 
MR and GR are shown.
Figure 3: MR and GR- level of activity and cognitive function. 
Based on (with permission): Brain 
development (in animals) under stress: 
Hypotheses of glucocorticoid actions 
revisited (30).
Van Rossum and colleagues reported an association between a GR polymorphism 
(ER22/23EK) and reduced risk for dementia in the general population (124) and 
less divided attention disturbances in depressed patients (65) indicating that this GR 
polymorphism may influence neuro-cognitive processes. It is hypothesized that one 
explanation could be a decreased direct effect of cortisol on brain tissue is mediated by 
a relatively insensitive GR (124). The MR is known to be involved in appraisal of critical 
situations and selection of behavioral adaptation (30). At a genetic level, MR haplotype 
2 (the -2G/C SNP) is known to be associated with reduced depression, reduced 








There are a number of indications that MR correlates to cognition; in patients with 
Addison’s disease, a role of MR in encoding learning material has been found (125). 
The authors show the interaction between GR and MR, with optimal performance on 
working memory tests, when both activated. Further evidence for a role of the MR in 
cognitive performance has been found in blocking the MR with spironolactone in healthy 
individuals, which leads to impairment of attention, visuospatial memory and mental 
flexibility (126). Still, the connection of the MR with cognition has been mainly studied 
in depression: the MR polymorphism rs5522 (I180V) moderates reward processing and 
stress-induced reward learning deficits (127). However, the complex interaction of GR 
and MR in cognitive performance in health and disease needs to be further clarified. 
One hypothesis is, due to a shift in the MR:GR balance by chronic stress, MR-mediated 
behaviors are altered and consequently, GR mediates the consolidation of these altered 
behaviors (30).
The HPA-axis functioning and cognitive functioning: the scar hypothesis
A new approach to explaining brain damage in mood disorders  is the scar theory 
(128), describing long lasting changes in the function of the brain (cognition, biological) 
following depression, increasing the risk for developing future depressive episodes. 
The pre-morbid regulated “set-point” of the HPA-axis is thought to be changed by 
epigenetic changes in DNA methylation of the GR caused by for example childhood 
abuse in suicide victims (129) or motherly depression during pregnancy (130). This can 
make an individual in advance more prone to be sensitized by stress. However, it is still 
questioned to what extend causes of depression lead to scarring, including sensitivity 
for stress (as measured by the ESM, TSST, cortisol assessments), and a changed set-point 
of the HPA-axis due to DNA methylation of the GR; on the other hand it is thought that 
depressive episodes themselves lead to further scarring of the functioning of the brain 
with respect to cognition and HPA-axis sensitivity.  This scarring process is possibly a 
structural phenomenon developed during life, starting at early childhood and never 
ending, probably influenced by protective, as well as harmful circumstances.
The Bipolar Stress Study
In 2006 a study named The Bipolar Stress Study, was started at the outpatient 
department for Bipolar Disorders of PsyQ The Hague. The general topic of the Bipolar 
Stress Study is to identify risk factors, that have impact on the clinical course of BD and 
treatment of these patients. In the study approach three levels and their interactions 
with the environment (stressful life events and social support) were distinguished: 1. 
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clinical functioning (phenotype) , 2. genetic variations and vulnerability (genotype) and 
3. cortisol exposure and cognitive functioning (endophenotypes).
In this dissertation, a part of the results is presented with the emphasis on the role of 
genotypes of the cortisol receptors and two endophenotypes, namely cortisol exposure 
and cognitive functioning. The results of the Bipolar Stress Study may help to develop 
clinically relevant interventions to improve the course of BD and subsequently the 
quality of life of patients with BD. 
In general, there is a trend in psychiatric research  towards early detection of disease 
and early identification of people at risk, also in research in the field of BD (131). It 
is expected that diagnostic processes will be more and more supported by genetic, 
biochemical, and neuropsychological assessments, to enable  focused treatment 
strategies. As Hyman already pointed out that “defining a rational nosology for disorders 
of the brain, the body’s most complex organ, is clearly one of the great challenges for 
modern medical science. Nonetheless, fundamental advances in our understanding of 
the genetic and environmental determinants of disease risk, and of the neural circuitry 
supporting normal and pathological mental processes promises to form the basis of 
improved classification in the coming decades” (132).
The Bipolar Stress Study is a project that consists of a cross sectional study followed by 
a 24 month longitudinal study, in part of the original patient group. The data analysis of 
the longitudinal study are ongoing. 
For the cross sectional study the data of 366 patients were collected ( genotype , 
phenotype and endophenotype ). In the 24 month longitudinal study 189 patients 
participated. 
The first patients were enrolled in 2006, data collection stopped at the end of 2011.
In figure 4, a flow chart is shown of our cohort.
Although in this thesis the cross sectional but not the longitudinal collected data are 
presented, a description of both the cross-sectional and longitudinal part is provided 
to clarify the study design and to be able to discuss the results within a consistent 
framework.
I. Cross-sectional part
First, in 2006, the first 245 patients were enrolled. They started with the assessment of 
the MINI, the QBP and GR and MR gene genotyping. In 2006 we extended the protocol, 








we asked the first 245 patients to participate again in the extended study. In total we 
included 366 patients for the cross-sectional baseline measurements. 
In 2007-2009, of these 366 patients, 189 participants were enrolled in the longitudinal 
study which also included the Test for Attentional Performance (TAP), which was not 
available for the complete 366 patients in the cross-sectional part. Please take note 
of the fact that the first visit includes the TAP and the MINI + QBP for most patients; 
however, the cross-sectional measurements with the patients of the cohort included in 
2006 were separated in time with the MINI QBP and genotyping measured by entrance 
of the study, the TAP was assessed by continuing in the extended study the next year.
II. Longitudinal part
In the follow-up period of 24 months, all patients filled in a monthly Life Chart, and every 
three months the Social Support List and the Life Event List. Every 6 months they did a 
subtest of the TAP, namely the Divided Attention Test, together with measurement of 
current mood (the QIDS and the YMRS). Data on cortisol levels and physical health were 
collected in a subgroup of 100 patients in hair and saliva during the 7th visit at 21 months. 
In figure 5, a timeline is provided with the various assessments during each visit in the 
longitudinal part of the study. 











2006: 245 patients included: MINI, QBP, 
GR + MR genotyping 
2007-2009: additional 121 patients included: 
MINI, QBP and GR + MR genotyping  
366 patients in cross-sectional  study, in 40 
patients genotyping of MR and GR failed. 
 
177 (48.3%) not willing to participate in 
longitudinal follow-up part and TAP 
189 (51.6%) participants 




In this thesis, the following results will be described: 
 The cross-sectional data of the first visit (t0) with emphasis on the genotype data 
and the role of GR and MR polymorphisms on the clinical course of BD;
 The cortisol levels in hair and saliva (21 month visit) in relation with clinical course of 
BD; 
 The results of the divided attention test after 6, 12, 18 and 24 months, in relation to 
the QIDS and YMRS scores, as first analysis of the longitudinal data set.
In chapter 1 and 2 an overview of current studies is provided in two reviews, thereby 
giving the further theoretical underpinning of our research project. Chapter 1 focuses 
on the regulation of the HPA-axis in mood disorders, and especially on how to assess 
the HPA-axis. Furthermore, in this chapter findings of deregulation of the HPA-axis and 
mood will be discussed. Chapter 2 will discuss findings regarding genetic polymorphisms 
in the GR and MR gene in relation to mood and cognition.
Figure 5: Timeline of longitudinal measurements
Abbreviations: MINI: Mini International Neuropsychiatric Interview; QBP-NL: 
Questionnaire for Bipolar Illnes- Dutch version; TAP: Test for Attentional Performance; 
YMRS: Young Mania Rating Scale; QIDS: Quick Inventory for Depressive Symptoms; LCM: 








In Chapter 3 and 4 we investigated the GR gene polymorphisms (chapter 3 and 4) and 
MR gene polymorphisms (chapter 4) in relation to cross-sectional retrospective collected 
data regarding previous illness course and clinical characteristics. These articles intend 
to identify the risk for the course of BD of these  genetic variations influencing stress 
sensitivity. 
In Chapter 5 hair and saliva cortisol levels are described and related to clinical correlates 
of BD. 
In Chapter 6 the cognitive functioning in relation to is described, in relation to clinical 
characteristics and medication use in BD patients is described. 
 Although the results presented in this dissertation are part of the larger ongoing Bipolar 
Stress Study, this thesis must be seen as a step forward in elucidating the role of cortisol 
exposure in relation to illness course and cognition. This may lead to new directions in 
future research and subsequent treatment. This will be discussed in more detail in the 
General Discussion.
In figure 6 an overview is provided from the content of this thesis.
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In this review we provide an overview of recent literature on glucocorticoid (GC) 
sensitivity in mood disorders.  Assessing GC sensitivity is often performed by measuring 
the Cortisol Awakening Rise (CAR), by challenging the Hypothalamic- Pituitary- Adrenal 
(HPA) -axis  using a Dexamethasone Suppression Test (DST) or a Dexamethasone/ 
Cortisol Releasing Hormone test (DEX/CRH); more recently by measuring cortisol as 
a retrospective calendar in scalp hair. The main findings in mood disorders are higher 
mean cortisol levels in hair samples and in the CAR, showing a hyperactivity of the HPA-
axis. This is in line with the mild resistance for GCs previously observed in challenge 
tests during mood episodes. GC sensitivity is partly determined by polymorphisms in 
the genes encoding receptors and other proteins involved in the regulation of the HPA-
axis. We shortly discuss the Glucocorticoid Receptor, as well as the Mineralocorticoid 
Receptor, the CRH-Receptor 1, and the GR co-chaperone FKBP5. Data clearly indicate 
genetic changes, along with epigenetic changes which influence the set point and 
regulation of the HPA-axis. Early trauma, as well as influences in utero, appears to be 
important. Future research is necessary to further clarify the biological background and 
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During daily life, mood is known to be largely influenced by circadian rhythms and stress. 
An individual’s risk to develop a mood disorder can depend on one or a combination of 
factors including vulnerability, defined by genetics, early life stress, and consequences 
of life events. The biological stress response has an important function in coping 
with life events, and differs between individuals with a genetically and epigenetically 
determined set-point during youth. The key systems in the stress response are regulated 
by fast adrenergic neurotransmitters (the sympathetic nervous system) and slower 
glucocorticoid hormones (the Hypothalamic-Pituitary-Adrenal-axis, the HPA-axis), of 
which cortisol is the main hormone in humans. It is complex to properly measure and 
assess the functioning HPA-axis in humans. However, it is important to evaluate the role 
of the stress response in the flexibility of the individual to cope with physical and mental 
changes in life in order to identify risk factors defining health and disease. In addition, 
an individual’s  level of chronic cortisol exposure in  brain areas related to affection 
and cognition, may be very important in mood disorders. Aside from the stress system 
reactivity, it is also important to mention the consequences of absolute high and low 
cortisol levels. The consequences of absolute high cortisol levels is best observed in the 
clinically well known Cushing’s syndrome, where cortisol levels are usually extremely 
high due to exogenous or endogenous causes. These symptoms can vary between 
physical symptoms, for example weight gain, increase abdominal fat, hyperhidrosis 
and hirsutism, and psychiatric symptoms, for example manic and depressive episodes, 
psychosis and anxiety. Also hypocortisolism as seen in Morbus Addison can have serious 
consequences on mental health, making patients vulnerable to mood disorders and 
anxiety. 
Cortisol is known to exert its effect through two receptors: the Glucocorticoid Receptor 
(GR) and the Mineralocorticoid Receptor (MR). Both receptors are also present in the 
brain. The GR is found throughout the brain, with a very high density in the hippocampus, 
the PreFrontal Cortex (PFC) , the paraventricular nucleus of the hypothalamus, the 
amygdala and the dentate gyrus. The MR is predominantly found in the hippocampus, 
the PFC and the amygdala (1). The GR is known to be an important regulator during the 
acute stress response, while both GR and MR are active under basal conditions. Both 
corticosteroid receptors are co-expressed in the limbic system and it seems obvious that 
both receptor systems have a balanced function in regulating the stress response (2). 
FKBP5, a co-chaperone of the GR, also influences GR activity (3). Finally, the Cortisol 




2. Assessment of Glucocorticoid Sensitivity in relation to mood
Functional evaluation of the HPA-axis is complex. The HPA-axis is characterized by 
daily rhythms, seasonal rhythms, and pulsation leading to varying cortisol levels in 
blood and saliva. The two most common approaches to evaluate HPA-axis functioning 
are the measurement of basal cortisol levels in response to awakening, as a model for 
an endogenous stress response; and the measurement of the HPA-axis functioning 
during challenging conditions, which gives an impression about the reactivity of the 
stress response itself.  This measurement is characterized by negative feedback at the 
pituitary level on the production of Adrenocorticotropic hormone (ACTH), and hence by 
diminished stimulation of the cortisol production in the adrenal glands.
a. The Cortisol Awakening Rise
It is best to collect samples immediately upon waking to evaluate the Cortisol Awakening 
Rise (CAR), which reflects the natural response to awakening with an increase in cortisol 
levels of 50-75% within half an hour after awakening (4). Several influences on the CAR 
are defined by Vreeburg et al., including sleep patterns (duration, awakening time), 
season of sampling, activities (working day, physical activity) and health indicators 
(smoking, cardiovascular disease, physical activity) (5).  Also psychosocial stressors and 
job stress have been found to result in higher CARs, whereas exhaustion and burnout 
resulted in lower CARs (6). 
In patients with mood disorders, a higher CAR was observed in both remitted (n=579) and 
currently depressed (n=701)  patients (7). In acutely depressed outpatients cortisol levels 
were 25% higher compared with healthy controls (8). In addition to this finding, a study 
among 230 late adolescents revealed that a higher CAR was predictive for developing a 
Major Depressive Disorder (MDD) within a year after sampling (9). In addition, subjects 
without a history of depression but with parents diagnosed with MDD had higher CARs, 
which were equal to the subjects with a current depression (10). It seems that these 
findings reflect higher basal cortisol levels as a trait phenomenon irrespective of current 
status.  
b. Challenging the HPA-axis
The Dexamethasone Suppression Test (DST) is a neuroendocrine test measuring GR-
mediated negative feedback. This test consists of a low dose administration (1 mg or 
0.25 mg) of dexamethasone, a synthetical glucocorticoid hormone, at 11 pm and the 
measurement of cortisol levels the following morning. Due to the negative feedback 







action at the pituitary and hypothalamic levels subsequent cortisol levels are suppressed 
the next day. Non-suppression of cortisol levels after dexamethasone indicates 
GR resistance. The strength of cortisol suppression reflects the negative feedback 
mechanism, which is largely variable between but rather stable within individuals (11). 
The test is very easy, however an important restriction to consider for use in psychiatry 
is the limited sensitivity in studying MDD (12). In particular in outpatients the sensitivity 
is low. It was reported that only 12 % of outpatients with non melancholic depression 
showed non suppression in the DST, while 64% patients with psychotic depression 
showed non suppression (13).  Low percentages of non suppression after 1-2 mg 
dexamethasone in moderately depressed patients (44%) were found, in contrast with 
severely depressed psychotic patients and bipolar patients (67-78%) (14). Heuser et 
al developed the combined DEX/Cortisol Releasing Hormone- test (DEX/CRH- test) as 
a refinement of the DST (15). This challenge test consists of administration of 1.5 mg 
dexamethasone at 11:00 pm followed by administration of 100 microgram CRH at 3:00 
pm on the next day. Cortisol and ACTH levels are sampled every 15 minutes from 2:00 
pm until 6:00 pm. This test was found to be more sensitive for MDD  (about 80%), and is 
even above 90% when the cohort was stratified for age. 
However, the DEX/CRH-test is more intrusive for patients, which limits the use in research 
among large cohorts of outpatients. Zobel et al found that in a cohort of 74 remitted 
patients, the DEX/CRH test was able to predict relapse of depression within six months 
(16).  In patients with a relapse within 6 months after discharge, there was a 4- to 6-fold 
increased cortisol response in the DEX/CRH-test just before discharge. In accordance to, 
Appelhof et al found in a sample of 45 outpatients with remitted major depression that 
higher cortisol levels in the DEX/CRH test were associated with relapse (17), which was 
confirmed by Ising et al (18). Rybakowski et al. also stressed that number of episodes 
was associated with more non-suppression. Bipolar patients in the same study were 
found to have most non-suppression when compared with healthy controls and unipolar 
depressed patients in remission. Watson et al confirmed that in bipolar patients, cortisol 
levels in response to the DEX/CRH test are increased, with no difference between a 
current depressive episode and remission (19). 
The issue whether this is a state or trait phenomenon is not yet solved. The studies 
including healthy family members suggest that hyperactivity of the HPA-axis is not only a 
reflection of current mood state (20). A new approach to this problem is the scar theory 
(21), describing long lasting changes in the function of the brain (cognition, biological) 
following depression, increasing the risk for developing future depressive episodes. 
The pre-morbid regulated “set-point” of the HPA-axis is thought to be changed through 
depression by for example epigenetic changes in DNA methylation in depressed suicide 
victims (22) and children of mothers who were depressed during pregnancy (23). This 
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scarring process is possibly a structural phenomenon developed during life. In section 4 
we will briefly discuss the influence of early life trauma on epigenetic phenomena.
c. Cortisol in scalp hairs
A novel and non-invasive parameter is measuring cortisol in scalp hair. Hair grows with an 
average of 1 cm per month, and it has been shown that cortisol can be reliably measured 
in hair (24-26). The use of hair provides the opportunity to measure long term cortisol 
levels (reflecting mean levels of the past months) in an easy way without limitations 
caused by the pulsatility and circadian rhythm of cortisol or acute circumstances.  Strong 
correlations of hair cortisol have been observed with tissue effects of cortisol in healthy 
individuals (e.g. waist circumference), as well as with cortisol exposure in patients 
with hyper-or hypocortisolism (26).This method has only preliminary been applied in 
psychiatry. Steudte et al found a decreased cortisol level in patients with generalized 
anxiety disorder (27). Our group recently found that cortisol levels were increased in 
patients with BD when having a co-morbid psychiatric diagnosis (28). Interestingly, hair 
cortisol levels were decreased when patients with BD were also diagnosed with panic 
disorder. Moreover, we found an association of higher hair cortisol levels with adult onset 
(older than 30 years) of BD, and impaired executive functioning, compared to patients 
with puberty onset, normal executive functioning and normal cortisol levels (29). 
3. Genetics of HPA-axis: consequences for physical and mental 
health
a. GR polymorphisms: physical health
There are several known genetic variations in the GR Gene NR3C1 with consequences for 
cortisol sensitivity (30). Subtle changes in cortisol signaling leading to relative resistance 
or hypersensitivity for Glucocorticoids (GCs) can have long term consequences. It 
is known that these changes can affect metabolic and inflammatory status and body 
composition. Cognitive performance and mental health can also be influenced by altered 
HPA-axis regulation.
Haplotype 4 (TthIIII + 9β) and haplotype 5 (TthIIII + 9β + ER22/23EK) are both associated 
with a relative resistance for GCs (31-34). The ER22/23EK polymorphism is associated 
with a healthy metabolic and inflammatory profile, characterized by lower total 
cholesterol and low-density lipoprotein cholesterol levels as well as lower fasting insulin 
concentrations, a better insulin sensitivity and lower C-reactive protein levels (32, 35).







This GR variant is also associated with a beneficial body composition, shown by young 
male ER22/23EK carriers (taller, stronger and more muscle mass than non-carriers) and 
female ER22/23EK carriers (tendencies for smaller waist and hip circumferences, lower 
body weight (33) and protective effect on weight gain during pregnancy (36). These 
associations of the ER22/23EK polymorphism are in line with a mild GR resistance. The 
clinical data are supported by in vitro experiments showing reduction of transactivating 
capacity in transfection experiments and in peripheral blood mononuclear lymphocytes 
of carriers of this polymorphism (37). In addition the underlying molecular mechanism 
of the GR gene variant has been revealed (38). 
The 9β-polymorphism seems to increase the stability of mRNA of GR-β, an alternative 
splice variant of the GR-gene (31). GR- β is thought to exert a dominant negative effect 
on the active GR-α. The association of the 9β polymorphism and the immune system has 
been shown by the higher risk of developing rheumatoid arthritis in carriers (31, 39). 
Patients with Multiple Sclerosis (MS) have been found to have a more aggressive course 
of disease when they carry at least one allele of haplotype 5 (TthIIII + 9β + ER22/23EK), 
which is possibly related with an altered inflammatory state due to GC resistance (40). 
Interestingly, in 2008 van den Akker et al reported that the 9β polymorphism is related 
to a more active pro-inflammatory system, and subsequently associated with the risk of 
cardiovascular disease (41). In line with these findings the Heart and Soul Study showed 
that the 9β SNP is associated with reduced heart function, partly mediated by low-grade 
inflammation (42).
Haplotype 2 (BclI), haplotype 3 (TthIIII + BclI) and haplotype 6 (N363S) have all been 
associated with a relative hypersensitivity to GCs and clinical signs of hypersensitivity to 
cortisol in various tissues (43). Carriers of N363S have in addition to increased cortisol 
suppression also an increased insulin response in the DST, a tendency towards lower 
bone mineral density, and increased body mass index (BMI) (33). Although other studies 
have reported associations with increased BMI, as expected as a result of glucocorticoid 
hypersensitivity, these findings have not been consistently confirmed (30, 44). The BclI 
polymorphism has been found to be associated with abdominal obesity (33), lower bone 
mineral density (45) and unhealthy body composition in young boys (46).
b. GR polymorphisms: mental health
Recently we reviewed the GR and MR SNPs in relation to mood disorders (47). The 
most important findings will be summarized and supplemented by recent progress in 
this area of research.  The ER22/23EK polymorphism has repeatedly been associated 
with a higher risk on developing a depressive episode (48-50), and a faster response 
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after antidepressant treatment (48). In the study of Bet et al. an association to this 
polymorphism and clinically relevant depressive symptoms in an elderly population 
was only found in combination with childhood adversity, indicating a gene-environment 
interaction. Recently, attention has been directed to the 9β SNP in relation to 
mood. In a sample of 245 bipolar patients, we found an association between the 9β 
polymorphism and reduced risk on (hypo) mania (51). In the aforementioned study of 
Bet et al. a relationship between this SNP and clinically relevant depressive symptoms, 
in combination with childhood adversity was found (50). Recently, in a sample of 173 
patients with bipolar I depressive episodes, the response to lamotrigine (anti-epileptic 
medication used in treatment of bipolar depression) in a subgroup of 88 patients 
was associated with the GR polymorphisms rs258747 and rs6198 (9β) (52). Finally, in 
a group of 526 outpatients with coronary heart disease the prevalence of depression 
was increased with an allele-dosage effect (from 24.4% of the non-carriers to 52.9% 
of the homozygous 9β carriers) (53). The BclI polymorphism is also associated with an 
increased risk on developing a depressive episode (48, 54-56), as well as with a reduced 
response after antidepressant treatment (54), which was not confirmed by Lee et al 
(56). Remarkably, in the latter study, it was found that in the Korean population there 
were no carriers of ER22/23EK and N363S.  This is consistent with other reports in Asian 
populations (57).
c. MR polymorphisms
In figure 1, 2 SNPs in the MR Gene and 3 haplotypes are shown. The V allele in the 
MRI180V SNP is associated with higher cortisol levels in saliva and plasma in healthy 
subjects performing the Trier Social Stress Test (a validated psychological procedure 
inducing acute stress under laboratory circumstances, allowing evaluation of biological 
measurements of differences in stress levels between individuals). In vitro testing, 
using transactivational assays, this I180V variant was shown to have a slight loss of 
function using cortisol as a ligand (58). This SNP was associated with higher frequency 
of depressive symptoms in an elderly cohort (participants aged > 85 years) (59) and 
with neuroticism in depressed patients (60). Another MR SNP, the -2G/C variant also 
affects the transactivational capacity of the MR in vitro in response to cortisol. Both SNPs 
modified cortisol suppression in a DST (0.25 mg DEX) in a sex specific manner (61).  
d. FKBP5 and CRH-R1 polymorphisms
An important co-chaperone protein functionally interacting with the GR is FK506 binding 
protein 5, better known as FKBP5, a member of the immunophilin protein family. Genetic 







variations in the FKBP5 gene lead to increased intracellular FKBP5 protein expression, 
which in turn leads to adaptation of the GR function. Healthy subjects carrying these 
SNPs show GR resistance and diminished negative feedback of the HPA-axis. Carriers 
of these variations have been found to be overrepresented in patients with mood 
disorders (MDD and BD) and post-traumatic stress disorder (62), as well as respond 
faster to antidepressant treatment (63).  Another gene, which is a key factor in the HPA-
axis is the CRH1- receptor (CRH-R1). This receptor has been considered as a mediator 
in initiating the stress response. The CRH-R1 is located in the paraventricular nucleus 
(PVN) of the hypothalamus, the hippocampus as well as widely distributed beyond 
the hypothalamus. It interacts with a wide range of neurotransmitters, for example, 
influences the activity of the 5-HT2A/C receptor (64, 65). Several SNPs in the CRH-R1 
gene have been recently identified and explored in relation with mood disorders. 
Liu et al found an over-representation of rs242939 in patients with major depression 
compared to healthy controls (66). They also found that rs242941 carriers with major 
depression and high levels of anxiety responded faster after treatment with fluoxetine 
in 127 Han Chinese patients (67). This was not confirmed by Dong et al in a population 
of 536 unrelated Mexican Americans from Los Angeles (68). In male suicide attempters 
a relation between illness severity and a haplotype of the CRHR1 has been found (69), 
as well as in their offspring with CRH-R1 haplotypes, who were found to score higher on 
the Beck Depression Inventory, which was found in the same study. 
Interestingly, these SNPs in the CRHR1 gene are also studied in relation with the 
environment and with other genes. Experiencing childhood abuse leads to a higher risk 
for developing a lifetime depressive episode specifically in carriers of polymorphisms of 
the CRH-R1 in combination with the short serotonin transporter gene 5-HTTLPR (70). 
In parallel, Bradley et al found an interaction between SNPS in the CRHR1 gene and 
childhood abuse as predictor for depressive episodes (71). In one cohort of more than 
1,000 female participants, Polanczyk et al found that carriers of a haplotype formed by 
rs7209436, rs110402, and rs242924 who were abused during childhood as measured 
by the Childhood Trauma Questionnaire (CTQ) are protected against depression in 
adulthood (72). This was not replicated in another cohort described in the same study, 
where childhood abuse was not measured by the CTQ.
A recent review by Binder and Nemeroff extensively summarized the relation between 
genetics of the CRH system in relation with psychopathology (64).
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4. Epigenetics of the HPA-axis: adversity in childhood
The influence of genetic variations in the DNA sequences of HPA-axis related genes on 
mood disorders is clear, but may only be one brick in the building of our understanding 
of mood disorders. Of all other influences, it is important to mention epigenetic changes 
in regulating the “set-point” of the HPA-axis. Epigenetic changes comprise changes in 
gene expression which remain stable during cell divisions, but do not affect the DNA 
sequence itself. Epigenetic changes are heritable and could be caused by changes such 
as those found in DNA methylation, the modeling of chromatin and the de-acetylation 
of histones in the DNA. 
Several circumstances can lead to epigenetic changes, for example intra-uterine influences 
and changes in early youth due to childhood adversity. A well-known example of intra-
uterine effects on health in adulthood is the Dutch Famine Birth Cohort study. Children 
of the women who were pregnant during the famine in World-War II scored lower in 
mental health, and this effect was repeated in their children’s children, suggesting an 
epigenetic effect (73). However, there was no relation found with changes in HPA-axis 
regulation (74). Other studies emphasize the importance of regulation of the HPA-axis 
in utero. Raised GC concentrations during pregnancy are associated with lower birth 
weight and later during childhood and adulthood with an increased cortisol response 
during HPA-axis activation (75). As a consequence these patients are at higher risk to 
develop obesity and/or diabetes. Yehuda et al report that women who were pregnant 
during the World Trade Centre Attack and developed Post Traumatic Stress Disorder had 
lower salivary cortisol levels, as did their 1-yr old offspring, suggesting they had already 
developed a risk factor for PTSD in later life (76). Animal studies show that prenatal 
stressed offspring developed hyper activation of the HPA-axis through epigenetic 
programming, and develop high anxiety levels and depression-like behavior (77, 78).  
In early childhood the regulation of the HPA-axis is further developed. Early life trauma 
could have devastating consequences for the HPA-axis “set-point”. In a recent review, the 
relation between early life trauma and the HPA-axis is characterized by hypocortisolism and 
an attenuated cortisol response during acute stress (79), which suggests a dysregulation 
of the negative feedback mechanism in the HPA-axis. This diminished stress response 
is continued throughout life and tends to worsen with ageing (80). Animal studies have 
shown that mouse pups that have been separated for several days from their mothers, 
have an increased GR expression in frontal cortical and hippocampal areas during 
the separation. After the separation they showed a diminished GR expression (81). In 
humans this was recently confirmed by McGowan et al, showing that suicide victims with 
a history of childhood abuse had decreased GR mRNA levels in the hippocampus, as well 
as increased cytosine methylation of the GR (82). Secure attachment is a central theme 







in the work of Bowlby and Ainsworth. The “strange situation” is a classic test, comprising 
a short separation between mother and child. After reunion the response of the child 
towards the mother is categorized in attachment styles, reflecting the involvement or 
neglect/abuse of the mother for her child (83). Neglect by the mother is devastating for 
the development of a secure attachment style of the child, with definite changes (e.g. 
alterations of methylation pattern of the GR) for the rest of its life.
5. Conclusive remarks
In conclusion, while accumulating evidence indicates that alterations in the HPA-axis are 
important biological factors in mood disorders, the exact pathophysiological mechanisms 
are at present not completely understood. This is partly due to the difficulties in assessing 
the HPA-axis. One of the promising future techniques could be the assessment of the 
long term cortisol levels through analysis of scalp hairs. The “set-point” of the HPA-axis is 
influenced by genetic changes in the GR gene, MR gene, CRH-R1 gene and FKBP5 gene, as 
well as polymorphisms in other genes involved in cortisol signaling. These changes have 
been associated with mood disturbances. During life this set-point is further defined by 
epigenetic changes due to intrauterine influences and/or childhood adversity.  Finally, 
during life this set-point could be influenced by mood episodes. As a result, hyperactivity 
of the HPA-axis may increase the vulnerability for future mood episodes.  
Future research should focus on new tools in order to obtain a clear indication of an 
individual’s cortisol status. This may provide better opportunities to understand possible 
causal relationships between cortisol exposure (in the brain) and mood disorders which 
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Previously, it has been suggested that hypothalamic pituitary adrenal (HPA) axis 
dysregulation and as a consequence increased cortisol levels, is not only a state 
phenomenon, but may also be a trait phenomenon in mood disorders. Cortisol exerts its 
effects mainly by binding to the glucocorticoid receptor (GR) and, in particular of interest 
in certain brain regions, the mineralocorticoid receptor (MR). Several GR polymorphisms 
have been shown to be associated with altered sensitivity of the HPA axis. Recently, the 
GR polymorphisms BclI and ER22/23EK have been associated with unipolar depression in 
several studies. In addition, the ER22/23EK polymorphism seems to be associated with 
a decreased risk of dementia in healthy individuals. Also during a depressive episode 
carriers of this ER22/23EK variant demonstrated a tendency towards better cognition, as 
measured by divided attention tests. 
In this overview, currently known clinically relevant GR and MR polymorphisms are 
discussed in relation to mood disorders (both unipolar depression and bipolar disorder) 
and cognitive functioning. 
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1.  Introduction: Glucocorticoids and Depression
Stressful life events often precede a major depressive episode. In the past decades a 
strong association between dysregulation of the hypothalamic-pituitary-adrenocortical 
(HPA) axis and depression has been found (1-6).  This association is even stronger in 
patients with either severe unipolar depressive disorder with psychotic symptoms or 
with bipolar disorder (BD) (4, 5). In recent literature this association has been cautiously 
considered to be a trait phenomenon of depressive episodes, rather than simply a state 
phenomenon (2, 7, 8). This was supported by Holsboer et al. who demonstrated that first 
degree family members of patients with unipolar depression display a similar, although 
quantitatively more modest, pattern of dysregulation then that observed during a major 
depressive episode (9). Also Ellenbogen et al found higher cortisol levels in the morning 
and afternoon in offspring of patients with BD compared to offspring of patients with 
MDD and healthy controls (10). In the past years, data concerning the associations 
between mood disorders and HPA-axis have been reviewed extensively (11, 12). The 
most consistent finding is hyperactivity of the HPA-axis. The combined dexamethasone-
suppression/ corticotropin-releasing hormone-stimulation (CRH) test (DEX/CRH test) has 
been reported to be the most sensitive test for detecting HPA-axis dysregulation, with 
approximately 80% of patients with a major depressive episode (uni- or bipolar) found to 
be non-suppressors (13). The test is not very specific for depression, as in all psychiatric 
patients cortisol levels were elevated in comparison with age-matched controls. Previous 
studies showed that the DEX/CRH test may also be useful as a predictor of relapse (14, 
15).
In the brain, the dysregulation of the HPA-axis in major depressive disorder (MDD) and 
BD is associated with neuro-endocrine and anatomical changes. The neuro-endocrine 
changes mainly occur in catecholaminergic systems, like dopamine and adrenalin, 
influencing heart rate and blood pressure (16), and serotonergic systems influencing 
behavior, mood and cognitive functioning (17). Animal studies have shown that 
glucocorticoids (GCs) enhance the effects of dopamine in the reward system of the brain, 
the mesolimbic region, thus influencing goal directed behavior in stressful situations (18). 
Sustained overdrive of GCs is negatively associated with activity of serotonergic neurons, 
reduced expression of 5-HT-1A receptors and reduced 5-HT-1A receptor binding, thus 
believed to influence mood  (7). 
Another regulatory hormone in the brain which can be affected in depression through 
diminished negative feedback action of GCs, is CRH. Overproduction of CRH (1) leads to a 
series of stress-like physiological and behavioral phenomena (7). The behavioral features 
indicate increased anxiety, while some phenomena are also observed in animal models 
of depression (7, 19). In the review of Van Praag, a role is suggested for CRH in the 
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pathophysiology of states of anxiety and depression, conditions that in humans often 
occur simultaneously. However, this overdrive is not sufficiently understood yet. It could 
be the result of a primacy of CRH overdrive, or a consequence of a down regulation of 
centrally localized glucocorticoid receptors (GRs).
Anatomical changes in the brain in patients with depression are found mainly in the 
prefrontal cortex (PFC), the amygdala and the hippocampal area consisting of smaller 
volumes and reduced metabolic activity (20, 21). These brain areas regulate executive 
function and memory. Sassi et al (22) found a significantly smaller pituitary volume in 
patients with BD compared with patients with unipolar depressive disorder and healthy 
controls. No differences between the latter two groups were found. Recently, Aihara 
et al (23) studied 24 patients with MDD and found 75% non-suppressors on the DEX/
CRH test. In positron emission tomography (PET) scans with a radiotracer, these patients 
also showed a hypo metabolism in various frontal regions and hyper metabolism in 
the right hippocampus and parahippocampal gyrus, both normalizing after successful 
antidepressant treatment. 
In depressed patients almost all abnormalities returned to a normal pattern after 
response to medication, indicating the influence of altered GC regulation in these brain 
regions. These findings are in line with results from animal studies showing the negative 
effects of stress on neuroplasticity, mainly in the hippocampal area (where the effects are 
largely reversible after stress has ended), the PFC and the amygdale (24, 25).  MacMaster 
et al found in a pediatric population that children with a family history of MDD had 
significantly smaller hippocampal volumes compared to healthy controls (26), indicating 
that this could be a risk factor for developing MDD. In addition, patients with Cushing’s 
disease, characterized by hypercortisolism, can also develop psychiatric syndromes like 
MDD, anxiety disorders and cognitive dysfunction, as well as a reduction of hippocampal 
volume (27). It has been shown that the decrease of hippocampal volume in these 
patients can be reversed after successful treatment of the Cushing’s disease and the co 
morbid psychiatric symptoms (28). It is still under discussion whether these structural 
changes in depression are reversible and what their exact relationship is with elevated 
cortisol levels (26, 29).
In summary, these findings are indicating that in the pathophysiology of MDD, GCs play 
an important role, affecting mood, executive function and memory through different 
neuronal networks in the brain as well as affecting several neuroendocrine systems. 
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2.  Glucocorticoid sensitivity during a depressive episode
The functioning of the HPA axis is characterized by negative feedback at the pituitary 
level on the production of ACTH, and consequently on the production of cortisol in the 
adrenal glands. A strong indication of this feedback functioning is obtained through an 
HPA axis challenge test. The dexamethasone suppression test (DST) was for years the 
most frequently used challenge test.  Due to its simple procedure, it is widely used in 
psychiatry by researchers and clinicians. Cortisol levels are measured after administration 
of 0.25 mg or 1-2 mg of the exogenous GC dexamethasone, providing an indication of 
adrenal negative feedback at the pituitary level. Sensitivity to exogenous GCs is highly 
variable between normal individuals (30), but within individuals it is rather stable, 
suggesting a set point of the HPA axis with respect to feedback action, which is possibly 
genetically determined. One of the main problems with the DST is its limited sensitivity 
in major depression (about 44%). In bipolar depression and psychotic depression the 
sensitivity is higher (67%-78%)(31). Also in manic states, non-suppression was found 
after a DST (32), as well as after a DEX/CRH test (4).
Heuser et al developed the combined DEX/CRH test as a refinement of the DST (13). 
This challenge test consists of administration of 1.5 mg dexamethasone at 11:00 pm 
followed by administration of 100 microgram CRH at 3:00 pm on the next day. Cortisol 
and ACTH levels are sampled every 15 minutes from 2:00 pm until 6:00 pm. This test 
is more sensitive for major depression (about 80%), and even more sensitive when 
clustering patients according to age groups. Zobel et al showed that the DEX/CRH test 
also may be used to predict relapse of depression within six months (15).  Despite 
the observation that cortisol and ACTH responses to the DEX/CRH test did not differ 
between the patients with major depression on admission, the responses were found to 
be significantly different just before discharge. The relapse rate in this study was found 
to be 4 to 6-fold increased in patients with an elevated cortisol response in the DEX/
CRH test just before discharge as compared to patients with a normal cortisol response. 
In accordance, Appelhof et al recently showed that in a sample of 45 outpatients with 
major depression in remission, higher cortisol levels in the DEX/CRH test were associated 
with relapse (14). In a group of patients with BD the cortisol response to a DEX/CRH test 
was significantly higher than in a group of unipolar MDD patients (5). This difference 
was not only found during a depressive episode, but persisted after remission. Watson 
et al confirmed that in BD patients cortisol levels in response to the DEX/CRH test are 
increased, both during a depressive episode and in remission (33).
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3.  The role of Glucocorticoid Receptors and Mineralocorticoid 
Receptors in Depression
GCs exert their effects by binding to the glucocorticoid receptor (GR) and 
mineralocorticoid receptor (MR).  In the brain the MR is predominantly localized in the 
hippocampus, the amygdala and the prefrontal cortex. The GR is widespread throughout 
the brain, but is expressed in high density in the hippocampus, the prefrontal cortex 
and the paraventricular nucleus of the hypothalamus, the dentate gyrus and amygdale 
(34). The affinity of the MR for cortisol is ten times higher than that for GR (35). Under 
normal non-stress circumstances, cortisol binds to the MR in the mentioned brain areas, 
whereas in stress situations it also binds to the GR. In the limbic system both MR and GR 
are co-expressed, thereby fine tuning the central effects of GCs (36, 37). The MR seems 
to be involved in the onset of the stress response, while the GR terminates the stress 
reactions and promotes memory storage preparing for future events (38). In situations of 
chronic stress, this balancing system is disturbed, with damaging consequences for brain 
functions like mood and cognition. Matsubara et al found a reduced expression of GR 
mRNA in peripheral blood cells in a population of bipolar as well as unipolar depressed 
patients. This finding seems to be, at least partially, a trait phenomenon, as they found 
the same results in remitted patients (bipolar and unipolar) and in first degree family 
members of bipolar patients (39).  Pariante stresses the importance of the dysfunction 
of the GR and the decreased expression of this receptor in the brain in patients with 
MDD [see chapter in this volume]. As a compensation for this GR dysfunction, cortisol 
levels increase to overcome the relative resistance (12, 40). Holsboer summarizes in his 
review the preclinical and clinical data supporting the hypothesis that GR signaling is 
impaired in MDD, yielding increased CRH levels in various brain regions, which in turn 
may lead to MDD (11) [see chapter in this volume].  
In line with this model are the effects of GR antagonists and agonists on the one hand and 
the effects of (other) antidepressants on the GR on the other hand. The GR antagonist 
RU-486, the well known abortifacient mifepristone, has antidepressant effects in patients 
with BD (41) or MDD with psychotic features (42, 43). In a study with chronically stressed 
rats, it has been shown that a 4-day treatment with mifepristone normalized the stress-
induced reductions in neurogenesis (44), possibly indicating the mechanism of action 
through blocking the GR. Interestingly, not only GR antagonists, but also GR agonists like 
hydrocortisone have been shown to exert antidepressant effects (45). 
GR function is also positively stimulated by antidepressants. Pepin et al found in vitro 
that addition of tricyclic antidepressants (desipramine, amitriptyline, imipramine 
and maprotiline) or lithium to primary cultures of rat hypothalamic, hippocampal or 
amygdaloid neurons, GR mRNA was stimulated (46, 47). However, it is interesting that in 
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rats the selective serotonin reuptake inhibitors (SSRIs) such as citalopram and fluoxetine 
had no effect on GR mRNA (48, 49), whereas MR mRNA was stimulated by citalopram, 
desipramine and amitriptyline (48). It is unclear to what extent these animal data can be 
extrapolated to the human brain.
Thus, summarizing these data, although GR is more extensively studied than MR, it 
seems that both GR and MR are important in balancing GC levels in the brain. Imbalance 
in this system through dysfunction of GR and/or MR, could lead to a compensatory 
elevation of cortisol levels. Although still under discussion, the GR is thought to be an 
etiological factor in developing MDD. Studies with GR antagonists, GR agonists, and 
tricylic antidepressants seem to confirm this hypothesis (50). The clues suggestive 
of a genetic trait contributing to the development of MDD and the alterations in GR 
expression, as well as the dysregulation of the HPA axis during a depressive episode 
make the GR gene an important candidate gene for associations with susceptibility to 
MDD and response to antidepressant treatment. This article provides an overview of 
polymorphisms of corticosteroid receptors (both GR and MR), which in previous studies 
have been shown to be functionally relevant, and their associations with unipolar and 
bipolar depression, as well as with cognitive functioning during a depressive episode.
4.  The relationship between GR polymorphisms and GC sensitivity
Previously, a few rare mutations of the GR gene in humans have been described, 
which lead to a generalized cortisol resistance. Patients present with hypertension and 
hypokalemic alkalosis (signs of adrenal overproduction of mineralocorticoids) and, in 
females, hirsutism, male pattern baldness and menstrual irregularities, as a consequence 
of overproduction of adrenal androgens. As a result of defects in the GR, the central 
negative feedback of GCs is reduced, GC production by the adrenal gland is increased, 
and cortisol binds with high affinity to the MR. The consequence is a hyperactivity of the 
HPA axis (51). These mutations, known to lead to the classical syndrome of GC resistance, 
are predominantly located in the ligand-binding and DNA-binding domains of the GR 
gene. Importantly, however, also in normal individuals, GC sensitivity, as measured with 
a low dose DST, varies considerably. Polymorphisms of the GR gene have shown to, at 
least partially, explain this variability in GC sensitivity (52).
Several important GR gene polymorphisms have been reported to yield altered GC 
sensitivity, and as a consequence, result in specific clinical features (see figure 1) (52):
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Figure 1: Overview of the GR gene showing the single nucleotide polymorphisms (SNPs) 
and haplotypes
 Haplotype 2 (TthIIII + 9β). The 9β polymorphism is a single nucleotide polymorphism 
(SNP) in exon 9β of the GR gene. An ATTTA sequence in the 3’ UTR is changed into 
GTTTA. This polymorphism is associated with an increased stability of the mRNA of 
the inactive GR-β isoform and may lead to a relative glucocorticoid resistance by 
increased inhibition of the active GR-α isoform (53). An in vitro study demonstrated 
that this polymorphism results in reduced transrepressional effects (by which, 
for example, genes important in the immune system are regulated), whereas the 
transactivational effects appeared to be normal (54). The 9β polymorphism has also 
been reported to be associated with rheumatoid arthritis (53), and a 68% reduced 
risk of carriage of  nasal Staphylococcus aureus in carriers of this polymorphism (55), 
consistent with this variant’s possible effect on activity of the immune system. It 
is known that IL-6 and IL-1β have activating effects on the HPA-axis. Interestingly, 
non-lithium treated bipolar patients have a low IL-1β  and a high IL-6 production, 
which returns to normal after lithium treatment, suggesting an association of 
dysregulation in the immune system and the HPA-axis in these BD patients (56), 
TthIIII is a restriction fragment length polymorphism (RFLP) in the promoter region 
of the GR gene, which has not been found to be associated with changes in cortisol 
sensitivity. However, a previous report showed an association with elevated basal 
cortisol levels (57).  
 Haplotype 3 (TthIIII + 9β + ER22/23EK) is also associated with a relative resistance to 
GCs, but in contrast to haplotype 2, this resistance is linked to the transactivational 
effects of the GR, by which most of the adverse effects of GCs are being mediated. 
The ER22/23EK polymorphism is located in the transactivation domain of the GR 
gene, and involves two nucleotide changes in codons 22 and 23 (GAG AGG -> GAA 
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AAG), which have been shown to be linked. This variant has been found to be 
associated with a healthy metabolic profile (lower C-reactive protein (CRP) levels, 
lower cholesterol levels and increased insulin sensitivity), longevity in the elderly 
and a beneficial body composition in young adults (52, 58). After a DST, carriers of 
this polymorphism showed a significantly smaller cortisol suppression, indicative of a 
relative GC resistance (58, 59). In addition, these ER22/23EK carriers displayed lower 
fasting insulin levels and lower total and LDL cholesterol levels than noncarriers 
(58, 59).  In a recent study, this polymorphism has also been associated with an 
increased risk of recurrent depression, and a faster response to antidepressant 
medication, as we will discuss later in more detail (60,83).  A relationship with 
cognitive performance has also been demonstrated. Carriers of the ER22/23EK 
polymorphism in a healthy elderly population were found to have a lower risk of 
developing dementia, and performed better on psychomotor speed tasks (61). No 
differences were observed in memory tasks. The ER22/23EK polymorphism was also 
studied in patients with multiple sclerosis and seemed to be associated with a more 
aggressive course of disease (as was observed clinically, as well as radiographically) 
(62). This might be due to an imbalance of the immune system and uncontrolled 
immune response against structural components of the central nervous system, 
since GCs are important factors in the pro-inflammatory signal transduction system.
 Haplotype 4 (TthIIII+ BclI) and haplotype 6 (BclI), both involving a C to G single 
nucleotide polymorphism at a polymorphic BclI restriction site, were associated 
with hypersensitivity to GCs (63). After both a 1 mg DST and a 0.25 mg DST both 
heterozygous (C/G) and homozygous (G/G) G-allele carriers had lower cortisol levels 
than CC-carriers, indicating increased sensitivity to the effects of GCs. This was 
confirmed in another study investigating GR haplotypes in relation to GC sensitivity 
(64). One GR haplotype, a G-A-T haplotype consisting of the G allele of the BclI 
polymorphism, the A allele of the intron B 33389, and the T allele of the intron B 
33388, was found to be associated with increased sensitivity to GCs as well (64).
 Several previous studies reported associations with unfavorable metabolic 
characteristics, such as increased body mass index (BMI), (65) increased abdominal 
visceral fat (66, 67), hypertension (68), and lower amount of lean mass in the elderly 
(63). Recently, Syed et al reported another polymorphism in intron 2 (rs2918419), 
which was associated with hyperinsulinaemia and insulin resistance in males, but not 
in females. The authors suggest that previous articles reporting an association of BclI 
polymorphism with obesity-related characteristics may reflect linkage to rs2918419, 
since they found that carriage of BclI variant alleles without the rs2918419 variant 
appeared not to be related to insulin resistance (69). 
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 Haplotype 5 (N363S). This polymorphism is located in codon 363 of exon 2 of the 
GR gene. The nucleotide change (AAT -> AGT) results in an asparagine to serine 
amino acid. It is associated with lower cortisol levels and higher insulin levels after 
DST, suggesting increased GC sensitivity (70). Several reports demonstrated an 
association between the N363S polymorphism and obesity as could be expected 
if sensitivity to GCs is increased. (70) (71-74) However, in some other studies no 
associations were found with BMI (75, 76).
In conclusion, these GR genotypes seem to have consequences for cortisol sensitivity, 
both at the level of the feedback regulation at the pituitary gland and numerous target 
tissues. Therefore, they may be expected to induce subtle alterations in the set point of 
the HPA axis and may be involved in a genetic profile related to a hereditary susceptibility 
for depression.  In the next sections the relationship between these GR polymorphisms, 
depression and cognition are discussed. Some relevant MR polymorphisms will also be 
briefly addressed.
5.  GR polymorphisms and depression 
A summary of data and an overview of studies concerning the associations between 
GR polymorphisms and depression are provided in Table 1. Research involving GR 
polymorphisms has only recently been focused on psychopathology and psychological 
stress (60, 77). Data are preliminary yet, but seem promising for future research. So 
far, several findings appear to be relevant in understanding the physiopathology of 
depression and will be discussed.
BclI polymorphism 
In 2006 the BclI polymorphism was shown to be significantly associated with major 
depression (60). In this study in a large Caucasian study population the frequency of 
homozygous carriers of the minor BclI allele were significantly higher in the depressed 
group compared to the healthy control group (15.5% versus 9.9% homozygotes, 
respectively). Recently, this finding was confirmed in two other studies (78, 79). Zobel 
et al found similar frequencies: respectively 15.5% and 12.2% homozygotes BclI minor 
allele carriers in depressive patients and controls (79). No differences in hippocampal 
or amygdala volumes were observed for carriers of the BclI polymorphism in this study. 
In addition, in a recent study in premenopausal women a significantly higher number 
of homozygous carriers of the minor allele of the BclI polymorphism was observed in 
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Table 1: Overview of studies and summary of data concerning associations of GR 
polymorphisms and depression.
Author, year Characterization participants Associations HPA axis param-
eters
Van Rossum et 
al, 2006(60)
490 inpatients with MDD (86% 
unipolar depression and 14% BD)
496 Healthy controls
Association between BclI  polymor-
phism and depression
Association between ER22/23EK 
and recurrent depression
Association between ER22/23EK 
and faster response to antidepres-
sants, as well as a slightly better 
cognition with respect to the di-
vided attention test 
No associations 
between SNPs and 
DEX/CRH test
Van West et al, 
2006(84)
180 Belgian patients with MDD, 
uni- and bipolar 
134 Swedish patients with MDD, 
unipolar
354 Healthy controls
Association between promoter 
region (NR3C1-1) SNP and MDD 
(Belgian sample) 
Association between ER22/23EK 
polymorphism (Swedish sample) 
and MDD
Not tested
Brouwer et al, 
2006 (82)
98 outpatients with unipolar MDD Trend of BclI SNP towards reduced 
response rate to antidepressants. 
In particular in a subpopulation 
of patients with the highest ACTH 
levels in the DEX/CRH test 
BclI  variant carri-
ers have increased 




53 premenopausal women with 
unipolar MDD, aged 21-45
29 healthy controls
Association between BclI SNP and 
depression
 Association between BclI SNP and 
higher WHR in    depressive women
No differences in 
plasma and uri-
nary cortisol.
Zobel et al, 
2008(79)
322 patients with unipolar MDD
298 healthy controls
TthIIII and rs1866388 SNPs less 
frequent in patient group, and 
associated with larger hippocampal 
volumes.
Not tested
Spijker et al, 
2008(85)
241 patients with BD
532 healthy controls
TthIIII SNP less frequent in patient 
group, and a trend for a lower 
frequency of the 9β polymorphism 
in BD patients. 
Association between the 9β poly-




15 patients with BD
12 healthy controls
No associations were found Not tested
Feng et al, 
2000(117)
100 patients with schizophrenia
40 patients with puerperal psy-
chosis
No associations were found Not tested
Bet et al, 
2008(81)
221 elderly subjects (aged > 65 
years) with depressive symptoms
685 healthy controls (aged >65 
years)
ER22/23EK and 9β: in combination 
with childhood adversity associated 
with an increased risk of clinically 
relevant depressive symptoms.
BclI heterozygotes 




ers with childhood 
adversity have a 
lower free cortisol 
index
Abbreviations; ACTH adrenocorticotrophic hormone; BD bipolar disorder; DEX/CRH test 
dexamethasone/ corticotrophin releasing hormone test; HRSD Hamilton Rating Scale for 
Depression; MDD major depressive disorder; SNP single nucleotide polymorphism; WHR 
waist hip ratio.
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women with unipolar MDD (78). Furthermore, in the study of Krishnamurthy a positive 
association between this polymorphism and abdominal fat, as measured by a higher 
WHR, was reported. This is of particular interest, since it has been well recognized that 
a relationship exists between MDD and obesity (80).  Bet et al recently observed lower 
levels of cortisol binding globulin in heterozygous BclI carriers (aged older than 65), but 
in this study no association between the BclI polymorphism and depressive symptoms 
was found (81).
Interestingly, Brouwer et al demonstrated a reduced response rate to antidepressants in 
depressive outpatients carrying the BclI variant (82). This finding applied in particular to 
a subpopulation of patients with the highest ACTH concentrations in the DEX/CRH test. It 
was suggested that the combination of both increased ACTH levels after administration 
of DEX/CRH, and carriage of the minor allele of the BclI polymorphism may be a more 
sensitive predictor of poor response to antidepressant treatment than these factors 
separately. 
It should be noted that the single nucleotide change at the polymorphic BclI restriction 
site in intron 2 is referred to as a C (major allele) to G (minor allele) alteration in some 
articles (63, 78, 82), while in other reports a G (major allele) to C (minor allele) change is 
described (79, 83). This variability in the presentation can be explained by the direction 
in which the sequence of the GR gene is read (starting from the p-telomere to the 
q-telomere or vice-versa). To avoid confusion and to enable comparison of several 
studies we also used the term “minor allele”.
ER22/23EK polymorphism
The combined ER22/23EK variant was found to be associated with recurrent depression 
(60). The frequency of this polymorphism was 5.7% when all patients, unipolar and 
bipolar, were included, and did not differ statistically from the control group. However, 
comparison of the control group to patients with a recurrent unipolar MDD yielded a 
significant difference. In the healthy control group 4.2% was found to be carrier of the 
ER22/23EK polymorphism, whereas a carriage frequency of 7.7% in the patient group 
with a recurrent unipolar MDD was observed. In accordance, Van West et al showed a 
significant relationship between the ER22/23EK variant and recurrent MDD (84). In a 
Swedish population 11% of the unipolar MDD patients were found to be carriers of the 
ER22/23EK polymorphism, while in their control group this was only 4%. In a Belgian 
population, which was studied by the same authors, no association was found with 
the ER22/23EK variant.  Recently, Bet et al found in presence of childhood adversity 
an association between the ER22/23EK and 9β polymorphisms and an increased risk of 
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clinically relevant depressive symptoms in a Dutch population of subjects aged 65 years 
and over (81).  In absence of childhood adversity there was no association between 
these polymorphisms and depressive symptoms. This study demonstrates clearly the 
importance of gene-environment interactions.
Other GR polymorphisms
In several recent studies associations between other GR polymorphisms and unipolar or 
bipolar depression have been found. However, until now they have not been replicated. 
In this paragraph we will describe them briefly. In our recent study involving 241 patients 
with BD, we found a significantly lower frequency of the TthIIII polymorphism and a trend 
towards a lower frequency of a polymorphism in exon 9β (85). In addition, presence of 
the exon 9β polymorphism was significantly associated with less frequent manic episodes 
in this study, but no differences were found in frequencies of the other polymorphisms. 
Moutsatsou et al studied two GR gene isoforms (GR-a and GR-b) for the presence of 
mutations in 15 patients with BD and 12 normal subjects (86). They did not detect any 
mutations in the GR gene, which might have been due to the small number of patients in 
that study. Van West et al also found a negative association with another polymorphism 
(NR3C1-1) in the promoter region of the GR gene in a Belgian sample (84). This finding 
is not confirmed yet in other studies. In a Swedish sample, which was investigated in 
the same study, no association with this SNP was observed. Recent studies reported no 
associations between depression and the N363S polymorphism (60, 78, 85).
GR polymorphisms and response to antidepressant treatment
In several of the earlier mentioned studies there is some evidence of an association 
between GR polymorphisms and prediction of response. In the study of Brouwer et 
al, response rate was defined as more than 50% reduction of Hamilton Rating Scale 
for Depression (HRSD) scores after 8 weeks treatment with paroxetine (82). In this 
population, carriers of the minor allele of the BclI polymorphism had significantly higher 
ACTH levels measured in a DEX/CRH test, which was additionally correlated with a lower 
response rate. In a large German group of depressive patients, an association between 
the ER22/23EK polymorphism and a faster clinical response to antidepressant treatment 
was observed (60). Clinical response was defined as a reduction of the HRSD in 5 weeks 
of antidepressant treatment with tricyclic antidepressant or SSRIs, whereas remission 
was defined as a score below 10 on the HRSD. A significant effect on the HRSD score was 
found and carriers of the ER22/23EK polymorphism were found to be in remission on 
average 5 days earlier. At admission and at discharge, however, the Hamilton scores did 
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not differ significantly between carriers and non-carriers. Unexpectedly, DEX/CRH tests 
yielded no differences between carriers of the polymorphisms. This may be explained 
by an overriding effect of the state-dependent increased activity of CRH and arginine 
vasopressin and GR resistance, yielding increased HPA axis activity, which is presumed to 
be present in all genotypes (11). 
To summarize, some evidence exists that unipolar MDD is associated with the BclI and 
the ER22/23EK polymorphisms. Additionally, the minor allele of the SNP NR3C1-1 in 
the promoter region of the GR gene was found to have a lower frequency in a mixed 
population of unipolar and bipolar depressed patients. Also, in a large group of patients 
with bipolar disorder a lower frequency of the TthIIII polymorphism and a trend towards 
lower frequency of the 9β polymorphism was found. 
6.  GR polymorphisms and cognition 
Mood disorders
In both unipolar MDD and bipolar disorder, cognitive dysfunction can occur. In fact, 
cognitive symptoms such as reduced ability to think, lack of concentration and 
indecisiveness are, according to the Diagnostic Statistic Manual (DSM)-IV, some of the 
core symptoms in diagnosing a depressive episode. Also in the definition of a manic 
episode, cognitive symptoms are included. During a depressive episode, most well 
known cognitive deficits include diminished performance on shifting attention tasks, 
memory impairments, and problems with executive function (87-89).  
While it is clear that cognitive impairment occurs during disturbed mood episodes, 
there is also growing evidence that these symptoms can persist in the euthymic phase 
of unipolar MDD and BD.  In euthymic patients with unipolar recurrent MDD a persistent 
impairment of executive function was found (90). Persistent  neuropsychological deficits 
present in BD also in the euthymic state, particularly impairment in sustained attention 
and working memory (91). This suggests that such deficits could be vulnerability trait 
markers of the illness (87). Additional evidence for this hypothesis is presented in studies 
of first degree family members of patients with BD, who show cognitive impairments in 
executive function, psychomotor speed and verbal ability, although milder than in the 
patient groups (90, 92). Some studies found that the deficits correlate with both the 
duration of illness and the number of episodes (93). However, Mur et al argue that these 
deficits, especially in executive function, are amongst the core symptoms of the disease, 
independent of course and severity of the disease (94). In BD, poor outcome is highly 
associated with cognitive impairment in remission, particularly executive dysfunction, 
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leading to impairment of psychosocial and occupational functioning (95). In a review on 
this topic, Glahn et al conclude that there are deficits in sustained attention, executive 
function and working memory in euthymic BD patients (96). These deficits are more 
severe in BD patients in comparison with unipolar patients, and could be trait markers 
of the illness. To enable interpretation of future studies on this topic, it is important to 
differentiate between patient groups (97), since patients with unipolar recurrent MDD 
seem to have different neurocognitive profiles compared to patients with BD and elderly 
patients with MDD (98). 
Recently, some studies focused on the association between cognitive impairment, 
structural cerebral changes and GR polymorphisms. Zobel et al found in 64 patients with 
unipolar MDD, that during treatment with citalopram, the cortisol patterns in a DEX/
CRH test changed and this finding was correlated with improvement of working memory. 
Other cognitive functions were not related to changes in HPA axis function in this study 
(99).  In the earlier mentioned study of Zobel (see table),  associations between the 
GR gene polymorphisms TthIII1 and rs1866388 and hippocampal volumes were found, 
possibly related to cognitive impairment, but this was not tested in this study (79).
In the German depressed patients a test for divided attention was performed (60). 
Impaired performance on this test in a group of depressed patients has been shown to 
be related to therapy resistance, as well as an elevated risk on to relapse within 6 months 
(100). During a depressive episode, ER22/23EK carriers showed a shorter reaction time 
with respect to the divided attention test than non-carriers. At discharge they also tended 
to perform better, although this effect was not statistically significant. This suggests that 
carriers of the ER22/23EK polymorphism may be relatively protected from potentially 
harmful consequences of increased HPA axis activity on cognitive functioning. 
Dementia
In elderly patients with recurrent MDD, there is an overlap between depression and 
Alzheimer’s disease. This is mainly because these patients exhibit a generalized pattern 
of cognitive deficits. One diagnostic feature is the reversibility of these symptoms of 
depression, which is clearly not the case in Alzheimer’s disease (101).  Over activity 
of the HPA axis has been associated with neurocognitive decline and dementia (102, 
103). This decline in neurocognitive functioning could possibly be explained by elevated 
cortisol levels, which is also associated with increased risk of cardiovascular pathology. 
Cortisol levels tend to increase with aging, both in healthy and demented elderly (104, 
105), but to a greater extent in demented patients. Magri et al conclude in their review 
that, besides the harmful effects of elevated cortisol levels on cognition, hippocampal 
Glucocorticoid Receptor Polymorphisms in Major Depression: 







neuronal impairment may in turn be responsible for reactive elevation of cortisol levels 
(106).
To our knowledge, only two studies have focused on the relationship between aging, 
neurocognitive decline and GR polymorphisms. First, in a Dutch population of more than 
6000 elderly, carriers of the ER22/23EK polymorphism were found to have a lower risk of 
developing dementia (61). At baseline, dementia was less prevalent in this group (with 
an 86% risk reduction). In a second group of more than 1000 Dutch elderly in the same 
study, a cerebral MRI was also performed. ER22/23EK carriers showed significantly less 
cerebral white matter lesions, as well as a decreased risk of progression of these lesions. 
In this study, non-demented ER22/23EK carriers performed better on psychomotor 
speed tests. However, no differences in memory tasks between genotypes were found 
(61). Another study of Kuningas et al confirmed in a cohort of 563 participants of 85 
years and over the association between cortisol levels  and  impaired global cognitive 
functioning, and in particular impairments in attention and  psychomotor speed. No 
associations between these test performances and GR polymorphisms were observed 
(107). 
7.  MR polymorphisms
Theoretically, it seems plausible that MR polymorphisms could also affect vulnerability 
for mood disorders, but until now this hypothesis has not been extensively studied. 
Kuningas et al found an association in the afore mentioned study between the MR SNP 
I180V, consisting of a GTT to ATT change in exon 2 (codon 180) and the prevalence of 
depressive symptoms in the elderly (107). Interestingly, this SNP is also associated with 
increased saliva cortisol and plasma cortisol responses and higher heart rate in reaction 
to a psychosocial stressor (the Trier Social Stress Test) in normal subjects (108, 109). 
8.  Future perspectives
To summarize, evidence is accumulating showing that carriers of GR polymorphisms BclI 
and ER22/23EK may be more vulnerable to developing MDD. In addition, carriers of the 
ER22/23EK polymorphism appear to be protected against dementia, but these data on 
cognitive functioning have not yet been confirmed. Other studies focusing on GR and 
MR polymorphisms showed associations with uni- or bipolar depression, but these data 
also need replication, preferably in larger populations. Future research should therefore 
invest in replicating these association studies in additional and larger patient groups. 
Another important aspect in future studies should be the proper definition of patient 
groups. Bipolar depressed and unipolar depressed patients seem to differ with respect 
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to the severity in HPA axis dysregulation and the clinical effects of GR polymorphisms 
(5, 10, 22). Therefore, it could be argued that these two types of patients should be 
investigated separately. On the other hand, others have demonstrated that BD and 
MDD patients are endophenotypically rather similar and even may be considered as one 
disease entity with both showing increased cortisol and ACTH release after stimulation 
with CRH following DEX suppression (11).  
Many discrepancies exist with respect to the relationship of GR polymorphisms with HPA 
dysregulation in various brain areas. It remains intriguing that the two GR polymorphisms 
(BclI and ER22/23EK) with opposite effects with respect to GC sensitivity to adrenal 
feedback and in peripheral tissues are both associated with depression. It is also known 
that increased as well as decreased levels of glucocorticoids in the brain can be associated 
with depression. Supporting this is the finding that GR antagonists as well as GR agonists 
have been shown to have antidepressant effects. These apparent contradictory findings 
could possibly be explained by the complex mechanism of action of the GR. GR acts 
like a transcription factor, and is able to both positively and negatively regulate target 
genes. The production of CRH in the brain is regulated by GCs through binding to GRs in 
different brain regions. While the GR stimulates the CRH expression in limbic regions like 
the amygdala, it inhibits CRH production through a negative feedback mechanism in the 
hypothalamus (110, 111). An important focus is the balancing system of GR as well as 
MR. Future research should elucidate the importance of the MR in the pathophysiology 
of MDD. Studies in rats have shown MR is up regulated in the brain after psychological 
stress, associated with inhibition of the HPA-axis (112). Blockade of the MR in the brain 
leads to activation of the HPA-axis, under basal and stressful conditions. This is reflected 
in the decrease in blood pressure, heart rate and corticosterone response in rats after 
administration of a MR antagonist (113, 114). Besides these autonomic responses, MR 
also enhances cognitive responses like spatial learning in rats (115) as well as behavioral 
responses, such as a dramatic decrease in aggressive behavior in rats towards an intruder 
after treatment with a MR antagonist (116). In humans, brain MR function has not yet 
been extensively studied, however, animal studies seem encouraging for future research 
in this field. 
It is of paramount importance to obtain more insight in the pathophysiology of 
depression and its clinical consequences, such as cognitive impairment. Identification 
of genetic markers for prediction of response to treatment and relapse is important in 
order to develop new treatment strategies. It will also be important in future research 
to differentiate between patient groups, since different neurocognitive profiles have 
been identified in unipolar, bipolar and elderly patients with unipolar MDD.  This may 
also have implications for treatment possibilities.  Elucidating the connections between 
GR and MR polymorphisms and depression may provide new insights from a combined 
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endocrine-genetic perspective and may in the future offer possibilities to classify patients 
in more homogeneous groups for whom treatment and risk of relapse predictions can 
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In affective disorders, dysregulation of the hypothalamus-pituitary-adrenal (HPA)-axis 
is a frequently observed phenomenon. Subtle changes in Glucocorticoid Receptor (GR) 
functioning caused by polymorphisms of the GR gene (NR3C1) may be at the base of the 
altered reaction of the HPA-axis to stress and subsequently related to the development 
and course of affective disorders. The aim of our study is to evaluate associations 
between GR gene polymorphisms and bipolar disorder (BD).
Methods
In this study 245 patients with BD were interviewed to confirm diagnosis and BD 
subtype. Data on medication use and sociodemographic details were also collected. 
The control group consisted of 532 healthy blood donors, of which data on sex and age 
were collected. To perform genotyping blood was collected from all patients and healthy 
controls. 
Results
A trend was found for a protective effect of the exon 9β-polymorphism (p=0.14) and the 
TthIIII-polymorphism (p<0.05) on the manifestation of the disease. These effects were 
significantly influenced by male gender for both polymorphisms. Patients with BD and 
the A/G variant in exon 9β had significantly less manic and hypomanic episodes than 
noncarriers (p<0.05).
No further associations were found with the other investigated GR gene polymorphisms 
and BD. These findings were not corrected for multiple comparisons.
Conclusions
We conclude that the exon 9β-polymorphism and the TthIIII-polymorphism of the GR 
gene may be associated with a protective effect on the clinical manifestation and course 
in patients with BD.  Furthermore no associations were found between the other studied 




Bipolar Disorder (BD) is a common illness, with a lifetime prevalence of 1.9 % (1) to 2.4% 
(2).  It is also associated with a high lifetime prevalence (82.8 %) of co morbid mental 
disorders, specifically  anxiety disorders (31.9%) (3). The course of the disease is highly 
variable and unpredictable. As it is known that there is a dysregulation of the stress 
response in  these patients, it is important to evaluate the influence of this dysregulation 
on the course of the disease.
Dysregulation of the stress response, or specifically dysregulation of the hypothalamus-
pituitary-adrenal (HPA)-axis is known to occur in several psychiatric disorders, including 
BD (4-10). Cortisol exerts its effects through the glucocorticoid receptor (GR) and 
the mineralocorticoid receptor (MR). Recently, several polymorphisms of the GR and 
MR have been demonstrated to influence the response of the HPA-axis to stress (11-
14). Figure 1 shows a schematic overview of the GR-gene NR3C1 with the functional 
polymorphisms, as well as their haplotypes.  
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Haplotypes 2-6 have been described as associated with a change in regulation of the 
HPA-axis. In two recent studies, haplotype 3 (TthIIII + 9β + ER22/23EK) was found to be 
associated with a higher risk of major depressive disorder (15, 16) and a faster response 
to antidepressant medication (15). In addition, the BclI-polymorphism (haplotypes 4 
and 6) was more prevalent in depressed patients (15). In a recent study, carriers of the 
BclI-polymorphism with a major depressive episode had higher AdrenoCorticoTropic 
Hormone (ACTH) levels and a tendency to worse treatment outcome (17).
In this study, the prevalence of these polymorphisms in the GR-gene of patients with  BD 
will be assessed, as well as their relationship with the course and severity of BD.   
Patients and Methods
Subjects
This study is a cross-sectional, explorative case-control study of outpatients with BD. 
Patients with BD type 1, BD type 2 and BD Not Otherwise Specified (NOS), according to 
DSM-IV criteria were included. The design of the study was approved by the independent 
Dutch national medical ethics committee. All patients treated in the outpatient Clinic for 
Mood Disorders in The Hague were invited to participate. All 412 patients being treated 
for BD by the Outpatient Clinic for Mood Disorders in The Hague (Netherlands) were 
invited to participate in the study, either by letter or directly by their treating physician. 
After written informed consent was obtained, 245 patients were enrolled. To assess the 
diagnosis and co morbidity according to the DSM-IV criteria, patients were interviewed by 
trained research assistants using the Mini International Neuropsychiatric Interview Plus 
(18). Sociodemographic and ethnic data were collected, and the Clinical Questionnaire 
(CQBP-C) (Dutch translation Akkerhuis, Groenesteyn, Nolen 1997) was used to specify 
subtypes of BD and its course over time. 
Blood samples from 532 healthy control subjects were randomly collected from the 
Rotterdam blood donation bank. Only the gender and age of these subjects are known. 
Genotyping
From each patient, 40 ml of blood were collected in EDTA tubes and DNA was extracted 
from fresh blood using the Puregene whole blood DNA-extraction kit (Gentra Systems 
Inc; MN). Allelic discrimination was performed to genotype the subjects, using TaqMan 
Universal PCR master mix, and custom designed primers and probes (Applied Biosystems, 
Nieuwerkerk aan den IJssel, Netherlands, see also Table 1 and an Applied Biosystems 
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7900 HT Sequence Detection System as previously described (13). Reaction components 
and amplification parameters were based on the manufacturer’s instructions. The 
genotypes were reanalyzed for all heterozygous and homozygous carriers of the single 
nucleotide polymorphisms (SNPs) and identical genotypes were identified. Both groups 
(controls and patients) were found to be in Hardy-Weinberg equilibrium with respect 
to all five polymorphisms. The accession number of the GR gene is NM_000176; the 
various polymorphisms have the following accession numbers:  TthIIII - rs10052957; 
ER22/23EK - rs6189 and rs6190; N363S: rs6195; BclI - rs41423247; 9β - rs6198.




N363S Fw 5’-CAACAGCAGGATCAGAAGCCTAT- 3’
Rev 5’-CCCAGAGAAGTCAAGTTGTCATCTC- 3’
ER22/23EK Fw 5 ’-TCCAAAGAATCATTAACTCCTGGTAGA- 3’
Rev 5’-GCTCCTCCTCTTAGGGTTTTATAGAAG- 3’







N363S Wt 5’-FAM-CCTATTCCAATTTTCGGAACCAACGG- 3’
Mu 5’-VIC- CCTATTCCAACTTTCGGAACCAACGG - 3’
ER22/23EK Wt 5’-FAM-ACATCTCCCCTCTCCTGAGCAAGC-3’
Mu 5’-VIC-ACATCTCCCTTTTCCTGAGCAAGC-3 ’
BclI Wt 5’-FAM-TCTGCTGATCAATCT -3’
Mu 5’-VIC-TCTGCTGATGAATCT - 3’
9-Beta Wt 5’-FAM-TTTATTTTTTCGTTTAAATTT-3’
Mu 5’-VIC-CTTTTATTTTTTCATTTAAATTT-3’
Fw=forward, Rev=reverse, Wt=wild type, Mu=mutant 
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Data were analyzed using SPSS (release 12.0.1 for Windows (SPSS, Chicago, IL)). Analyses 
for binary outcomes (case-control and dichotomous response variables) were performed 
with logistic regression analysis. The patient group and the control group significantly 
differed in age and gender. Therefore all analyses were corrected for age and gender. 
First, frequencies of polymorphisms were analyzed in the patient and the control group. 
Because only age, gender and genotype were known from the control group, in the 
logistic regression analysis only these variables were added as independent explanatory 
variables. 
Second, clinical data within the patient group were analyzed in relation to genotypes. 
Phenotyping was focused on current situation, and little was known about course and 
severity of the disease. Therefore, number of episodes was chosen as an indicator of 
severity of the disease. Groups concerning number of depressive or (hypo-) manic 
episodes were chosen based on the median number of episodes (see Table 2).
To reduce the problem of multiple testing, only the logistic regression analysis was 
performed for each genotype using frequency and number of episodes as dependent 
variables. As this is an explorative, hypothesis generating study, data mining is not 
completely avoidable. In this study the statistical power was not big enough to apply the 
Bonferroni’s correction or the split sample method. 
Haplotypes were not included in the analyses as the number of patients was not 
sufficient. 
Results
Of the 245 patients enrolled in the study, genotyping failed in three patients and one 
patient did not have BD as defined by the MINI and the CQBP. The baseline characteristics 
of the remaining 241 patients and the control group are described in Table 2.
The TthIIII polymorphism was only analyzed in a subgroup of 320 controls. In 23 patients 
data on number of (hypo) manic episodes were missing.
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Table 2 Baseline Characteristics 
Bipolar Patients Controls
Number 241 532
Age (years) 47.8 ± 10.8 42.7 ± 12.2
Gender (% male) 102 (42%) 285 (54%)
Ethnicity 229 (95%) Caucasian
Bipolar Disorder type 1




















Inter-episode functioning 142 (58,9%) well functioning
61 (25,4 %) some problems, most of the 
time well functioning
16 (6,6%) severely disturbed
22 (9,1%) no difference between episodes





Comorbidity 108 (47%) ≥1 Comorbid disorders
91 (39%) Anxiety disorder
10 (4%) Somatoform disorder
9 (4%) Pain disorder
6 (3%) Boulimia nervosa
5 (2%) Drug dependency
12 (5%) Alcohol dependency
6 (3%) ADHD
15 (11%) of all women have premenstrual 
dysphoria
Functional Polymorphism of the Glucocorticoid Receptor Gene associates 







Comparison of frequencies of GR polymorphisms 
In subjects of the patient group, a significantly lower frequency of heterozygous TthIIII 
carriers compared to the control group was found: 36.9% vs. 45.0%  (p= 0.03, OR 
0.51, 95% CI: 0.27-0.95). We found no differences in frequency of homozygous TthIIII 
variation, nor any other differences in genotype frequency between healthy controls 
and the group of bipolar patients (Table 3).  Age had no significant effect: OR 1.0, 95%CI 
0.98-1.01. Male gender appeared to have a significant effect in this analysis: OR 0.40, 
95%CI 0.28-0.57, p<0.0001.
We found a non-significant trend for a lower frequency of the A/G or G/G variation in 
exon 9β in the patient group vs. the control group (respectively 24.5% vs. 31.0%, OR 
0.76, 95%CI= 0.5-1.0; p=0.14, corrected for age and gender).  Both age and gender had 
significant influences (for age: OR 1.04, 95%CI 1.02-1.05, p=0.000; for male gender: OR 
0.52, 95%CI 0.37-0.72, p<0.0001).
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Table 3 Frequencies of five polymorphisms of the Glucocorticoid Receptor Gene 
in healthy control subjects and bipolar patients, and frequencies in patients 
with 0-5 hypomanic and manic episodes versus patients with >5 manic epi-
sodes; number (percentage) 
Legend: *p= 0.03, OR 0.51 (95% CI: 0.27-0.95); ** p= 0.14, OR 0.76 (95% CI:  
0.53-1.09)
#p= 0.04, OR= 0.5 (95% CI:  0.27-0.98); ## p = 0.02, OR 0.46 (95% CI: 0.23-0.91)
Healthy controls Bipolar patients
Polymorphism with 0-5 manic and 
hypomanic episodes
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Association of the GR polymorphisms with number of depressive and 
manic episodes 
We further explored the association between number of mood episodes and the GR 
polymorphisms (Table 3). The number of episodes was dichotomously analyzed in four 
groups, based on the median number of episodes (see Table 2): the number of depressive 
episodes is 0 to 6 or more than 6, and the number of manic and hypomanic episodes is 0 
to 5 or more than 5.  Table 3 shows the frequencies of the GR polymorphisms in relation 
to number of manic and hypomanic episodes. 
The most important finding is the difference in frequency of the exon 9β polymorphism 
between the group of patients with more and the group with less than 5 manic and hypo 
manic episodes (respectively 19.2% and 31.1%; p= 0.04, OR 0.5, 95%CI = 0.27-0.98). 
This difference is even more significant for heterozygous carriers (respectively15.2% and 
27.7%; p=0.02, OR 0.46, 95%CI: 0.23-0.91). In both analyses age and gender had no 
significant effects. Additional analyses using nearby cut- off points yielded similar results. 
With respect to the number of depressive episodes, no significant differences between 
the group of patients with 0-6 episodes and the group of patients with >6 episodes, were 
found in the frequency of exon 9β-carriers.
None of the other comparisons (see Table 3) reached statistical significance. 
Discussion
The major findings in this study are the lower prevalences of the TthIIII and exon 
9β polymorphisms in the patient group compared to controls. These findings are 
consistent, since the 9β polymorphism is always present in combination with the TthIIII 
polymorphism, as is shown in Figure 1. Furthermore, those patients who carry the exon 
9β polymorphism have significantly fewer manic episodes. This may indicate that the 
presence of the exon 9β-polymorphism has a (subtle) protective effect on both the 
prevalence and the clinical course of the disease. Clearly, these findings need replication 
to confirm the observations.
A possible limitation of the chosen cut-off points in number of episodes (mania more 
or less than 5, and depression more or less than 6) is that this is not based on clinical 
guidelines, but only on median number of episodes in our study population.  However, 
other cut-off points in number of manic and hypo manic episodes yielded similar results. 
In future research, the course or severity of the disease will have to be carefully defined 
and prospectively followed to test these results. 
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We found no differences in the frequencies of the other GR gene polymorphisms 
between the controls and the patient group. In a recent study by Van Rossum (15) a 
higher prevalence of  BclI and ER22/23EK polymorphisms was found in 495 hospitalized, 
severely depressed patients (13.2% with BD, 86.8% unipolar depressive disorder). In our 
study, patients differed considerably with respect to the severity of their illness, and none 
of the patients suffered from unipolar depressive disorder. Furthermore, the number of 
patients in our study was smaller, which potentially resulted in a lack of statistical power 
to detect minor differences. 
This negative finding seems to indicate that these polymorphisms have no major effect 
on the etiology of the illness. 
This study was the first to explore the theoretically relevant association between BD and 
genetically determined stress vulnerability as reflected by different GR polymorphisms. 
A limitation of this study is that the findings are not replicated yet in another population 
of patients with BD. It is clear that further research is needed to confirm these results.
Both findings in this study (the lower frequency of the TthIIII and exon 9β polymorphisms 
in the patient group, and the association of the G/A-polymorphism in exon 9β with less 
manic episodes) are in line with the modest conclusion that this haplotype may be 
associated with a protective effect on the illness. We found significant associations, but 
we cannot rule out that these associations are explained by a type I error.
The question remains, what could be the possible cause of the negative relationship 
between BD and the G/A-polymorphism in exon 9β of the GR gene. This polymorphism 
has a stabilizing effect on the mRNA levels of the GR-β isoform (19). This could result 
in a rise of GR-β levels, leading to a relative resistance to glucocorticoids since GR-b 
has been shown to exert a dominant negative inhibition of the active GR-α isoform. 
This polymorphism is also associated with the functioning of the immune system 
(19,20). This seems important, as several abnormalities in the functioning of the 
immune system are present in patients with BD. These include elevated IL-6 production, 
increased risk of autoimmune phenomena (such as autoimmune thyreoiditis, and 
raised thyroperoxidase auto-antibodies) and abnormalities in monocyte differentiation, 
indicating a dysregulation of the immune system (21, 22). However, the mechanisms for 
these associations among GR-β expression, changes in the functioning of the HPA-axis, 
and abnormalities in the immune system are largely unknown. 
As mentioned in the introduction, there is ample evidence of dysregulation of the HPA-
axis in patients with BD, possibly due to GR dysfunctioning. Our study found evidence 
that two commonly occurring GR gene polymorphisms are associated with the clinical 
manifestation and the course of bipolar disorder. Further research is needed to elucidate 
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the influence of stress vulnerability as revealed by GR and MR gene polymorphisms on 
the prognosis of BD. This might offer avenues for the development of new therapeutic 
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The Hypothalamus-Pituitary-Adrenal (HPA)-axis is often found to be dysregulated 
in Bipolar Disorder (BD) while stress and changes in day-night rhythms can trigger 
a new mood episode. Genetic variants of the Glucocorticoid Receptor (GR)- and 
Mineralocorticoid Receptor (MR)-gene influence both the reactivity of the stress-
response and associate with changes in mood. In this study we tested the hypothesis 
that these polymorphisms associate with different clinical characteristics of BD.
Method. We studied 326 outpatients with BD and performed GR genotyping of the 
TthIIII, ER22/23EK, N363S, BclI, and 9β polymorphisms, as well as MR genotyping of the 
2G/C and I180V variants. All patients were interviewed for clinical characteristics.    
Results. Seasonal patterns of hypomania are related to the BclI haplotype and the 
TthIIII+9β haplotype of the GR gene (respectively crude p=.007 and crude p=.005). 
Carriers of the ER22/23EK polymorphism had an almost 8 years earlier onset of their 
first (hypo) manic episode than non-carriers (crude p=.004, after adjustment p=.016). No 
evidence for a role of the MR in modifying clinical manifestations was found.
Conclusion.  Polymorphisms of the GR–gene are factors which influence some clinical 




Bipolar disorder (BD) is a common mood disorder with a prevalence of around 2% in the 
general population. Several subtypes are distinguishable, of which Bipolar Disorder type 
1 (BD1) is more prevalent than Bipolar Disorder type 2 (BD2) (1). BD1 is characterized by 
at least 1 manic episode and BD2 is characterized by at least one hypomanic episode and 
one depressive episode. The course and characteristics of the disease are highly variable 
and unpredictable. A clinically remarkable characteristic of BD are seasonal patterns of 
mood episodes in around 25% of all BD patients (2). Currently known predictors of an 
adverse course and higher severity include incomplete recovery between episodes, a 
history of rapid cycling and more than 10 episodes in the medical history, a history of 
childhood abuse, co-morbid panic disorder, substance abuse (3) and suicide attempts 
(4). 
Stress and (abrupt) changes in day-night rhythms are common triggers of new mood 
episodes (5-7). The Hypothalamic Pituitary Adrenal (HPA)-axis is a central component of 
the stress-response and there is ample evidence that in BD the HPA-axis is dysregulated 
(8, 9). The most prominent finding is hypercortisolism in challenge tests like the 
Dexamethason Suppression Test (DST) and the Dexamethason/ Corticotropin Releasing 
Hormone (DEX/CRH)-Test. Moreover, hypercortisolism after the DEX/CRH-test is found 
during depressive episodes, manic episodes, as well as during remission, as compared to 
healthy controls (Schmider et al.,to healthy controls and family members (10), indicating 
that hypercortisolism is a feature predominantly observed during the stress responses 
and during active disease, but not in basal conditions.
The cortisol signal is mediated by two receptors, the low affinity Glucocorticoid Receptor 
(GR) and the high affinity Mineralocorticoid Receptor (MR). Under non-stress conditions, 
the low levels of cortisol already occupy a substantial number of the MR and GR, while 
only during stressful situations high levels of cortisol predominantly bind to the GR 
(11, 12). The activity of both these receptors regulates the stress-response, including 
the HPA axis and the autonomic output (13-15). Furthermore, the clinical relevance 
of these findings has become clear in the therapeutic effect of GR-antagonists, like 
mifepristone, improving mood and neurocognitive functioning in bipolar depression 
(16). Administration of the MR-agonist fludrocortisone as add-on to antidepressants 
greatly speeded up treatment response in depressed patients (17). The mood stabilizers 
lithium and valproate may mediate their therapeutic effects by up regulation of central 
GR (18) and by influencing GR-co-chaperone proteins (19).
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Several polymorphisms of the GR- and MR-gene are involved in regulating the HPA-axis 
and may contribute to differences in the sensitivity of the stress-response (12, 20, 21), 
they are summarized in Figure 1. 
Figure 1. Schematic overview of the GR and MR gene structures with their respective 
most frequent haplotypes. The orientation of the gene is marked by arrows, with the 
genes transcribed from left to right. Some exons are not translated into protein (light 
gray). The gene encoding the GR consists of 17 exons, with the untranslated exons 1A-1H 
and 9a and 9b resulting in different mRNA splice variants. The five SNPs (rs 10052957 
[Tth///I], rs6189/rs6190 [ER22/23EK], rs6195 [N363S], rs41423247 [BclI], and rs6198 
[9β]) that were genotyped are indicated with arrows. Six main haplotypes are known 
(52). The gene encoding the MR consists of ten exons, exon 1a till exon 9. The two 
SNPs that were genotyped are indicated with arrows. The functional MR -2 G/C SNP 
(rs2070951) is located in exon 2, two nucleotides before the first translation start site. 
The functional MR I180V SNP (rs5522) is located in exon 2 and results in an Isoleucine to 
Valine amino-acid change. Both SNPs are located in a haplotype bin that extends into the 
promoter region. Three main haplotypes are known (53). 
114
Chapter 5
GR polymorphisms have repeatedly been associated with mood disorders; the BclI 
and the ER22/23EK polymorphisms of the GR gene and, to a lesser extent the 9β 
polymorphism, may be most prominently associated with psychopathology (for review: 
(22)). In addition, two polymorphisms in the MR gene, the I180V SNP and the -2G/C SNP, 
have recently been found to be associated with the regulation of the stress-response 
in healthy subjects (13, 23).  The I180V SNP was found to be associated with a higher 
frequency of depressive symptoms in an elderly cohort of participants aged 85 years and 
above (24) and with neuroticism in adult depressed patients (25).
Together these findings suggest a role of these GR- and MR-gene polymorphisms in the 
course and severity of bipolar mood disorders. To our knowledge no clinical study focused 
on the relationship between GR and MR polymorphisms and clinical characteristics of 
BD. We investigated whether different polymorphisms are associated with different 
clinical manifestations of BD.
2.  Materials and Methods
2.1  Study design
This is a cross-sectional study in patients with BD. The study protocol was approved by the 
Medical Ethical Committee in Utrecht (METiGG) and has been carried out in accordance 
with the Declaration of Helsinki. All participants signed for informed consent. 
2.2  Study population
All 702 patients, diagnosed and treated in the Department of Mood Disorders, PsyQ 
The Hague, with BD type 1, BD type 2, cyclothymia (a cyclic pattern of mood episodes 
which do not completely fulfill DSM-IV criteria), or bipolar disorder Not Otherwise 
Specified according DSM-IV-TR diagnosis, and older than 18 were selected to be asked 
to participate in this study. They were requested during a time frame of two years, 
by their psychiatrist and psychologist or by letter. Of these 702 patients 328 patients 
(46.7%) who responded and agreed to participate were enrolled in the study. The other 
374 patients did not respond for largely unknown reasons, as they did not reply on 
repeated invitation by letter. Two more participants were excluded from the analysis, 
because only genotypic data and no clinical data were collected. Therefore, the present 
analyses were based on 326 (46.4%) subjects, yet some variables were missing in some 
participants due to logistical reasons. The included 326 patients did not differ from 
the 304 non-participating patients with respect to gender (39.9% male versus 41.4% 
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male respectively, p=.53). The included patients differed from the non-responders with 
respect to BD subtype (80% BD1, 19% BD2 and 1% BD NOS/cyclothymia versus 68% BD1, 
26% BD2 and 6% BD NOS/cyclothymia, respectively, p<.001) and with respect to age 
(mean 48.0 ± 11.2 years versus 45.7 ± 12.5 respectively, p=.02) . 
Data on seasonal patterns were complete in 301 (92.3%) subjects for depressive episodes, 
298 (91.4%) subjects for manic episodes and 295 (90.5%) subjects for hypomanic 
episodes. Data on number of episodes and age of onset for mania were complete in 
289 (88.7%) subjects and for depressive episodes in 292 (89.6%) subjects. Data on BD 
subtype were complete in 309 (94.8%) subjects. Age, gender and the presence of an 
anxiety disorder were assessed in all participants.
2.3  Assessments 
All patients were diagnosed with bipolar disorder by a psychiatrist during their first visit 
on our Department. For the purpose of this study they were subsequently interviewed 
by one out of three trained psychologists who collected sociodemographic and disease 
characteristics, under supervision of a psychiatrist. Diagnostic status according to the 
DSM-IV-TR was assessed with a standardized diagnostic interview the Dutch version of 
the MINI International Neuropsychiatric Interview Plus (version 5.00-R; MINI-PLUS (26)). 
The age of onset of first symptoms of either (hypo)mania or depression, the number 
of episodes of (hypo)mania and depression, and the presence of co morbid anxiety 
disorders (according DSM-IV-TR) were assessed with the MINI. Psychiatric co-morbidity 
was assessed with the MINI and included lifetime and current anxiety disorders, 
somatoform disorders, eating disorders, and substance disorders. Current anxiety 
disorder was summarized into one dichotomous variable representing the presence or 
absence of any anxiety disorder. Suicide risk was classified according to the MINI in low, 
moderate and high risk.
 Bipolar Disorder was further characterized by the Questionnaire for Bipolar Illness-
Dutch Translation (QBP-NL) (27, 28). The QBP-NL BD was used to subtype BD into BD1, 
BD2, cyclothymia or BD Not Otherwise Specified (BD NOS). Due to small numbers the last 
two variables were aggregated in BD NOS. All patients were questioned in detail about 
seasonal patterns of depressive, hypomanic and manic episodes with the QBP-NL. Mood 
episodes were classified according to seasonal patterns, which was defined as whether 
the onset of the episode (i.e., depressive, hypomanic, or manic) was predominantly 
in the same season (winter, spring, summer or autumn). Age of onset and number of 
episodes were nominal variables, all other variables were categorical.
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2.4  DNA analysis
From all 326 patients, blood samples of 40 ml were drawn with standard venapuncture 
techniques, collected in EDTA tubes, to analyze GR and MR gene polymorphisms (see 
Figure 1). Genomic DNA was isolated from fresh blood samples using the Puregene whole 
blood DNA-extraction kit (Gentra Systems Inc; MN). Genotyping was performed through 
PCR-based techniques. GR genotyping was performed in the Laboratory of Endocrinology 
of the Erasmus MC Rotterdam. MR genotyping was performed by Department of 
Pharmacology in Leiden in collaboration with the aforementioned laboratory in 
Rotterdam. Allelic discrimination was performed to genotype the subjects, using TaqMan 
Universal PCR master mix, primers and probes (Applied Biosystems, Nieuwerkerk aan 
den IJssel, Netherlands) and a Taqman ABI Prism 7900 HT Sequence Detection System 
as previously described (15, 29). Reaction components and amplification parameters 
were based on the manufacturer’s instructions using an annealing temperature of 60°C 
and optimized concentrations for primers of 400 nmol/L for each polymorphism. The 
genotypes of all heterozygous and homozygous carriers of the polymorphisms were re-
analyzed and yielded identical genotypes. 
GR genotyping was completed for TthIIII in 307 (94.2%) subjects, for the ER22/23EK 
in 310 (95.1%) subjects, for N363S in 313 (96.0%) subjects, for Bcl1 in 310 (95.1%) 
subjects and for 9β in 314 (96.3%) subjects. MR genotyping was completed for -2G/C 
in 302 (92.6%) subjects and for I180V in 305 (93.6%) subjects. Due to small numbers, 
frequencies of the ER22/23EK (GA=17, AA=2), N363S (AG=20, GG=0) and I180V (AG=67, 
GG=10) Single Nucleotide Polymorphisms (SNPs) were combined into one group for the 
hetero- and homozygote carriers of the minor allele.
2.5  Statistical analysis
Haplotypes were created with SNPHAP (version 1.3, www-gene.cimr.cam.ac.uk/clayton/
software/snphap.txt). All SNPs were tested for Hardy-Weinberg equilibrium. Thesias 
(Tregouet & Garelle, 2007) was used to assess inter-marker linkage disequilibrium 
scores (LD scores), expressed as D’. All further analyses were performed with Statistical 
Packages for Social Sciences (SPSS) version 17. 
For analyses of baseline data t-tests and chi-square tests were used, when appropriate. 
All variables were normally distributed, except for “number of manic episodes” and 
“number of depressive episodes”. These two positively skewed variables were therefore 
log transformed in all analyses and back-transformed geometric means values were 
presented in our results. Analyses of disease characteristics in relation to SNPs and 
haplotypes (see Figure 1) were performed with t-tests, Analysis of Variance (ANOVA) 
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and Chi Square tests. Adjustment for age, sex and subtype of BD was performed with 
Analysis of Covariance (ANCOVA) and multivariable logistic regression analysis. Results 
were considered statistical significant with p-value < 0.01 for GR SNPs and haplotypes and 
with a p-value <.025 for MR SNPs and haplotypes, to take multiple testing into account 
for SNP analyses. Post hoc Dunnett’s method was used in post hoc tests to correct for 
multiple testing in haplotype analyses.
3.  Results 
3.1  Patient characteristics
Sociodemographic and disease characteristics are summarized in Table 1. In total 326 
patients were enrolled in this study, of whom 80% were diagnosed with BD1, 19% with 
BD2, and 1% with BD NOS. Age ranged from 18-80 years, with a mean of 48 years (SD 
11.2). In a total of 94 patients (31.2%) a seasonal pattern was present. Of all patients 
with seasonal depressive episodes, 87% had autumn and/or winter episodes. Eighty per 
cent of all seasonal manic episodes and 93% of all seasonal hypomanic episodes were 
spring/summer episodes. In further analyses seasonal patterns were dichotomized for 
hypomanic, manic and depressive episodes. 
3.2  Genotypes and haplotypes
All SNPs were in Hardy-Weinberg equilibrium, except for ER22/23EK (χ2 = 8.15, p<.01). 
The frequencies of the GR and MR Single Nucleotide Polymorphisms (SNPs) are presented 
in Tables 2 and 3. Comparisons between the GR SNPs resulted in different LD scores, D’ 
ranged from 0.2-1.0 with an average of 0.9. Linkage of the two MR SNPs was high, with 
D’=1.0. Haplotypes created with SNPHAP was successful in 99.9% for the GR gene and 
100% for the MR gene. Haplotypes are described in Figure 1, and numbering as used in 
Table 4 is defined there. Both GR and MR haplotypes 1 were the most prevalent wild-
type haplotypes, and were therefore used as the reference category in further analyses. 
Age and sex distributions did not differ among the GR and MR haplotypes.  
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Table 2. Association of GR and MR gene polymorphisms with co-morbid anxiety disorder 
and seasonal pattern in 326 BD patients
Geno-
type











CC 155 (50.5) 36 (23.2) .12 39 (26.7) .64 18 (12.7) .67 10 (7.1) .25
CT 118 (38.4) 25 (21.2) 34 (31.5) 15 (13.9) 14 (13.2)
TT 34 (11.1) 13 (38.2) 8 (25.0) 6 (18.8) 4 (12.5)
rs6189 
(ER22/23EK)
GG 291 (93.9) 73 (25.1) .05 78 (28.7) .32 36 (13.5) .70 28 (10.6) .15
GA+AA 19(6.1) 1 (5.3) 3 (17.6)  3 (16.7) 0
rs6195 (N363S) AA 293 (93.6) 70 (23.9) .91 80 (29.5) .06 38 (14.3) .59 27 (10.2) .48
AG 20(6.4) 5 (25.0) 2 (10.0) 2 (10.0) 1 (5.3)
rs41423247 
(Bcl1)
CC 125 (40.3) 27 (21.6) .74 28 (24.1) .29 17 (15.0) .70 7 (6.2) .05
CG 138 (44.5) 35 (25.4) 38 (29.5) 16 (12.3) 13 (10.2)
GG 47 (15.2) 12 (25.5) 16 (36.4) 7 (17.1) 8 (19.0)
rs6198 (9β) AA 227 (72.3) 53 (23.3) .25 58 (27.4) .49 26 (12.4) .45 16 (7.7) .02
AG 75 (23.9) 22 (29.3) 22 (32.4) 12 (18.2) 12(18.2)




GG 86 (28.5) 21 (24.4) .85 22 (27.5) .98 9 (11.3) .79 10 (12.3) .70
GC 140 (46.4) 34 (24.3) 35 (26.7) 18 (14.1) 11 (8.7)
CC 76 (25.1) 21 (27.6) 20 (28.2) 10 (14.7) 7 (10.3)
rs5522 (I180V) AA 229 (75.1) 56 (24.5) .75 62 (29.0) .29  29 (13.8) .63 22 (10.6) .63
AG+GG 76 (24.9) 20 (26.3) 16 (22.5)  8 (11.6) 6 (8.6)
Associations are tested with Chi square tests and logistic regression analyses with age, 
sex and subtype of BD as covariates. P values of Chi square analyses are mentioned. All 
results are written as n(%).
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Table 3. Association of GR and MR gene polymorphisms and clinical characteristics in 
326 BD patients 
Geno-
type N (%)
Age of onset of 
depression















CC 155 (50.5) 24.5 (11.8) .53 28.6 (11.0) .74 6.4 (5.2-7.8) .84 7.7 (6.4-9.3) .76
CT 118 (38.4) 28.8 (11.9) 29.5 (12.8) 6.2 (4.9-8.0) 7.8 (6.1-9.8)
TT 34 (11.1) 26.5 (11.8) 30.4 (12.3) 7.3 (4.1-12.5) 9.2 (5.7-14.4)
rs6189 
(ER22/23EK)
GG 291 (93.9) 26.1 (12.0) .26 29.7 (12.1) .004 6.4 (5.4-7.6) .73 8.2 (7.0-9.6) .05
GA+AA 19(6.1) 22.8 (10.9) 21.9 (9.3) 5.8 (2.5-12.5) 4.3 (2.0-8.4)
rs6195 
(N363S)
AA 293 (93.6) 26.0 (11.9) .71 29.4 (12.0) .15 6.3 (5.4-7.5) .76 8.0 (6.9-9.4) .65
AG 20(6.4) 24.9 (11.5) 25.6 (10.6) 6.9 (3.2-14.0) 6.4 (3.1-12.2)
rs41423247 
(Bcl1)
CC 125 (40.3) 25.0 (11.9) .24 27.4 (11.5) .05 5.8 (4.7-7.2) .62 7.8 (6.1-9.9) .30
CG 138 (44.5) 27.1 (11.9) 31.2 (11.7) 6.5 (5.2-8.1) 7.3 (6.0-8.9)
GG 47 (15.2) 23.0 (11.2) 27.7 (12.7) 7.2 (4.4-11.3) 10.1 (7.0-14.5)
rs6198 (9β) AA 227 (72.3) 25.0 (11.7) .59 29.0 (11.7) .96 6.5 (5.5-7.8) .87 8.0 (6.8-9.4) .71
AG 75 (23.9) 27.0 (12.0) 29.3 (12.1) 6.1 (4.3-8.4) 7.2 (5.2-9.9)
GG 12 (3.8) 28.2 (13.3) 30.5 (15.0) 5.7 (2.2-13.0) 9.4 (3.9-21.2)
MR SNP      
rs2070951 
(–2G/C)
GG 86 (28.5) 26.4 (12.3) .52 29.4 (12.5) .54 5.4 (4.0-7.3) .36 7.4 (5.6-9.8) .75
GC 140 (46.4) 24.7 (11.3) 28.3 (11.4) 6.5 (5.3-8.1) 8.5 (6.8-10.5)
CC 76 (25.1) 26.3 (12.2) 30.6 (11.9) 7.4 (5.3-10.2) 7.7 (5.7-10.1)
rs5522 
(I180V)
AA 229 (75.1) 25.5 (12.2) .45 28.9 (12.0) .52 6.1 (5.0-7.3) .44 7.9 (7.7-9.5) .71
AG+GG 76 (24.9) 26.8 (11.5) 30.0 (11.9) 7.4 (5.3-10.3) 7.8 (5.6-10.7)
Associations are tested with ANOVA and t-test analyses, and ANCOVA to adjust for 
age (number of episodes), sex and BD subtype (age of onset and number of episodes). 
P-values of t-tests and ANOVA’s are mentioned. Number of episodes variables were both 
log transformed during analyses, and back transformed in this table.
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Table 4. Association of GR and MR gene haplotypes with clinical characteristics in BD 
326 patients 
Variables Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4 Haplotype 5 Haplotype 6 P 
value
No. of haplotypes; 
n (%)
289 (44.3) 155 (23.7) 91 (13.9) 78 (11.9) 21 (3.2) 19 (2.9)
Age (yr); mean (SD) 47.3 (11.2) 47.9 (10.7) 50.0 (11.4) 49.1 (11.9) 46.2 (10.3) 46.7 (11.1) .34
Male sex; n (%) 111 (38.7) 64 (41.6) 39 (42.9) 25 (32.5) 12 (57.1) 8 (42.1) .40
Age of onset of 
depression; mean 
(SD)
25.6 (11.8) 25.8 (12.2) 26.0 (11.7) 28.2 (12.0) 22.7 (10.8) 25.5 (11.5) .53
Age of onset of 
(hypo)mania; 
mean (SD)








7.5 (6.4-8.0) 7.6 (6.3-9.2) 9.0 (6.9-11.8) 8.8 (6.3-12.0) 4.7 (2.7-7.9) 7.0 (3.4-13.3) .35
Current anxiety 
disorder; n (%)
67 (23.3) 37 (24.0) 27 (29.7) 23 (29.9) 1 (4.8) 5 (26.3) .21
Seasonal pattern 
depression; n (%)
67 (25.5) 46 (32.2) 25 (30.1) 21 (29.2) 5 (26.3) 2 (10.5) .39
Seasonal pattern 
mania; n (%)
33 (12.6) 19 (14.0) 12 (14.1) 11 (16.4) 5 (25.0) 2 (10.5) .71
Seasonal pattern 
hypomania; n (%)
14 (5.4) 19 (14.0)** 10 (12.0)* 12 (17.1)** 0 1 (5.6) .008
Associations of haplotypes are always in comparison with haplotype 1 (wildtype). 
Associations of haplotypes and dichotomous variables are tested with chi square tests 
and adjusted in logistic regression analyses for age, sex and subtype of BD. P-values 
are considered significant when <.01 to correct for multiple testing. Associations of 
haplotypes and continuous variables are tested with ANOVA. ANCOVA is applied to 
adjust for age, sex and subtype of BD. Post Hoc Dunnett’s methods were used in post-hoc 





3.3  Glucocorticoid receptor (GR) genotype and bipolar phenotypic 
characteristics
Table 3 shows that the ER22/23EK carriers had slightly different characteristics with 
respect to age of onset. These carriers were significantly younger during the first (hypo)
manic episode (crude 29.7 vs. 21.9, p<.004; however, after adjustment this was only a 
statistical trend with ages of respectively 29.5 vs. 23.1, p=.016). The onset of the first 
depressive episode also showed a tendency to a lower mean age in ER22/23EK carriers 
vs. noncarriers, but did not reach statistical significance.
Analyses on haplotype level (table 4) revealed that there was a tendency for a difference 
in age of onset of (hypo) mania among GR haplotypes (p=.03). Further analysis revealed 
a trend for an earlier age of onset of mania in subjects with GR haplotype 5 (crude 28.8 in 
GR haplotype 1 vs. 21.7 in GR haplotype 5, p=.06; after adjustment 29.0 vs. 22.2, p=.02). 
Number of episodes and age of onset of depressive episodes did not differ significantly 
among haplotypes.
Analyses at haplotype level showed that a seasonal pattern of hypomania was more 
frequent in carriers of the GR haplotypes 2 and 4 (Table 4). In GR haplotype 1 the 
frequency of seasonal hypomania was 5.4%. In GR haplotype 2 this was 14.0% (crude 
p=.004; after adjustment p=.007, OR= 2.83, 95%Confidence Interval [CI]:1.3-6.0), in GR 
haplotype 4 this was 17.1% (crude p=.001; after adjustment p=.005, OR=1.50, 95% CI: 
1.13-1.98). GR haplotype 3 revealed a tendency for an association with seasonal pattern 
of hypomania with a frequency of 12.0% (crude p=.04; after adjustment p=.06, OR= 1.52, 
95% CI: 0.98 - 2.34).
3.4  Mineralocorticoid receptor (MR) genotype and bipolar 
phenotypic characteristics
Table 2 and 3 present the associations between disease characteristics in relation to 
MR SNP analyses. No statistically significant associations between clinical disease 
characteristics of BD and any of the MR SNPs or haplotypes were found. 
4.  Discussion
In this study we investigated whether GR- en MR-gene polymorphisms were 
correlated with clinical manifestations of BD. We found evidence for a minor role of 
GR polymorphisms in influencing clinical aspects of BD. First, we found an association 
between seasonal patterns of hypomania and the BclI haplotype 2 and the TthIIII+9β 
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haplotype 4. This result was also found as a statistical trend association at the SNP level 
for the BclI SNP and the 9β SNP. Second, carriers of the ER22/23EK SNPs (located in 
haplotype 5) had an almost 8 years earlier onset of their first (hypo) manic episode 
than non carriers. Similar results were obtained in the haplotype analysis, showing that 
the TthIIII+9β+ER22/23EK haplotype 5 was associated with 7 years earlier age at the 
onset of the first manic episode. No evidence for a role of the MR in modifying clinical 
characteristics was found.
To our knowledge this is the first study showing a relationship between seasonal 
patterns of mood episodes in BD and genetic variation in the GR gene. Several studies 
have investigated the relation between seasonal changes of the HPA-axis responsivity 
in animals, healthy humans and depressed inpatients. Some studies found elevated 
morning cortisol levels in healthy humans during winter (30, 31). However, in a study 
with depressed patients a decreased sensitivity to Dexamethasone feedback of the HPA-
axis was measured in autumn and spring, and an increased sensitivity in summer and 
winter (32). In mice the highest GR expression was found in January (33), also illustrating 
an increased GC sensitivity during winter. In parallel, mice studies showed which higher 
GR expression in the hippocampus of mice during short days and a faster return to basal 
cortisol levels after restraint (34). One of the mechanisms leading to seasonal changes 
in cortisol sensitivity is thought to be the direct effect of change in day lengths on the 
activity of the suprachiasmatic nucleus (SCN) in the hypothalamus (35, 36). This is thought 
to be mediated by reduced expression of clock genes in the suprachiasmatic nucleus 
(SCN) of the anterior hypothalamus and the hippocampus, which was found in European 
hamsters (37).  In order to understand the relation between seasonal changes of the HPA-
axis and mood episodes in BD patients with GR SNPs, it is important to emphasize that 
these SNPs alter HPA-axis sensitivity. The BclI and the N363S SNP are known to increase 
Glucocorticoid sensitivity (38-40). The 9β and the ER22/23EK SNP are both associated 
with a mild resistance for GCs (41, 42). We hypothesized that these genetic variants in 
corticosteroid receptor genes confer susceptibility for the precipitation of psychiatric 
disorders under less favorable conditions (43). In the context of seasonal changes these 
SNPs could bring the precisely regulated HPA-axis off balance when adjusting for seasonal 
changes. This gene-variant – environment interaction might well play a role in patients 
with BD where seasonal changes of daylight are known to influence mood (44), which 
could be worsened by the described SNPs. We found associations between haplotypes 2 
(BclI) and 4 (TthIIII+9β) only with seasonal patterns of hypomanic episodes, and not with 
manic episodes. This is in line with the finding of a 10-year prospective study among 302 
bipolar patients, revealing more seasonal episodes in patients with BD2 (2). Besides, 
when looking at seasonal patterns in mood episodes, irrespective of subtype of bipolar 
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disorder, a clear association with depression as well as with hypomania was found, but 
not with mania.  
The finding that carriers of the ER22/23EK SNPs had an earlier onset of the first (hypo) 
manic episode has not been reported earlier. Earlier onset may be related to a worse 
outcome (27, 45). The finding that carriers of the ER22/23EK SNP were younger when the 
first symptoms of BD appeared and may consequently have had a higher risk on a poorer 
outcome with more mood episodes, is in accordance with previous studies demonstrating 
that the ER22/23EK variant correlated to an increased susceptibility for dysregulation of 
mood (17, 46-49). On the other hand these studies indicate a more beneficial outcome 
for carriers of these SNPs (or this haplotype). In line with the hypothesis of a beneficial 
outcome, we found a statistical trend towards less prevalent anxiety disorders in patients 
with the ER22/23EK variant (5.3% vs. 25.1% in non carriers). Previously, Russcher et al 
showed that the transcriptional activity of the GR in ER22/23EK carriers is decreased 
because more of the less transcriptionally active GR-A isoform is formed, which seems 
to be caused by altered secondary mRNA structure (50). The subtle resistance for GCs 
in ER22/23EK carriers may result in compensatory higher cortisol levels, which may 
have tissue-specific increased effects in the limbic system yielding mood disturbances. 
Another explanation we could speculate on is that the insensitive GR signaling due to the 
ER22/23EK variant leads to intracellular deficit of cortisol in the limbic system yielding an 
increased vulnerability for mood disturbance, and at the same time a protective effect 
on the long-term with respect to other brain areas related to anxiety. However, further 
research is needed to confirm these speculations and elucidate the neurobiological 
pathways.
The MR is known to be involved in the regulation of both low levels of cortisol and the 
reactivity of the stress-response following a challenge (13, 15). There is some evidence 
for an association between MR gene polymorphisms and social stress situations in 
adults. In one study (24) an association between depressive symptoms and the V-allele 
has been found, and another study provides evidence for an association between MR-
SNPs and neuroticism (25). No such associations were found in adolescents (51). Since 
we found no evidence for a role of the MR in modifying number of episodes, age of onset 
and co morbidity in BD this might indicate that environmental influences predominantly 
interact with gene-variants of the GR but less so with the MR.
There are several limitations in this study. First, the ER22/23EK SNPs were not in Hardy 
Weinberg equilibrium, which may be explained as a chance finding in combination with 
a low allele frequency. Yet, it is unlikely that this deviation influenced the outcomes of 
the analyses. A second limitation of this study is the absence of measurements of serum 
cortisol levels and other endocrinological clinical parameters. Serum cortisol could 
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provide information about the potential mediating effects of cortisol on the relationship 
between GR and MR SNPs and clinical characteristics in BD patients. However, serum 
cortisol measurements may fail to adequately reflect cortisol’s true impact because of 
the circadian rhythm of cortisol levels and the pulsatile way cortisol is secreted. Also, 
large daily variations due to e.g. acute stress or infection are also an important limitation 
of measuring cortisol levels. Using information from genetic variations known to be 
associated with altered cortisol sensitivity may better contribute to understanding the 
relationship between glucocorticoids and BD. Third, we used a relatively small sample 
size for a genetic association study, although we used functionally characterized genetic 
variants. Moreover, we were not able to perform a replication study in a different sample. 
Fourth, in this study no data were obtained with regard to premorbid functioning, known 
to be an important predictor for outcome of first episode psychosis. However, information 
on premorbid functioning is often based on patients recalling and difficult to assess in 
an unbiased way.  Fifth, our study design was cross-sectional with clinical data gathered 
retrospectively, leading to potential recall bias. This could have affected the reliability 
of the retrospectively collected data on age of onset. Patients were questioned about 
their first illness symptoms, which hamper a sharp differentiation between hypomania 
and mania symptoms. Finally, BD is genetically a very complex disease. Besides HPA-axis 
related factors, numerous other environmental and genetic factors also influence clinical 
BD characteristics. Therefore, findings on number of episodes and seasonality need to 
be further explored and replicated in larger and prospective studies. Future prospective 
studies should include clinical characteristics like cognition and physical health. The 
ultimate goal is to obtain more insight in risk factors for poor outcome and subsequently 
develop individualized therapeutic interventions.  
We conclude that GR SNPs affect several clinical manifestations of BD. Seasonal mood 
episodes are likely to develop in BD patients with altered HPA-axis regulation, at least 
partly caused by genetic variation in the GR. Together with natural changes of GC 
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Dysregulation of the hypothalamic-pituitary-adrenal (HPA-)axis is hypothesized to play a 
role in the pathogenesis of bipolar disorder (BD). Conflicting results have been reported 
when saliva or serum was used to measure cortisol levels. A recently developed method 
is to measure cortisol in scalp hair, with one cm of scalp hair representing one month. 
We studied whether there are differences in long-term hair cortisol levels between 
BD patients and healthy individuals and whether there are associations between hair 
cortisol and disease characteristics.
Methods 
Hair samples were collected in 100 BD patients and 195 healthy controls. Long-term 
cortisol levels were determined in 3 cm hair segments. Saliva samples were collected on 
two consecutive evenings. Documented disease characteristics were disease state, age 
of onset and psychiatric co-morbidity.
Results
Hair cortisol levels were not statistically different in BD patients compared to healthy 
controls (p=0.233) and were not associated with the disease state at the moment of 
sample collection (p=0.978). In the subgroup of patients with age of onset ≥30 years, hair 
cortisol levels were significantly elevated compared to the subgroup with age of onset 
<30 years and to healthy controls (p=0.004). Psychiatric co-morbidity was associated with 
elevated cortisol levels (44.87 versus 31.41 pg/mg hair; p=0.021), with the exclusion of 
panic disorder, which was associated with decreased cortisol levels (22.13 versus 34.67 
pg/mg hair; p=0.019).
Conclusions 
Elevated long-term cortisol levels might play a role in a subgroup of patients with BD. 





Cortisol, the main glucocorticoid in humans, is released in response to stress as part 
of the hypothalamic-pituitary-adrenal (HPA) axis that affects mineralocorticoid and 
glucocorticoid receptors throughout the brain. Dysregulation of the HPA-axis is known 
to occur in several psychiatric disorders, such as anxiety disorder (e.g. post traumatic 
stress disorder) (1) and mood disorders including bipolar disorder (BD) (2-7). In addition, 
depression and mania are common psychiatric symptoms seen in patients treated with 
corticosteroids or suffering from Cushing’s Syndrome, a disorder caused by cortisol excess 
(8, 9). Dysregulation of the HPA-axis in BD is also supported by several studies that have 
found more non-suppression after dexamethasone (dex) administration and increased 
cortisol secretion after corticotrophin releasing hormone (CRH) in patients with BD (10, 
11). However, conflicting data have been published concerning HPA-axis dysfunction 
during episodes and during euthymic phases of the disease. Furthermore, there are only 
a few studies reporting dexamethasone suppression tests (DSTs) or combined dex/CRH 
tests in patients with bipolar disorder (10, 11). 
In the majority of previous studies salivary or serum cortisol levels have been used to 
evaluate HPA-axis functioning. However, these studies yielded conflicting findings. Some 
studies reported no differences in basal salivary or serum cortisol levels in patients with 
BD (12-15), whereas others described elevated cortisol levels (16, 17). These conflicting 
findings might be the result of methodological differences between the studies. Some 
studies reported cortisol levels in patients in remission, while others measured cortisol 
levels during active depression or mania. Furthermore, there is a large discrepancy in 
the methods used to evaluate cortisol levels in BD patients. Some studies evaluated the 
cortisol awakening response, whereas others investigated diurnal rhythms of cortisol 
secretion or cortisol levels at single time points. Cortisol is secreted in a circadian rhythm 
and with a pulsatile pattern, which complicates the interpretation of serum and salivary 
cortisol levels. Furthermore, in blood, only 10% of the circulating cortisol is free, 75% 
is bound to cortisol binding globulin (CBG) and 10% to albumin (18). In most studies 
describing serum cortisol levels, the concentration of CBG is not taken into account. 
Therefore the concentrations of unbound, biologically active, cortisol are not known. 
In addition, since cortisol is a stress hormone, acute psychological or physical stress will 
also influence serum and saliva cortisol levels. A recently developed method to measure 
cortisol levels in scalp hair is a feasible method to determine long-term cortisol levels 
and appears to yield a reliable estimate of long-term HPA-axis activity (19, 20). Since hair 
grows with an average rate of 1 cm per month, a hair segment of e.g. 3 cm would reflect 
mean cortisol levels over a period of approximately 3 months. This long-term cortisol 
measurement is therefore not influenced by the time of sample collection or acute 







stress due to daily circumstances or the research setting. Steudte et al. (21) used hair 
cortisol levels to measure HPA-axis activity in generalized anxiety disorder (GAD) and 
found decreased cortisol levels in hair of patients with GAD, but no differences in salivary 
cortisol levels between GAD patients and healthy controls (22). This suggests that hair 
cortisol levels may reflect the chronic cortisol exposure, whereas the results found with 
saliva or serum cortisol levels might also include acute responses to the measurement 
circumstances. Several other studies have shown that hair cortisol is indeed a marker of 
long-term cortisol exposure (19, 23-26). 
The aim of this study was to explore the role of long-term endogenous cortisol exposure 
by comparing long-term cortisol levels in BD patients with healthy controls using cortisol 
measurements in scalp hair. We aim to obtain insight in the long-term assessment 
of cortisol in patients with bipolar disorder, since chronic subtle changes in HPA-axis 
functioning appears to be involved in the pathophysiological processes leading to mood 
episodes. We hypothesized that hair cortisol levels are higher in BD patients compared 
to healthy individuals. In addition, we explored the relation between cortisol levels in 
hair and clinical course of the disease, with characteristics like disease state, age of 
onset, and psychiatric co-morbidity. Furthermore, we measured saliva cortisol levels in 
order to compare the observed findings of hair cortisol.
Materials and methods
Study design
This is a cross-sectional study involving outpatients with BD. The study was approved by 
the local medical ethics committee and is carried out in accordance with the declaration 
of Helsinki. After complete description of the study to the participants, all participants 
gave informed consent. 
Participants
Bipolar Disorder patients
Patients with BD (type I, type II and Not Otherwise Specified) included in our previous 
study (27) concerning the role of glucocorticoid and mineralocorticoid receptor 
polymorphisms were asked to participate and the first 100 eligible patients were included 
in this study. Patients were eligible for inclusion if they had not been using glucocorticoids 
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in the six months prior to hair sample collection and if they had sufficient hair growth 
at the posterior vertex.  Detailed description of the assessment methods of the patients 
has been described elsewhere (27, 28). In brief, participants were interviewed by trained 
psychologist to collect socio-demographic data and disease characteristics. Diagnoses of 
BD and psychiatric co-morbidities were based on DSM-IV criteria and were assessed with 
a standardized diagnostic interview developed by Sheehan et al. (29) using the Dutch 
version of the MINI International Neuropsychiatric Interview Plus (version 5.00-R; MINI-
PLUS) (30). The Questionnaire for Bipolar Illness, Dutch translation (31, 32) was used to 
specify subtypes of BD, its course over time and detailed information about age of onset of 
first symptoms regarding hypomanic, manic and depressive episodes. The Questionnaire 
for Bipolar Illness, Dutch translation is a widely used questionnaire, developed by the 
National Institute of Mental Health. In addition, detailed information was gathered to 
define whether patients suffered from depression, mania or a combined episode during 
the three months prior to hair sample collection (this timeframe corresponds with 
cortisol measurements in 3 cm hair segments). Based on this information, disease state 
was categorized as stable disease, depressive episode, manic episode or mixed episode. 
Data on age of onset were present in 84 patients and data concerning psychiatric co-
morbidities were present in 99 patients.
Healthy controls
A group of 195 healthy controls were used as control group. Detailed information of this 
study group has been reported previously (19). Both patients and healthy controls filled 
out a questionnaire concerning hair treatment (dyeing/bleaching/permanent waving/
straightening), the use of hair products (gel, wax, hair spray) and frequency of hair wash. 
Sample collection
In all patients and healthy controls, a lock of hair of approximately 100-150 hairs was cut 
of from the posterior vertex as close to the scalp as possible. Hair was taped to a paper 
and stored until preparation. In addition, in 90 patients with BD also saliva samples were 
collected on two consecutive evenings at 2200h. Collection at 2200h was chosen since 
several studies showed that saliva samples collected in the late evening on separate days 
show the lowest variation in cortisol levels compared to diurnal cortisol measurements 
and the cortisol awakening response (33-35). This suggests that late evening cortisol 
levels are slightly less influenced by acute stressors and daily influences than e.g. the 
cortisol awakening response, and may thereby be a better reflection of basal cortisol 
status. Participants were instructed not to eat, drink or brush their teeth 30 minutes prior 







to the saliva collection. Saliva was collected by spitting into a Salicap plastic tube. Saliva 
samples were stored at -20°C until analysis. Cortisol levels were measured separately in 
both saliva samples and we calculated the mean salivary cortisol levels afterwards. We 
used the mean salivary cortisol levels in the statistical analyses. 
Hair sample preparation
Hair samples were measured, weighted and put into separate glass vials. The 3 cm 
segment most proximal to the scalp was used in the analysis, which corresponds roughly 
to a period of three months. In the glass vial, hair segments were cut into small pieces and 
1 mL of methanol was added to extract cortisol from the hair samples. After overnight 
incubation for 16 hours at 52°C while gently shaking, the methanol was transferred to 
another glass vial and was evaporated under a nitrogen stream and the samples were 
dissolved in 250 μL phosphate buffered saline (pH 8.0).
Cortisol measurement
Saliva samples were thawed and vortexed. After this, saliva samples were centrifuged 
for 5 minutes to separate the mucins. Cortisol in saliva as well as in the hair extracts was 
measured using a commercially available salivary ELISA cortisol kit (DRG Instruments 
GmbH, Marburg, Germany). Cross reactivity of the kit’s antibodies with other steroids 
was reported as follows: Corticosterone (29.00%), Cortisone (3.00%), 11-Deoxycortisol 
(<1.00%), 17-OH Progesterone (<0.50%), other hormones (<0.10%). Intra-assay variation 
was below 5% and the inter-assay variation below 8% as stated by the manufacturer. 
The low end detection limit for this assay is 1.5 nmol/L. To test the recovery of the assay, 
we created cortisol standards in PBS with concentrations of 5, 10, 20, 40, 80 and 160 
nmol/L and measured the recovery in duplicate. We also spiked two hair samples with 
20 nmol/L hydrocortisone, to measure recovery when hydrocortisone was dissolved in 
hair extract. The recovery of 5, 10, 20, 40, 80 and 160 nmol/L cortisol standards from PBS 
was 96.0%, 94.0%, 94.0%, 95.0%, 96.8% and 89.9% respectively. When hydrocortisone 
was added to hair extracts, the mean recovery was 101.3%.  
Statistical analysis
SPSS 17.0 for Windows and GraphPad 5.0 were used for statistical analysis. Differences 
between group characteristics were tested with Chi-square and Kruskal Wallis tests. 
After log transformation hair and saliva cortisol levels were normally distributed. 
Differences in cortisol levels between healthy controls and BD patients and between 
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disease characteristics of BD patients were tested with ANCOVA and linear regression. 
The association between saliva cortisol and hair cortisol levels was tested using linear 
regression analysis. All hair cortisol analyses were adjusted for gender, age, frequency of 
hair wash, hair treatment (dyeing, bleaching, permanent straightening or waving) and 
the use of hair products. Saliva cortisol analyses were adjusted for gender and age. 
Results
Hair cortisol measurements were completed in 100 BD patients and 195 healthy controls. 
Saliva cortisol levels were available in 90 BD patients. Group characteristics are shown in 
Table 1. All BD patients were treated in the outpatient Department of Mood Disorders 
in The Hague, the Netherlands. BD patients were significantly older than healthy 
controls and had significantly higher BMI. Furthermore, BD patients washed their hairs 
less frequently and used less hair products, but dyed/bleached their hairs more often 
compared to the healthy control group (Table 1).
The number of patients on lithium, antidepressants, antipsychotics and other mood 
stabilizers are shown in Table 1. There were only 2 (2.0%) BD patients that did not use 
anti-depressants, antipsychotics, lithium or other mood stabilizers, 30 patients (30.0%) 
used only 1 type of medication, 31 patients (31.0%) used 2 types of medication and 19 
patients (19.0%) used 3 types of medication. There was no correlation between log-
transformed saliva cortisol and hair cortisol measurements (b=0.157, p=0.140) (Figure 
1). 













Age (years) – median (range) 52.0 (20-82) 32.0 (18-63) <0.001
Number of women – n (%) 62 (62.0%) 103 (52.8%) 0.18
BMI (kg/2) – median (IQR) 25.3 (23.5-28.0) 23.7 (21.7-26.5) <0.001
Frequency of hair wash – n (%)
≤ 2 times/week 53 (53.0%) 50 (25.6%)
≥ 3 times/week 47 (47.0%) 143 (73.3%) <0.001
Hair treatment* 40 (40.0%) 43 (22.1%) 0.001
Use of hair products** 32 (32.0%) 90 (46.2%) 0.018
Age of onset Bipolar Disorder
median (IQR) 21.0 (15.5-35.0)
< 30 years of age – n (%) 55 (55%)
> 30 years of age – n (%) 29 (29%)
One or more psychiatric co morbidities – n 
(%)
42 (42.0%)
Co morbid panic disorder 14 (14.0%)
Co morbid anxiety disorder 16 (16.0%)
Co morbid agoraphobia 21 (21.0%)
Co morbid pain disorder 1 (1.0%)
Co morbid somatoform disorder 2 (2.0%)
Medication
Lithium – n (%) 68 (68.0%)
Other mood stabilizers – n (%) 17 (17.0%)
Antidepressants – n (%) 31 (31.0%)
Antipsychotics – n (%) 34 (34.0%)
Disease state in the period covered by the 
hair sample
Stable disease– n (%) 43 (43.0%)
Depressive episode – n (%) 29 (29.0%)
Manic episode – n (%) 3 (3.0%)
Mixed episode – n (%) 8 (8.0%)
*    Hair treatment: dyeing, bleaching, permanent waving, permanent straightening of hairs
** Hair products: includes hair spray, wax, mouse and gel and other not wash-related hair products.
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Figure 1. Relationship between the mean cortisol level in two evening saliva samples 
(collected at 22.00h) and the hair cortisol levels on logarithmic scales. The Pearson’s 
correlation coefficient and its accompanying p-value are given with a regression line.
Hair cortisol
There were no correlations between hair cortisol levels and age in healthy controls 
(r=0.062, p=0.39) or BD patients (r=-0.047, p=0.64). There were also no differences in 
hair cortisol levels between men and women in healthy controls (p=0.87) or BD patients 
(p=0.12) and hair cortisol levels did not correlate with BMI in BD patients (r=0.163, 
p=0.11) or in healthy controls (r=0.042, p=0.59). Hair cortisol levels in the total group of 
BD patients were not different from hair cortisol levels in healthy controls (31.84 pg/mg 
hair (95% Confidence interval (CI): 28.38 – 35.81) versus 28.18 pg/mg hair (95% CI: 25.94 
– 30.62); p=0.233, adjusted for gender, age, hair treatment, hair products and frequency 
of hair wash). Since there was variability in the state of disease at the moment of sample 
collection, the group of BD patients was split up into groups with a stable period (n=43), 
depressive episode (n=29), manic episode (n=3) or combined episode (n=8) in the 3 
months prior to sample collection. There were no significant differences between hair 
cortisol levels in the groups with various disease states in the three months prior to hair 
sample collection (unadjusted p=0.868; adjusted for gender, age, hair treatment, hair 
products and frequency of hair wash p=0.978). In addition, there was no effect of lithium 
(p=0.357), other mood stabilizers (p=0.388), antidepressants (p=0.816) or antipsychotics 
(p=0.278) on cortisol levels. 







We found no significant correlation between age of onset of BD (age at which the first 
episode of (hypo)mania or depression presented) and hair cortisol levels (b=0.156, 
p=0.179). . However, when assessing the distribution of hair cortisol throughout the 
different age of onset groups divided in decades, we found significantly elevated hair 
cortisol levels in the group of patients with their first depression or mania ≥ 30 years of 
age compared to the group of patients with their first depression or mania before 30 
years of age (p=0.004) (Figure 2). Hair cortisol levels in the group with onset of BD < 30 
years of age were similar to those in the healthy controls (p=0.886, adjusted for gender, 
age, hair treatment, hair products and frequency of hair wash) (Figure 2). There were no 
differences in use of lithium (p=0.536), other mood stabilizers (p=0.384), antidepressants 
(p=0.397) and antipsychotics (p=0.278) between the group of patients with an older 
age of onset of BD compared to the group of patients with an age of onset <30 years. 
Furthermore, there was no correlation between duration of the disease and hair cortisol 
levels (r=-0.105, p=0.34).
Figure 2. Hair cortisol levels in healthy controls, bipolar disorder patients with younger 
and older age of onset. HC, healthy controls; p-values are adjusted for age, gender, use 
of hair products, hair treatment and frequency of hair wash. Error bars represent SEM. 
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Interestingly, in patients with co-morbid panic disorder (n=14) hair cortisol levels were 
significantly lower than in BD patients without panic disorder (22.13 versus 34.67 pg/mg 
hair, p=0.019, adjusted for gender, age, hair treatment, hair products and frequency of 
hair wash) (Figure 3). These hair cortisol levels in patients with co-morbid panic disorder 
were even lower than hair cortisol levels in healthy individuals (p=0.05, adjusted for 
gender, age, hair treatment, hair products and frequency of hair wash). Furthermore, 
we found elevated hair cortisol levels in the group of BD patients with other psychiatric 
co-morbidities (e.g. anxiety disorders, agoraphobia, pain disorder, somatoform disorder) 
compared to the BD patients without psychiatric co-morbidities (44.87 pg/mg hair (95% 
CI: 34.36-58.61) versus 31.41 pg/mg hair (95% CI: 26.06-37.76) in patients without co-
morbidities, p=0.021). When patients with co-morbid panic disorder were included in 
the group of total co-morbidities, there was no significant difference in hair cortisol 
levels between BD patients with and without psychiatric co-morbidities anymore (34.67 
versus 31.33 pg/mg, p=0.448). Additional adjustment for BMI did not change any of the 
results. 
Figure 3. Hair cortisol and salivary cortisol levels in bipolar disorder patients with and 
without co-morbid panic disorder. Hair cortisol analyses are adjusted for age, gender, use 
of hair products, hair treatment and frequency of hair wash. Saliva cortisol analyses are 
adjusted for gender and age. Error bars represent SEM. 








There were no significant differences in salivary cortisol levels between BD patients with 
a depressive episode, manic episode or stable disease at the moment of saliva collection 
(p=0.304). In addition, we found no differences in salivary cortisol levels between age of 
onset of disease before the age of 30 years and after the age of 30 years (p=0.155). In 
contrast to the results with hair cortisol levels, co-morbid panic disorder was associated 
with a trend towards increased salivary cortisol levels (5.5 (95% CI: 4.0-7.5) nmol/L versus 
4.1 (95% CI: 3.6-4.7) nmol/L, unadjusted p=0.094). However, this was not statistically 
significant after adjustment for gender and age (p=0.245) (Figure 3). Furthermore, we 
found no differences between the group of BD patients with psychiatric co-morbidities 
(panic disorder excluded) and without psychiatric co-morbidity (p=0.562). Also, when 
panic disorder was included in the total group of psychiatric co-morbidities, there were 
no significant differences in salivary cortisol levels between the BD patients with and 
without co-morbidities (p=0.306). An overview of all results for hair and salivary cortisol 
is given in Table 2. 
Table 2. Overview of the hair cortisol and saliva cortisol results of disease characteristics 
in patients with Bipolar Disorder













Age of onset Bipolar Disorder 
(<30 versus ≥ 30 years)
0.249 0.022 0.335 0.004 0.166 0.146 0.163 0.155
Co morbid panic disorder -0.211 0.036 -0.243 0.019 0.187 0.094 0.122 0.245
Psychiatric co morbidity (excl. 
panic disorder) 0.227 0.036 0.253 0.021 0.020 0.865 0.068 0.562
Psychiatric co morbidity 0.087 0.389 0.078 0.448 0.153 0.329 0.142 0.306
The Beta was calculated with linear regression. Hair cortisol analyses were adjusted for 
age, gender, use of hair products, hair treatment and frequency of hair wash. Saliva 




In this study, we measured long-term hair cortisol levels of patients with bipolar disorder 
and healthy individuals. In addition, we measured evening salivary cortisol levels in 
bipolar disorder patients. The main finding of this study is the elevated hair cortisol level 
in patients with older age of onset BD compared to the group with a younger age of 
onset and healthy controls. We also found that BD patients with co-morbid psychiatric 
disorders (excluding panic disorder) had higher hair cortisol levels than patients with 
only BD. Interestingly, in patients with co-morbid panic disorder, hair cortisol levels were 
significantly decreased, whereas saliva cortisol levels were slightly elevated. No further 
correlations between hair and salivary cortisol measurements were found.
This is the first study that measured long-term hair cortisol levels of patients with BD. 
Several studies have measured cortisol levels in serum and saliva and results have 
been inconclusive with reports of increased (16, 17) and normal cortisol levels (12-
15) compared to healthy individuals. Serum and saliva cortisol measurements reflect 
cortisol levels at one time point and are influenced by the pulsatile pattern and circadian 
rhythm of cortisol secretion, as well as by acute stress due to daily circumstances. These 
limitations do not apply to hair cortisol measurements which makes hair cortisol a better 
marker of HPA-axis functioning on the long-term. Recently, two studies measured hair 
cortisol levels and related them to mood disorders (36, 37). Dettenborn et al. showed 
that hair cortisol levels were elevated in medicated patients with major depression (37) 
and Dowlati et al. showed that there was no difference in hair cortisol levels between 
depressed and non-depressed patients with coronary artery disease (36). However, hair 
cortisol levels of both depressed and non-depressed patients with coronary artery disease 
were higher than those in healthy controls. The possible psychological stress associated 
with suffering from coronary artery disease and the presence of coronary artery disease 
itself could have abolished the differences in hair cortisol between depressed and non-
depressed patients, resulting in different results than the observations of Dettenborn 
et al. Since both studies only included patients with major depression and not BD, it is 
difficult to compare their results to our findings.
In our study, we found that patients with younger (<30 years of age) and older (≥30 years 
of age) onset BD clearly differed in their mean hair cortisol levels. Our finding of elevated 
hair cortisol levels in BD patients with older age of onset supports the hypothesis of 
dysfunction and hyperactivity of the HPA-axis which has been described in BD patients 
and their offspring (15, 38-43). However, cortisol levels in patients with earlier age of 
onset BD were comparable to hair cortisol levels in healthy individuals. In the past decade, 
several studies have found that there might be differences in disease characteristics and 
pathogenesis of early and late onset BD. Early onset of BD seems to be associated with 







greater severity and a poorer long term outcome (44, 45). In addition, several genetic 
differences have been described between early and late onset BD (46, 47). Differences in 
cortisol levels and HPA-axis functioning between subtypes of BD based on age of onset 
have not been studied previously. Our hair cortisol data suggest that elevated cortisol 
levels may play a role in late onset BD, but not in early onset BD. This suggests that 
BD onset at younger age may be less influenced by dysregulation of the HPA-axis, but 
more by other mechanisms e.g. changing regulation of sex hormones or differences in 
genetics of the disease. Later onset of the disease might be influenced by dysregulation 
of the HPA-axis through e.g. stressful life events, which are thought to be a trigger for 
manifestation of the disease (48). Furthermore, it can also be hypothesized, that long-
term elevations in cortisol affect proneness for mood disorders by neuronal damage in 
the brain (49), which may lead to a higher risk of developing mood disorders. As seen in 
patients with endogenous hypercortisolism, psychopathology continues even after cure 
(8, 9), suggesting that long-term elevations in cortisol can have irreversible effects on the 
brain, resulting in mood disorders.
We did not observe these differences in age of onset with saliva cortisol, suggesting that 
saliva cortisol may be an acute marker of cortisol rather than an estimate of the HPA-
axis activity on the long-term. It supports the additional value of measuring hair cortisol 
levels. Furthermore, we found no differences in hair cortisol levels between patients in 
different disease states. The same applied to the observed findings of salivary cortisol 
in relation to BD, which is consistent with several other studies (15, 16). This suggests 
that the increased HPA-axis activity may be a trait phenomenon rather than a state 
phenomenon in the subgroup of patients with older age of onset.
Moreover, we found that psychiatric co-morbidity was associated with elevated hair 
cortisol levels within the group of BD patients. With respect to the different types of 
co-morbidities, we found significantly lower cortisol levels in BD patients with co-morbid 
panic disorder. In contrast to this, evening saliva cortisol levels tended to be higher in 
this group. Our study is the first study that describes both hair and saliva cortisol levels 
in patients with panic disorder. These data again suggest that hair cortisol levels may 
reflect cortisol levels over a larger time frame (about three months is this study, since 
we used three cm length of hair), whereas saliva cortisol may provide an estimate of 
one time point including potential acute effects of the circumstances. Steudte et al. (22) 
previously demonstrated similar results in a group of patients with generalized anxiety 
disorder. In this group they found that hair cortisol levels were decreased compared 
to healthy individuals, whereas there was no difference between saliva samples of 
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GAD patients and healthy individuals (22). The increased saliva cortisol levels in our BD 
patients with panic disorder compared to those without co morbid panic disorder, might 
be explained by more perceived stress in the participants with panic disorder prior to a 
visit to the research center than BD patients without panic disorder. Reports of saliva, 
serum and urine cortisol levels in patients with panic disorder have shown conflicting 
results (50-55), which emphasizes the need for a new reliable measurement of long-
term cortisol exposure. 
There are several limitations of this study. First, the healthy individuals were significantly 
younger than the BD patients, which may have affected our findings. However, there 
was no effect of age on cortisol levels in the control group (19) or in the bipolar disorder 
group. In addition, other studies reported no effect of age on hair cortisol levels (56, 
57), and all analyses were adjusted for age. Second, several studies have shown that 
other factors, such as suicide attempts and childhood trauma can have a significant 
effect on the HPA-axis (58, 59). In our study population, there was no significant effect 
of childhood abuse (sexual, physical and verbal) on hair cortisol levels (data not shown), 
but we did not collect data concerning suicide attempts. In future studies, other factors 
that might influence the HPA-axis such as childhood trauma and suicide attempts should 
be taken into account as well.
Third, our study lacked data concerning smoking status and somatic health. However, 
we found no differences in hair cortisol levels between smokers and non-smokers in our 
group of healthy individuals (data not shown), and a recent study of Dettenborn et al (37) 
did not find differences in hair cortisol levels between smokers and non-smokers as well. 
Furthermore, our results of possible increased saliva cortisol levels with decreased hair 
cortisol levels in patients with panic disorder were found in a group of only 14 patients 
with co-morbid panic disorder in addition to bipolar disorder. The pathogenesis of panic 
disorder in BD patients might be different from the pathogenesis of panic disorder in 
patients without BD or another psychiatric disorder. Therefore, these results have to 
be interpreted carefully and it is not certain whether the results can be extrapolated to 
patients with panic disorder without other psychiatric disorders. Finally, measurement 
of cortisol in scalp hair is a relatively new and promising method but many details 
concerning hair growth rate and incorporation of cortisol in hair are still unknown.
Despite these limitations, our results support the hypothesis that elevated long-term 
cortisol levels play a role in a subgroup of patients with bipolar disorder. Since we found 
that cortisol levels were only elevated in the group of patients with a relatively late age 
of onset of BD, we hypothesize that there may be differences in pathogenesis among 
patients with early and late onset BD yielding two different disease entities. Future 







research should focus on exploring these subtypes of BD based on age of onset with 
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Attention, memory and executive cognitive functions are frequently impaired in patients 
with Bipolar Disorder (BD). These impairments seem to be a trait phenomenon, but 
may also be influenced by medication and alcohol use. Approximately one-third of 
BD patients use more than one drug simultaneously, known as polypharmacy. In this 
study, the associations between medication use as well as clinical characteristics were 
investigated in relation to cognitive performance in 187 euthymic BD patients.
Methods
 Sociodemographic and illness characteristics, as well as medication use were related 
to 3 cognitive domains (i.e., attention, memory and executive function) of the Test for 
Attentional Performance (TAP) using multivariable regression analyses.
Results
The main finding was that the use of multiple types of medication was associated 
with poorer cognitive performance in all three cognitive domains, but only statistically 
significant for executive functioning (b= -0.19, P=0.004). Particularly the use of 
antipsychotics was associated with impaired executive functioning, whereas Lithium use 
was not associated with cognitive performance. As we included only euthymic patients, 
our findings cannot be extrapolated to chronically unstable patients. 
Conclusions
Our findings suggest that the use of multiple types of medication adversely affects diverse 
cognitive domains in BD patients, but specifically executive functions. Clinicians should 
be aware of these potential side effects when prescribing medication to BD patients.
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Bipolar Disorder (BD) is a common mood disorder, characterized by mood swings like 
depression and (hypo) mania.  In addition to mood episodes, recent evidence shows that 
cognitive deficits are important clinical features of BD (1) related with poorer social and 
global functioning. In BD, attention problems, slowing of processing speed, and deficits 
in working memory and executive functioning appear to be most consistently observed 
(2), and have negative influence on treatment adherence and outcome of the disease(3). 
The disturbances are partly state-dependent and partly determined by trait factors 
of BD that may have a genetic origin, however, cognitive performance seems mostly 
linked to specific sociodemographic and clinical factors like age, level of education, 
medication use, residual mood symptoms and early adversity (4). The impact of Lithium 
use on cognition appears to be minimal (5, 6), but antipsychotic use seems associated 
with deficits in memory and executive functioning in BD patients (5). Despite available 
research, little attention has been given to the cognitive side effects of the number of 
different types of medication, known as polypharmacy, which is common practice in the 
treatment of BD (7). Other clinical characteristics of BD related to cognitive performance 
include BD subtype (8), and with some controversy, substance abuse (9). 
However, studies are small, with a number of included patients between 10 -76 (10). 
In this study we aimed to further disentangle the associations between cognitive 
performance in a large cohort of 187 BD patients, medication use and a number of 
sociodemographic and clinical characteristics. We hypothesize that medication use and 
specifically use of multiple types of medication would adversely associate with specific 





This is a cross-sectional study involving outpatients with BD. This study was approved 
by the Medical Ethical Committee (METTIG) in Utrecht, The Netherlands, and was 
performed in accordance with the declaration of Helsinki.
Out of a cohort existing of 364 patients with BD, a subgroup of 187 (51.4%) agreed to 
perform cognitive tasks. The cohort of 326 patients has been described in a previous 
publication (11), currently extended to 364 patients. These 187 patients fulfilled the 
inclusion criteria of being diagnosed with BD1, BD2, cyclothymia or BD not otherwise 
specified, all according DSM-IV-TR diagnosis and being older than 18 years. Due to small 
numbers, cyclothymia and BD no otherwise specified were included in the BD2 group 
in all analyses. They were all euthymic at the time of the investigation. All patients are 
treated in the Program for Mood Disorders at PsyQ in The Hague, The Netherlands. An 
exclusion criterion in this study were schizo-affective disorder and age below 18 years old. 
Participants were comparable with the non participants with regard to age and gender 
and clinical characteristics, but differed with respect to subtype of BD (respectively 
66.8% and  80.4% BD1; p=.05), number of depressive episodes (median respectively 6.5 
and 5; p=.02), Lithium use (respectively 27.3% and 15.7% used no Lithium; p=.006) and 
alcohol use (respectively 35.1% and 46.7% used no alcohol; p=.03). 
Assessment of clinical characteristics and medication use
Detailed information about the protocol regarding data collection of diagnostic status 
and sociodemographic information, is described in our previous publication (11). In 
addition, to assess euthymia, all patients were questioned about current mood with 
the Quick Inventory of Depressive Symptomatology- Self Report (QIDS-SR) (http://www.
ids-qids.org) and the Young Mania Rating Scale (YMRS) (12). Euthymia was prospectively 
defined as score ≤7 for the YMRS and a score of ≤12 for the QIDS-SR. Early adversity was 
assessed with questions of the Childhood Trauma Questionnaire (CTQ) (13).
The psychotropic medication types that were used most frequently, were coded 
according to the Anatomical Therapeutic Chemical Classification System (http://www.
whocc.no/) and included Lithium (ATC code: N05AN01), anti-epileptics (ATC code: 
N03AF01, N03AG01, N03AX09) antipsychotic medication (ATC code: N05Ax with 
exclusion of N05AN01), benzodiazepines (ATC codes: N05BA, N05CD, N03AE01, N05CF), 
and antidepressants (N06A).  Lithium is regarded as drug of first choice in the treatment 
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of Bipolar Disorder, therefore it was not included in antipsychotic medication but coded 
separately. In case of more than 1 used medications of the same type (for example the 
use of 2 antidepressants), this was counted as 1 type.  
Test for Attentional Performance (TAP)
Cognitive performance was assessed by means of the Test for Attentional Performance 
(‘Testbatterie für Aufmerksamkeitsprüfung’ (TAP), version 2.1, http://www.psytest.net/ 
; Zimmermann & Fimm, 2002). The TAP is a widely used computer based standardized 
test battery and is easy to use in clinical practice (5, 14, 15). In this study, 8 out of 12 
subtests were used to evaluate cognitive performance in the patient group, including 
attention (phasic and tonic), sustained attention, divided attention, working memory, 
cross-modal integration, flexibility, go/no-go and incompatibility.  The other four 
subtests included eye movement, visual neglect, visual field scanning and vigilance. 
These subtests were initially developed for patients with brain damage, but are of less 
interest for our research question and were therefore excluded. In previous studies raw 
scores as well as compound scores were used in further analyses (for references see 
http://www.psytest.net/). All skewed variables were log transformed to fulfill normal 
distribution criteria. To summarize the results in further analyses and avoid multiple 
testing problems, compound scores and z-scores were created and averaged for 3 
domains of closely related cognitive component item test results, namely attention (11 
component items, including alertness median reaction time in two series,  alertness 
errors and total performance index; sustained attention errors in four series, sustained 
attention omissions in four series), working memory (2 component items: errors and 
omissions) and executive functioning (13 component items, including flexibility, total 
performance scores of 2 series, divided attention errors, omissions and correct scores in 
two series, go/ no go errors and median, incompatibility median and errors in two series, 
cross modal integration errors and omissions). Intercorrelations between the component 
items of each compound z-score were highly significant, with the exception of two 
component items in the z-score for executive functioning. However, when re-analyzing 
the data excluding these 2 component items, results remained largely similar. Lower 
z-scores reflect more mistakes, longer reaction times and more omissions. Attention 
includes phasic and tonic attention, as well as a separate subtest for sustained attention. 
Executive functioning comprises divided attention, flexibility, Go/No go, incompatibility 




All of the analyses were conducted using SPSS version 17.0 statistical software (SPSS Inc, 
Chicago, Illinois). First, analyses were performed to describe the clinical characteristics, 
with use of t-tests and Chi-square tests when appropriate to compare participants 
with non-participants. For TAP results z-scores were created, tested for normality, and 
used to analyze the possible relationships between domains of cognition and baseline 
characteristics. For assessing correlations between z-scores, Pearson’s correlation scores 
were used. Based on linear regression analysis with z–scores as dependent variables and 
baseline characteristics as independent variables, we decided to use age, gender and level 
of education as covariates in multivariate regression analysis.  Variables with positively 
skewed distributions (e.g., number of depressive episodes and number of (hypo) manic 
episodes) were logarithmic transformed for all analyses. Back-transformed geometric 
medians with Inter Quartile Rates are presented in the tables, when appropriate. To 
correct for multiple testing with 10 analyzed variables per cognitive domain (medication 
use; BD subtype; childhood adversity; current anxiety disorder; psychiatric co-morbidity; 
alcohol use; drug use; smoking; age of onset; current mood), we used the compound 
scores in our analyses. Results are considered significant with a p-value < .05. 
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In table 1 all population characteristics are summarized. 
Anxiety disorder was mentioned separately, due to the high prevalence. All participants 
were euthymic with a mean QIDS score of 7.7 (SD=5.0), reflecting no or mild symptoms 
(http://www.ids-qids.org) and a mean YMRS score of 1.6 (SD=2.9), meaning no manic 
or hypomanic symptoms. The Pearson’s correlation scores between the three cognitive 
domains were respectively r=.45, p<.001 (for the association between working memory 
and attention); r=.40, p<.001 (for attention- executive functioning); and r=.35, p<.001 
(for working memory and executive functioning). Out of 187 participants, 184 (98%) 
completed the attention tests, 147 (79%) completed the working memory subtest and 
166 (89%) completed all executive function subtests. All these patients were included, 
however for the in domain attention 42 patients and for the domain executive functioning 
26 patients had 3 or more missing component tap items. When re-analyzing the data 
with exclusion of patients with >3 missing variables, effects reflected by β- coefficients 
were largely similar, though of slightly less strength.
On all component items of the TAP, the patient group showed longer mean reaction 
times with larger standard deviations, more omissions and more mistakes in comparison 
with persons from the general population described in the TAP manual as reference 
populations. They showed longer mean reaction times with larger standard deviations, 
more omissions and more mistakes in comparison with persons from the general 




Table 1: Characteristics in 187 participants with BD
Participants 
Total N



















Age of onset; mean (SD)
Age of onset first (hypo-) mania
Age of onset first depression
Age of onset disease
Number of episodes; median (IQR)
No. of manic episodes
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Abbreviations: BD indicates Bipolar Disorder; IQR indicates Inter Quartile Range; YMRS 
indicates Young Mania Rating Scale; QIDS indicates Quick Inventory of Depressive 
Symptomatology.
Influence of sociodemographic and clinical characteristics, medication 
use and substance use on cognition
In table 2, the sociodemographic and clinical characteristics are presented in relation to 
the three described cognitive domains.
Older age was significantly associated with all three cognitive domains: poorer 
attention (unadjusted b=-.35; p<.001), working memory (unadjusted b=-.19; p=.02), 
and executive functioning (unadjusted b=-.38; p<.001). Higher level of education was 
associated with better working memory (unadjusted b=.35; p< .001) and executive 
functioning (unadjusted b=.45; p<.001), but not with better attention. Mood scores on 
QIDS and YMRS were not associated with TAP scores. In table 3, b-coefficients with the 
accompanying p-values are presented, adjusted for gender, age and level of education. 
With respect to clinical characteristics, we found that BD 2 was related to better attention 
(unadjusted b=.19; p=.009; adjusted b=.16; p=.03) and we found a trend towards better 
executive functioning in BD2 patients (unadjusted b=.15; p=.05; adjusted b=.11; p=.10). 
The number of manic episodes was also positively related to executive functioning 
(unadjusted b=.12; p=.13; adjusted b=.14; p=.04).
With respect to medication use, we found that the number of different types of 
psychotropic medication was associated with poorer performance on executive 
functioning (unadjusted b=-.19; p=.01; adjusted b=-.19; p=.004). When analyzed per 
medication type, Lithium use versus no Lithium use was not associated with cognitive 
function on any domain. However, when Lithium use was compared with Lithium plus 
other medication types, a statistical trend was observed that showed lower performance 
on executive functioning in the group using Lithium and other medication (unadjusted 
b=-.13; p=.13; adjusted b=-.19; p=.01). The use of anti-psychotics was related with lower 
scores on executive functioning (unadjusted b=-.22; p=002; adjusted b=-.20; p =.002). A 
statistically significant association was found for the use of antidepressants and lower 
attention scores (unadjusted b=-.16; p=.03; adjusted b=-.16; p=.02). Figure 1 shows the 
associations between the number of different types of psychotropic medication and 
cognitive function on the three domains. 
When trying to gain insight in whether medication worsens cognitive function or 
whether the severity of illness confounded the association, all analyses with the number 
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of medication were additionally adjusted for severity of illness course variables age of 
first episode, number of depressive and number of manic episodes, QIDS score and 
YMRS score. Most associations persisted with beta-coefficients that did not decrease in 
strength. 
Finally, with respect to substance use, we found an association between moderate alcohol 
use and attention, that remained significant after adjustment for gender, age, level of 
education, indicating that moderate alcohol use (of 1-2 units per day) was associated 
with slightly better attention versus no alcohol use. Smoking was also associated with 
better attention (unadjusted b=.15; p=.05; adjusted b=.16; p=.03).
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N b P N b P N b P
Female (vs male gender) 111  .02   .84 90  .04   .67 111 -.07   .37
Age 184 -.35 <.001 147 -.19   .02 185 -.38 <.001
Level of education::
- primary (ref)* 40 Ref. 25 Ref. 40 Ref.
- secondary 55  .08   .44 44  .21   .08 55  .29   .01
- higher 89  .13   .15 78  .35 <.001 90  .45 <.001
Clinical characteristics
Diagnostic information:
BD 2 (BD 1 ref.) 122  .19   .01 101  .16   .06 123  .15   .05
Childhood adversity  54 -.08   .31 39  .01   .91 55 -.02   .82
Current anxiety disorder   55 -.10   .18 42 -.04   .65 55  .05   .55
Psychiatric co-morbidity 75 -.03   .67 61 -.04   .68 75  .07   .34
Age of onset:
Age of onset first mania 163 -.15   .05 130 -.05   .58 164 -.21   .01
Age of onset first depres-
sion 167 -.24   .002 131 -.01   .94 168 -.14   .07
Age of onset disease 183 -.21   .004 146 -.05   .52 184 -.12   .10
Number of episodes:
No. of manic episodes 163  .02   .76 130 -.01   .95 164  .12   .13
No. of depressive episodes 167 -.00   .96 131  .00   .97 168 -.01   .85
QIDS 180 -.02   .80 143 -.06   .51 181 -.04   .62
YMRS 181 -.01   .85 144 -.03   .76 182  .08   .23
Medication use:
Lithium
  - no lithium (ref)* 50 Ref. 38 Ref. 50 Ref.
  - only lithium 49 -.02   .88 40 -.11   .36 48 -.00   .97
  - lithium + other medica-
tion 85 -.06   .50 69 -.06   .57 87 -.13   .13
Anti-epileptics 38  .04   .58 30  .03   .73 40  .02   .83
Anti-psychotics 42 -.06   .44 35 -.12   .16 43 -.22   .002
Benzodiazepines 53 -.09   .25 40 -.06   .45 54 -.18   .01
Antidepressant 64 -.16   .03 48 -.06   .48 64 -.08   .29
No. of psychotropic med. 
types 184 -.10   .18 147 -.09   .30 185 -.19   .01
Substance use:  
Alcohol:
  - none (ref.)* 63 Ref. 43 Ref. 63 Ref.
  - 1-2 units/day 99  .20   .01 84  .18   .04 100  .16   .05
  - ≥3 units/day 20  .09   .44 18 -.11   .40 20  .01   .96
Drug use (no drug use ref.) 14 -.08   .31 12  .08   .37 14  .12   .10
Smoking  (non-smoking ref.) 77  .15   .05 61  .06   .48 77 -.02   .78
* For reference category no β can be estimated
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Table 3: Clinical characteristics in relation with cognitive performance in 3 domains, 








N b P N b P N b P
Clinical characteristics
Diagnostic information:
BD 2 (BD 1 ref.) 59  .16 .03 45  .12 .13 59  .11 .10
Childhood adversity  54 -.10 .16 39  .03 .76 55  .01 .90
Current anxiety disorder   54 -.13 .06 42  .01 .94 55  .09 .18
Psychiatric co-morbidity 75 -.09 .24 61  .01 .95 75  .08 .24
Age of onset:
Age of onset first mania 163 -.01 .87 130  .01 .97 164 -.03 .74
Age of onset first depression 167 -.15 .06 131  .03 .74 168  .01 .92
Age of onset disease 183 -.11 .12 146 -.03 .72 184  .02 .80
Number of episodes:
No. of depressive episodes 167  .02 .80 131  .05 .53 168  .06 .42
No. of manic episodes 163  .02 .76 130  .04 .62 164  .14 .04
QIDS 180 -.02 .79 143 -.03 .72 181  .00 .99
YMRS 181 -.04 .54 144 -.04 .59 182  .06 .36
Medication use:
Lithium use:
  - no lithium (ref)* 50 Ref. 38 Ref. 50 Ref.
  - only lithium 49 -.01 .95 40 -.07 .56 48 -.05 .58
  - lithium + other medication 85 -.07 .38 69 -.07 .44 87 -.19 .01
Anti-epileptics 38  .03 .39 30 -.02 .83 40  .00 .95
Anti-psychotics 42 -.06 .40 35 -.11 .18 43 -.20 .002
Benzodiazepines 53 -.02 .75 40 -.02 .80 54 -.08 .26
Antidepressant 64 -.16 .02 48 -.10 .21 64 -.09 .17
No. of psychotropic med types 184 -.10 .17 147 -.12 .13 185 -.19 .004
Substance use:  
Alcohol use:
  - none (ref.) * 63 Ref 43 Ref 63 Ref .40
  - 1-2 units/day 99  .16 .04 84  .14 .10 100  .06 .79
  - ≥3 units/day 20  .10 .35 18 -.08 .56 20 -.03 .07
Drug use (no drug use ref.) 14  .06 .43 12  .09 .25 14  .12 .85
Smoking  (non-smoking ref.) 77  .16 .03 61  .08 .31 77 -.01 .74
* For reference category no β can be estimated
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Mean standard scores (with error bars representing standard errors) for attention 
(n=184), working memory (n=147), and executive functioning (n=185) in BD patients 
according to the use of antipsychotic medication, the use of antidepressant medication, 
and the total number of psychotropic medication used. The grey reference line shows the 
mean cognitive score. The size of each square is proportional to the number of patients. 
Scores are adjusted for sex, age, and education. Beta-coefficients and P values are 
calculated by multivariate linear regression analysis.
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We studied the relationship between cognitive performance and sociodemographic and 
clinical characteristics of BD, medication use and substance use. In this study we found 
that the non-illness related variables age and level of education were strongly associated 
with cognitive performance assessed with the TAP. With respect to clinical characteristics 
we found that BD2 is associated with better attention and more manic episodes are 
associated with better executive functioning. Second, the number of different types of 
medication was inversely associated with executive functioning, and non-significantly 
with poorer levels of attention and working memory. When focusing on the individual 
types of medication, antipsychotics were in particular associated with poorer executive 
functioning, while antidepressant use was associated with poorer attentional 
performance. Remarkably, Lithium had no influence on cognitive performance. Smoking 
and moderate alcohol use (1-2 units/day) was related to better attention, but was not 
associated with working memory or executive functioning. 
Sociodemographic characteristics: Age and level of education
Age is a well known determinant of cognition, with mainly processing speed, reasoning, 
memory and executive functions declining with advancing age (16). This is referred to 
as cognitive ageing starting in early adulthood, which is in line with our results. The 
influence of the level of education on cognition has also been studied thoroughly in the 
elderly, whose educational level positive associated with late life cognition (17). This is in 
line with our findings that educational level was strongly associated with better cognitive 
performance.
Clinical characteristics
BD2 was found to be associated with a slightly better cognitive functioning on all three 
domains (though only significantly for attention) compared to patients with BD1. This 
finding was partly consistent with the findings from a meta-analysis (8), showing that BD2 
patients performed slightly better only on memory tasks but furthermore the patients in 
this meta-analysis were equally severely impaired on other cognitive domains. Criteria 
to differentiate BD1 and BD2 are soft and hypomania is difficult to diagnose, leading 
to a risk of misclassification. For all these reasons, differences between BD1 and BD2 
need to be more thoroughly studied.  Regarding the influence of the number of mood 
episodes, it was recently found that a history with more manic and depressive episodes 
was associated with poorer working memory (18). However, no longitudinal studies 
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are available to further specify the influence of number of episodes. Our finding that 
number of manic episodes was positively associated with executive functioning should 
therefore be interpreted with caution. Longitudinal studies are needed to investigate the 
influence of the number of episodes. 
Use of multiple types of medication
Many BD patients, even one third after one year medication use,  use more than one 
drug simultaneously (7). In our patient group, an impressive percentage of 59.9% used 
2 or more types of psychotropic medication. Kupfer et al. found that more than one 
third of bipolar patients even uses 3 or more different types of psychotropic medications 
(19). This could be explained by selection bias (see Strengths and weaknesses). Without 
taking into account the problematic side effects, interaction risks and health problems, 
use of multiple types of medication itself has previously been found to be negatively 
associated with cognition in 76 patients with bipolar (spectrum) disorder (18). Elie 
et al (20) also found negative effects on cognition in 56 patients who suffered from 
schizophrenia or schizoaffective disorder, possibly (partly) explained by high doses of 
antipsychotics. Although one explanation for the link may be that use of multiple types 
of medication adversely affects cognition in BD patients, the direction of causality may 
be more complex. It could indicate a higher degree of disease severity explaining both 
use of multiple types of medication and cognitive dysfunction. Another possibility is that 
patients with more cognitive deficits and subsequent worsening clinical outcomes, end 
up using more medication which may lead to use of multiple types of medication and 
as such to cognitive impairment. However, by adjusting our analyses for clinical severity 
parameters, all findings remained, thereby strengthening the hypothesis that medication 
use influences cognitive deficits.
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Antipsychotic use and cognition
In observational research, it is not possible to completely disentangle the direction of 
this association. Besides a direct adverse effect of antipsychotics on cognition, it is again 
possible that third factors, like more severe disease activity or history of psychosis (21) 
could explain both the prescription of antipsychotics and poorer cognition. One argument 
supporting the hypothesis that cognitive deficits are adverse effects of antipsychotics 
is given by a recent study of Arts et al. (18), who followed cognitive performance in 
76 bipolar patients over a period of 2 years.  Use of second generation antipsychotics 
was associated with negative effects on cognition, mainly affecting motor speed and 
information processing. In particular antipsychotics were repeatedly correlated with 
worsening of cognitive performance and IQ in bipolar patients  (22). Moreover, these 
findings seem to be rather specific for bipolar patients (5). Effects of antipsychotics 
in patients with schizophrenia were conflicting. However, Elie et al. (20) found that 
increasing antipsychotic daily doses as well as use of multiple types of medication were 
associated with poorer cognitive functioning. 
Antidepressants and attention
Antidepressants may also be responsible for the occurrence of some of the side effects 
on cognitive dysfunction. Anticholinergic effects (for example resulting from the usage 
of paroxetine) are known to influence cognition, especially memory retrieval (23). The 
authors state that these effects might be even more pronounced in elderly patients. 
However, studies in patients with BD are scarce. In the study of Arts et al. no influence of 
antidepressants on cognition was found in BD patients (18). However, as antidepressants 
differ in pharmacological profiles it is difficult to assess this medication type as a group. 
Lithium use and cognition
In our study, lithium use was not related to cognitive decline. In literature, short term 
and long-term use of lithium have been recognized to exert differential effects on 
cognition. Short term use could negatively affect processing speed (18). Subjective 
complaints of Lithium users clearly include mental slowness as well (24).  Chronic lithium 
use was associated with minor (6) or no (25) cognitive problems. Recently, it has been 
shown that long-term lithium exposure in brain injured mice is leading to attenuation 
of neuronal degeneration in areas of the hippocampus (26), accompanied by improved 
performance in spatial learning and memory tasks during a 14 day follow-up. In human 
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patients with Bipolar Disorder, Arts et al. (18) also found that long term use of Lithium 
positively predicted  longitudinal improvement in verbal learning. 
Substance use
We found that smoking as well as daily alcohol use of 1-2 glasses is associated with 
improved attention. It is known that smoking is directly influencing the nicotinergic 
receptors, involved in for example attention, learning and working memory (27). 
Therefore, direct smoking effects cannot be ruled out. Light to moderate daily alcohol 
use is known to have preventive effects on (vascular) dementia (28). Our study included 
middle aged patients (mean age=48.6; SD=11.1). We hypothesize that light to moderate 
alcohol use could protect also against mild cognitive decline in these middle aged 
patients. 
Strengths and weaknesses of this study
A strength of this study is the high number of patients compared to previous studies 
in BD that included a total of 10 to 76 subjects (10). Moreover, all patients were in a 
euthymic phase of the illness, thus ruling out the effects of current manic or depressed 
mood state and the median number of medication was high, suggesting a high disease 
severity on average. This limits the external validity of our findings and the possibility 
to extrapolate the conclusions to chronically unstable patients and patients with milder 
symptoms. 
This study focuses on clinical characteristics and medication use. We are aware of the fact 
that other factors, for example, physical risk factors summarized in metabolic syndrome, 
are known to be related with worse performance on cognitive tasks (executive function, 
working memory) as well (29). This needs attention in future studies.
Two weaknesses should be noted. Firstly, because of the cross-sectional design, it was not 
possible to disentangle the direction of causality. More severe illness is likely associated 
to more extensive use of medication, and therefore it cannot be ruled out that disease 
severity rather than medication adversely affected cognition. However, antipsychotics 
and use of multiple types of medication are known to negatively influence cognition 
in other studies. In our study the findings remained alike after adjustment for disease 
severity parameters, suggesting a separate role for medication in influencing cognition. 
Secondly, selection bias is not ruled out, showed by the high percentage of patients 
using 2 or more different types of medications. This could have led to a more severe 
patient population included. Therefore, conclusions are only justified for a subgroup 
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of severely ill patients. Thirdly, information about the history of psychotic symptoms 
for example during manic episodes, was unavailable. Finally, it needs to be remarked 
that cognitive deficits is not automatically related with subjective cognitive complaints 
(30). Therefore, clinical relevance has to be further assessed in future research. It will 
also improve insight in clinical relevance, when it is possible to compare the cognitive 
performance of our group with a matched healthy control group. 
Conclusion
We conclude that use of multiple types of medication, specifically with antipsychotic 
medication, is associated with poorer performance in three important cognitive domains 
in patients with BD. In the light of the aforementioned, we carefully recommend clinicians 
to take into account the long term side effects on cognition of antipsychotics and use of 
multiple types of medication when deciding about pharmacological treatment options 
in patients with BD. 
Influence of medication use and clinical characteristics of  Bipolar Disorder on attention, 








1. Burdick KE, Goldberg JF, Harrow M. Neurocognitive dysfunction and psychosocial outcome 
in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr Scand. 2010; 122:499-
506.
2. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar 
disorder: a meta-analysis. Acta Psychiatr Scand. 2007; 116:17-26.
3. Martinez-Aran A, Scott J, Colom F, Torrent C, Tabares-Seisdedos R, Daban C, et al. Treatment 
nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry. 2009; 
70:1017-23.
4. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis 
of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect 
Disord. 2009; 113:1-20.
5. Jamrozinski K, Gruber O, Kemmer C, Falkai P, Scherk H. Neurocognitive functions in euthymic 
bipolar patients. Acta Psychiatr Scand. 2009; 119:365-74.
6. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: 
a meta-analysis. J Clin Psychiatry. 2009; 70:1588-97.
7. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients 
with bipolar disorder in the United States: polytherapy and adherence. Psychiatric Services. 
2008; 59:1175-83.
8. Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic review of neurocognition in bipolar II 
disorder. Acta Psychiatr Scand. 2010.
9. Sanchez-Moreno J, Martinez-Aran A, Colom F, Scott J, Tabares-Seisdedos R, Sugranyes G, et 
al. Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history 
of alcohol use. J Clin Psychiatry. 2009; 70:1120-7.
10. Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in 
euthymic bipolar patients and their first-degree relatives.[Erratum appears in Psychol Med. 
2009 Mar;39(3):525]. Psychol Med. 2008; 38:771-85.
11. Spijker AT, Giltay EJ, van Rossum EF, Manenschijn L, Derijk RH, Haffmans J, et al. Glucocorticoid 
and mineralocorticoid receptor polymorphisms and clinical characteristics in bipolar 
disorder patients. Psychoneuroendocrinology. 2011; 36:1460-9.
12. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and 
sensitivity. Br J Psychiatry. 1978; 133:429-35.
172
Chapter 7
13. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and 
validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse 
Negl. 2003; 27:169-90.
14. Riecher-Rossler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, et al. 
Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry. 
2009; 66:1023-30.
15. Hofer A, Niedermayer B, Kemmler G, Rettenbacher MA, Trebo E, Widschwendter CG, et 
al. Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to 
neuropsychological testing. Schizophrenia Research. 2007; 92:126-31.
16. Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni RE, et al. Age-associated cognitive 
decline. Br Med Bull. 2009; 92:135-52.
17. Jefferson AL, Gibbons LE, Rentz DM, Carvalho JO, Manly J, Bennett DA, et al. A Life Course 
Model of Cognitive Activities, Socioeconomic Status, Education, Reading Ability, and 
Cognition. Journal of the American Geriatrics Society. 2011; 59:1403-11.
18. Arts B, Jabben N, Krabbendam L, van Os J. A 2-year naturalistic study on cognitive functioning 
in bipolar disorder. Acta Psychiatr Scand. 2011; 123:190-205.
19. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical 
characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002; 
63:120-5.
20. Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. Cognitive effects of 
antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia 
and schizoaffective disorder. Journal of Psychopharmacology. 2010; 24:1037-44.
21. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, et al. Neurocognitive 
dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis 
rather than diagnostic group. Schizophrenia Bulletin. 2011; 37:73-83.
22. Donaldson S, Goldstein LH, Landau S, Raymont V, Frangou S. The Maudsley Bipolar Disorder 
Project: the effect of medication, family history, and duration of illness on IQ and memory in 
bipolar I disorder. J Clin Psychiatry. 2003; 64:86-93.
23. Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic pharmacological profiles and 
associated cognitive effects of serotonin reuptake inhibitors. Journal of Psychopharmacology. 
2001; 15:173-9.
24. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. 
Psychopharmacology (Berl). 2003; 170:225-34.
Influence of medication use and clinical characteristics of  Bipolar Disorder on attention, 







25. Lopez-Jaramillo C, Lopera-Vasquez J, Ospina-Duque J, Garcia J, Gallo A, Cortez V, et al. 
Lithium treatment effects on the neuropsychological functioning of patients with bipolar I 
disorder. J Clin Psychiatry. 2010; 71:1055-60.
26. Zhu Z-F, Wang Q-G, Han B-J, William CP. Neuroprotective effect and cognitive outcome of 
chronic lithium on traumatic brain injury in mice. Brain Research Bulletin. 2010; 83:272-7.
27. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: 
behavioral characterization, pharmacological specification, and anatomic localization. 
Psychopharmacology (Berl). 2006; 184:523-39.
28. Ruitenberg A, Van Swieten JC, Witteman JCM, Mehta KM, Van Duijn CM, Hofman A, et al. 
Alcohol consumption and risk of dementia: The Rotterdam Study. Lancet. 2002; 359:281-6.
29. Hassenstab JJ, Sweat V, Bruehl H, Convit A. Metabolic syndrome is associated with learning 
and recall impairment in middle age. Dementia & Geriatric Cognitive Disorders. 2010; 
29:356-62.
30. van der Werf-Eldering MJ, Burger H, Jabben N, Holthausen EAE, Aleman A, Nolen WA. Is 
the lack of association between cognitive complaints and objective cognitive functioning in 













In 2005, we started a study named The Bipolar Stress Study, at the outpatient department 
for Bipolar Disorders of PsyQ The Hague. The general topic of the Bipolar Stress Study 
was and is to identify risk factors that have impact on the clinical course and treatment 
of BD. In the study three levels and their interactions with the environment (stressful 
life events and social support) were distinguished:  clinical functioning (phenotype), 
genetic variations and vulnerability (genotype) and two endophenotypes, namely 
cortisol exposure and cognitive functioning. For the cross-sectional study the data of 
366 patients were collected (genotype and phenotype); 189 patients participated in the 
extended part of the study including the cognitive test at first visit and the 24 month 
longitudinal study.
In this dissertation, a part of the results is presented with the emphasis on the role 
of two endophenotypes, namely cortisol exposure and cognitive functioning. Here, the 
main findings will be critically presented, including the strengths and limitations.
Subsequently will be discussed:
1 GR /MR polymorphisms and clinical course of BD;
2 Cortisol levels in saliva and hair, the relation with clinical course of BD;
3  Associations of cognitive functioning with medication use in BD.
1. GR /MR polymorphisms and clinical course
Of the 366 patients enrolled in the cross-sectional part of the study, 326 patients were 
included in the genotypic assessments. Due to organizational reasons, the last 40 patients 
could not be genotyped. We found that several GR gene polymorphisms altering cortisol 
sensitivity associate with seasonal patterns of mood episodes, especially hypomania. In 
particular the 9β (rs6198), and, to a lesser extent, both the ER22/23EK (rs6189/rs6190) 
and the BclI (rs41423247) polymorphisms seem to associate with clinical characteristics 
of BD.
Even though this cohort is a large group with bipolar patients, for genetic association 
studies it is rather small. For example, only 8% of a healthy population (n=350; age 
is between 13-36 years old; not screened for psychiatric diagnoses), is carrier of the 
ER22/23EK on at least one allele. More frequent polymorphisms in healthy populations 
are the BclI (63% is carrier in the healthy population) and the 9β (31%) (1). However, 
contrary to Genome Wide Association Studies needing thousands of patients to find 
genetic associations with disease, this study is not designed to detect causes of BD. It 








genetic polymorphisms involved in regulation of cortisol sensitivity at the cellular level. 
The associations we found with clinical course of BD shed some light on the influence of 
changes in HPA-axis regulation on the disease. For example, the activity of the HPA-axis is 
known to be regulated by seasonal changes, with mild hypersensitivity for glucocorticoids 
during the winter. BD patients who also have a genetic vulnerability for dysregulation 
in the HPA-axis by GR polymorphisms may be more likely to develop seasonal mood 
episodes.  However, several limitations have to be noticed. First, in this part of the study, 
the approach was cross-sectional with clinical data gathered retrospectively, leading 
to potential recall bias. This might have affected the reliability of the retrospectively 
collected data such as the reported age of onset of symptoms. On the other hand, we 
expect that due to the impact of first hypomania and mania these might be remembered 
quite well. Second, patients were questioned about their first illness symptoms, which 
hamper a sharp differentiation between symptoms and episodes. Third, results should 
be taken with caution, since we cannot rule out false positive genetic findings. Future 
studies are needed to replicate our findings.
Our findings of a relationship between GR polymorphisms and the course and 
characteristics of BD and the effect of treatment, can be added to a growing number of 
studies, in which the regulation and functioning of the GR has been shown to be related 
to clinically relevant aspects of mood disorders. One study showed a lower frequency of 
the G –allele of the BclI polymorphism in patients with excellent Lithium response (2). 
Other haplotypes are also more frequent in patients with partial or no Lithium response, 
further underlining the influence of differences in stress hormone (cortisol) sensitivity on 
medication response defining course of the disease(2). In another study, three GR gene 
polymorphisms in exon 9 (among which the 9β variant) were found to be associated with 
response to Lamotrigine but not to Olanzapine/Fluoxetine treatment (3). This is evidence 
in the body of literature supporting the relevance of GR polymorphisms in effect of 
antidepressant and mood stabilizing treatment. In addition to genetic variations in the 
GR, also changes of the GR function through gene activity and expression appears to be 
important (4-7). However, the exact mechanism is not elucidated yet. Direct evidence of 
involvement of the GR in BD has been shown by effects of GR antagonist mifepristone 
in bipolar depression, improving cognitive function and mood after one week treatment 
compared with placebo (8, 9, 9b). 
In more detail it is interesting to notice the differences in direction of influence between 
polymorphisms. Specifically the 9β and the ER22/23EK polymorphisms are known to 
lead to mild glucocorticoid resistance, whereas other GR gene polymorphisms in this 
study (most important is the BclI polymorphism) are leading to mild glucocorticoid 
hypersensitivity (10-12). In trying to grasp this paradox, some issues have to be noted.
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First, higher susceptibility to develop depressive episodes is found for both mild 
glucocorticoid hypersensitivity due to the BclI polymorphism (13), as well as mild 
glucocorticoid resistance due to the ER22/23EK polymorphism (13). This might 
indicate that the HPA-axis functioning knows an optimal set point with a U-shaped 
curve. Polymorphisms leading to relative resistance as well as SNPs leading to relative 
hypersensitivity in response to GCs, can both be involved in development of mood 
disorders. In this thesis we found that the ER22/23EK polymorphism is associated with an 
almost 8 years younger age of onset of BD (14). With the influence of GR polymorphisms, 
specifically the 9β or BclI  polymorphism, on HPA-axis regulation, other influences, like 
seasonal induced changes in cortisol sensitivity, can further deregulate the system, 
leading to proneness for seasonal episodes as shown in chapter 4 (14). 
Second, polymorphisms differentially affect intracellular signaling pathways of the GR, 
which might explain why for example both the ER22/23EK and 9β polymorphisms lead 
to resistance for GCs, but seem to differ in susceptibility for mood episodes. The 9β 
polymorphism has been shown to increase mRNA stability of the GR-β splice variant. 
This may result in more of the GR-β at the protein level, which dominantly inhibits 
the active GR-α  isoform. Carriers of the 9β polymorphism have a higher susceptibility 
to develop rheumatoid arthritis (15, 16). Additionally, homozygous carriers of this 
polymorphism have been shown to be 70% less likely to be carrier of nasal S. Aureus 
(17). This indicates that the increased level of the GR-β splice variant leads to activation 
of inflammatory activity and resistance for GCs. The ER22/23EK polymorphism on the 
other hand is inducing decreased transcriptional activity because of an increase in a less 
transcriptional active translation isoform of the GR (the GR-A) (18), leading to diminished 
effects of GCs. This might be one of mechanisms involved in differences for susceptibility 
for developing mood episodes. However, further research is needed to shed light on 
exact consequences of GR signaling pathways in relation to mood. 
Third, the already mentioned effects on the immune system should be taken into 
account to understand the effects of the polymorphism in relation to mood. In the afore 
mentioned study of Van Oosten et al. (15), in addition to the 9β polymorphism carriers, 
also the ER22/23EK carriers show a higher risk on developing rheumatoid arthritis, 
indicating a possible indirect effect on inflammation and the immune system. This is in 
line with the effect of the other polymorphisms, the BclI and N363S (rs6195), known 
to induce hypersensitivity for glucocorticoids, which lead to a lower risk on developing 
rheumatoid arthritis. Both may reflect a reduced (ER22/23EK and 9β) or increased (N363S 
and BclI) GC induced immunosuppression. Hypothetically, this may result in a more pro-
inflammatory state of the immune system, which is also known to be the case during 
mood episodes and in BD in general (19, 20). The intertwining of the immune system 








future research to study both systems in relation to each other. This may help to identify 
new pathways for treatment.
To conclude, further understanding is needed about the relation between functional 
polymorphisms of the GR gene, like BclI, 9β and the less frequent but influential 
ER22/23EK and clinical phenotypes in BD (and other mood disorders) like seasonal 
patterns, age of onset of disease and clinical course as well as therapy response. The role 
of MR gene polymorphisms in BD is not related to these factors in BD. However, future 
analyses will focus on elucidating the role of GR and MR polymorphisms in cognitive 
impairments in BD. 
Furthermore, a complicating factor in understanding the role of GR and MR polymorphisms 
is that serum cortisol seems to fail in providing information about the potential mediating 
effects of cortisol on the relationship between GR and MR polymorphisms and clinical 
characteristics in bipolar patients. This might be due to the circadian rhythm of cortisol 
levels and the pulsatile way cortisol is secreted. Also, large daily variations due to e.g. 
acute stress or infection are also an important limitation of measuring serum cortisol 
levels. Using information about genetic variations known to be associated with altered 
cortisol sensitivity, results in a more adequately assessment of the lifelong true impact 
of cortisol at the tissue level. Taking GR genotypes into account may contribute to better 
understanding the relationship between glucocorticoids and BD. In the next paragraph 
this relation will be further discussed.
2. Cortisol levels in saliva and hair, the relation with clinical course of 
BD
In the introduction, an overview with different methods to evaluate HPA-axis functioning 
is provided. Previous studies used salivary or serum cortisol levels to evaluate HPA-axis 
functioning. With these assessment methods, insight in total cortisol levels, the Cortisol 
Awakening Response and changes in cortisol levels during the day can be obtained. 
However, these assessments do not provide insight in long-term functioning of the HPA-
axis, due to the frequent fluctuations and influenceable cortisol levels. In BD studies, 
as well as in other studies with patients categorized according DSM-IV diagnoses, there 
were conflicting results. In addition to the changing levels of cortisol during the day, 
these results could reflect the limitations of the DSM-IV categories. Recently, clusters 
of symptoms in patients with depression and/or anxiety have been shown to correlate 
nonlinearly with the cortisol awakening rise (21), indicating the added value of analyzing 
symptom clusters above DSM-IV categories in depression and anxiety. In studies including 
bipolar patients, results vary from no differences in basal salivary or serum cortisol levels 
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in patients with BD versus healthy controls (22-24) to elevated cortisol levels in other 
studies(25, 26). Vreeburg et al, found that smoking has been found to associate with 
resistance for GCs, other factors influencing different HPA-axis measurements included 
sampling factors, health factors, sex and age. In order to minimize the influence of all 
factors involved in this variability, it is necessary to adjust analyses for confounders (27). 
In order to obtain insight in long-term functioning of the HPA-axis, we used a newly 
developed assay with which cortisol can be measured in scalp hair. This method offers 
the opportunity to determine mean long-term cortisol levels and appears to yield a 
reliable estimate of long-term HPA-axis activity (28, 29). Furthermore, it is unique in its 
ability to retrospectively assess cortisol levels, an approach which can help evaluating the 
consequences of life events, or therapy interventions (28). Recent evidence shows that 
in veterans higher hair cortisol relates with PTSD and number of traumatic events (30). 
Additionally, long-term cortisol was higher in patients admitted for acute myocardial 
infarction compared to patients with other indications for admission on internal wards 
(31): cortisol levels were raised 3 months prior to the event. Shift work is also associated 
with higher long-term cortisol levels in hair, as well as with higher BMI in shift workers 
and healthy persons (32). This method seems promising for the future in following HPA-
axis functioning over prolonged periods of time. 
However, several issues regarding cortisol assessment in scalp hair have to be addressed: 
First, it is not clear what is measured in hair: free or total cortisol. In the circulation 
approximately 75% of cortisol is bound to cortisol binding globulin (CBG), which is 
thought to be the biologically inactive state, circa 20% is bound to serum albumin, 
and around 4% is free cortisol. It is already convincingly found that total cortisol levels, 
vary significantly within and between individuals, thereby affecting the interpretation 
of HPA-axis test results (33). Still under debate but with support of recent evidence is 
the hypothesis that hair cortisol is reflecting free circulating cortisol levels. Evidence to 
support this is found in estrogen users.  Oral contraceptives (OAC) stimulate CBG levels, 
but in OAC users, cortisol levels in scalp hair are similar to non users. This suggests that 
hair cortisol reflects free (biologically active) cortisol levels, and not total cortisol levels 
(28). 
Second, long-term hair cortisol and short term saliva cortisol do not relate (34), which is 
also found in our study (chapter 5). The retrospective calendar provided by long-term hair 
cortisol could provide information about mean cortisol exposure and reflect long-term 
(weeks to months) gradual changes (28, 35-38), in contrast to saliva samples reflecting 
levels of acute stress response (minutes to hours). This indicates that these two methods 
could be nicely applied together, serving different purposes in evaluating the HPA-axis. 








to life events, chronic stress, cardiovascular diseases, and treatments, e.g. treatment of 
Cushing’s Syndrome (28). Saliva cortisol provides information of daily cortisol changes, 
with the CAR as awakening stress response, responsivity during the day by Experience 
Sampling Method and the cortisol day curve as information about the daily changes 
and diurnal rhythm. Challenge tests on the other hand, such as the Dexamethasone 
Suppression Test (DST) or the more sensitive Dex/CRH-Test, provide information about 
the magnitude and variability of the sensitivity of the negative feedback at pituitary level 
on cortisol production. 
Third, the clinical relevance of this novel method of hair cortisol measurement has to 
be further investigated. Currently, evidence is swiftly mounting in a growing number 
of patient populations. For example, in generalized anxiety disorder (GAD), decreased 
cortisol levels in hairs have been found, but no differences in salivary cortisol levels 
between GAD patients and healthy controls (39). This is in line with our findings of 
lower hair cortisol levels in BD patients with co-morbid panic disorder and suggests 
also that hair cortisol levels may reflect the long-term cortisol secretion, whereas the 
results found with saliva or serum cortisol levels might include acute responses to the 
time and circumstances of assessment. Depressed medicated patients were found to 
have higher cortisol levels during 6 months before cutting hair strands, compared with 
healthy controls (40). In the future it would be very interesting to analyze hair cortisol 
levels in relation to clinical parameters such as medication effects, life events, remission 
and recurrence of mood episodes.
Fourth, it is not yet clear to what hair length retrospective cortisol levels can be measured 
reliably. The maximum length of hair strands differs between laboratories, differing 
between 6 cm (=6 months) (41) to several years depending on the length of the hair 
(28). This is probably due to differences in processing of the hair samples which slightly 
differs between laboratories.  
Fifth, it seems that over time cortisol levels in scalp hairs remain stable. In over 2000 
years old mummies changes in hair cortisol levels were assessed, with possibly one case 
of  pathological cortisol raise (42), indicating the reliability over time of found cortisol 
levels. However, this needs further replication. Currently, a growing number of studies is 
validating this method and define the clinical relevance.
As already stated in the introduction of this thesis, in addition to medication use, 
the chronic course of the disease is also defined by another endophenotype, namely 
cognition. This endophenotype will be discussed below, but in this paragraph we will 
discuss the relation between cognition and long-term hair cortisol. In our study cognitive 
performance was measured at baseline, while the hair strands were in some cases cut 
almost 2 years later, at the end of the study period, which is leading to difficulties in 
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interpreting the results. Hair cortisol reflects long-term cortisol levels, and cognitive 
deficits are thought to be related with high cortisol levels on the long-term as well (43). 
It is known that patients with Cushing’s Syndrome defined by chronic excessive cortisol 
levels suffer from early aging in cognitive performance and general cerebral loss of 
volume (44-46), specifically hippocampal atrophy.  
 In our preliminary analyses a negative relationship was found between executive 
functioning and hair cortisol levels. Patients with an above average score showed lower 
cortisol levels (p=.02; after adjustment for age, gender, and hair treatment, the use 
of hair products and frequency of hair wash, p=0.015). It has to be noted that these 
analyses need further replication and comparison with healthy controls. Although 
in healthy controls hair cortisol levels are stable over time, the fact that the cognitive 
tests in BD patients have been performed at baseline of the study and the hair analyses 
includes the period between the 18th and 21th month of the study complicates the 
interpretation of the results. Taken together, these findings underline the preliminary 
and explorative character of this new technique, which is in need for further validation 
and interpretation in a clinical relevant way. 
To conclude, we and others found associations of hair cortisol with psychopathology 
(mood and anxiety), which are promising for future research. Hair cortisol measurements 
have a promise to serve as an endophenotype in identifying the role of regulation of 
the HPA-axis in the long-term course of BD. As we did not find any difference between 
healthy controls and BD as disease entity, we would recommend to study long-term 
hair cortisol levels in relation to cognitive performance over time, and also focus on 
symptom level like for example mood and anxiety over time. This is in line with recent 
studies focusing on symptoms clusters or dimensions in relation with for example HPA-
axis functioning and metabolic syndrome (21, 47).
3.  Associations of cognitive functioning with medication use in BD
In our study, cognitive performance was assessed by means of the Test for Attentional 
Performance (‘Testbatterie zur Aufmerksamkeitsprüfung’ (TAP), version 2.1, http://
www.psytest.net/ ; Zimmermann & Fimm, 2002). The TAP is a widely used computer 
based standardized test battery and easy to use in clinical practice (48-50). However, 
when we started our study, no international consensus was reached about the use of 
instruments. Recently, the International Society for Bipolar Disorders (ISBD) proposed 
a more complete neurocognitive battery to asses global cognitive impairment and 
improvement, the ISBD Battery for Assessment of Neurocognition (ISBD-BANC)(51). 








patient-control effect size differences across the literature. Cognitive domains tested 
with this battery, include attention/ vigilance, processing speed, verbal learning and 
memory, executive functioning and working memory, visual learning and memory. 
Of these domains, the TAP considered attention, executive functioning and working 
memory. However, using a common set of standardized procedures will probably lead 
to more comparable results across different research groups spanning the international 
community.
As stated in the introduction, cognitive deficits are known to have “trait” as well as 
“state” features. 
Cognitive deficits, as “trait” feature, are thought to be mainly caused by genetic factors 
and thus are an endophenotype of BD (52). This is in line with findings in unaffected 
siblings of BD patients performing worse on memory and executive functioning tasks 
compared with healthy controls (53), arguing that cognitive functioning could serve as 
an endophenotype in future research. This is also concluded in an earlier meta-analysis 
of Bora et al., finding that impairments of executive functioning, sustained attention and 
verbal memory were common both for patients as well as for relatives with larger effect 
sizes for the patient group (54). 
However,  in this meta-analysis deficits in processing speed and visual memory were 
only observed in patient groups, not in relative groups. Possibly, these functions 
reflect the influence of patient specific factors such as medication use (associated with 
psychomotor slowing) and earlier age of onset (associated with psychomotor slowing 
and verbal memory impairment). Thus, other, more “state-like” factors influencing 
cognitive abilities, seem important as well. This means that, in addition to the “trait” 
part of cognitive impairments in BD, it is clear that also “state” dependency like current 
mood, as well as other factors like medication use, are worsening cognitive performance 
(52).  In this dissertation, before using cognition as endophenotype, we decided to first 
investigate the influences on the “state” of cognitive performance. 
In chapter 6, we showed an association between use of number of medication types 
and worsening of executive functioning; antipsychotics and antidepressants associate 
respectively with poorer executive functioning and attention. Lithium showed no 
association with cognitive functioning. Regarding the literature about the relation 
between medication and cognition in BD, our results seem in line with previous 
findings: 1) Lithium induces mainly a slight slowing of processing speed and subjective 
impairment of cognitive functioning; no strong other significant influences on cognitive 
performance have been found (48, 55, 56). 2) Antipsychotic  use was associated with 
level of memory and executive functioning in a group of 40 BD patients compared with 
40 healthy controls (48). 3) Despite the large body of research, little attention has been 
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given to the long-term consequences for cognition of polypharmacy, a common practice 
in the treatment of BD. Moreover, long-term studies are scarce. One 15 year longitudinal 
study showed in patients with non-schizophrenic psychosis a more than twice better 
functioning and social adjustment in non medicated patients compared with patients on 
any psychiatric medication (46). 
To conclude, the results in this thesis underline the importance of thoughtful prescription 
of medication, and especially caution in prescribing antipsychotics as well as in the use of 
2 or more different types of medications. However, an important limitation of our study 
was the cross-sectional study design, which made it impossible to make statements 
about causality. For example, it could well be  that patients with a more severe course 
of illness use more types of medication as well as suffer from more severe cognitive 
deficits. To be able to elucidate the direction of causality, we adjusted our analyses for 
all variables regarding severity of the disease, which did not change any finding. This 
supports our view that polypharmacy and especially antipsychotics, seem to negatively 
influence executive functioning.
In thinking about causes of cognitive impairments in BD, the “trait” as well as the “state” 
need attention. Moreover, as the scar hypothesis (57) suggests, cognitive performance 
can evolve during life under influence of for example number of mood episodes. This, 
together with medication use, current mood, and the genetically vulnerable profile 
(possibly caused by genetic vulnerability for BD) of cognitive performance could result 
in a detrimental evolution of cognition during the disease course. However, this topic 
should be considered more in detail, with attention for different domains of cognitive 
performance. 
Strengths and limitations
In general, this thesis presents the first results of a cross-sectional and longitudinal study, 
based on a relatively large and well phenotyped cohort. Proper phenotyping is known to 
be crucial for this type of epidemiological genetic association studies (58). In addition to 
clinical information, data were also thoroughly collected with respect to endophenotypic 
(biological data, cognitive performance) and genotypic information, to explore the 
influence of cortisol exposure on BD. Selection of genetic polymorphisms was based on 
functionality of polymorphisms and was driven by the hypothesis that HPA-regulation 
(mediated by GR and MR) is influencing the parameters chosen on endophenotypic as 
well as phenotypic level. The functionality of the GR and MR polymorphisms has been 
convincingly shown, which is quite unique, for all polymorphisms in in vivo studies (with 








in in vitro bio-assays (GR: ER22/23EK, 9β, N363S; MR: I180V and -2G/C (59)) and even on 
molecular level (GR: ER22/23EK (18) and 9β(16)).
In the analyses of the cross-sectional data, several limitations have to be noticed: 
First, data regarding illness characteristics were gathered by interviewing the patients 
with questionnaires, with a risk of recall bias.
Second, it is not possible yet at this point of the study to already claim clear causative 
conclusions, but only associative findings. However, our findings give direction to our 
future analyses of the longitudinal data. The longitudinal data hopefully will provide 
insight in the long-term influence of medication on cognition; furthermore, the influence 
of cortisol exposure on the longitudinal outcome will be analyzed. 
Third, the clinical relevance of our genetic analyses of the MR and GR is yet limited. For 
a genetic association study, our cohort is relatively small. This is foremost of importance 
for less frequent polymorphisms like the ER22/23EK and the N363S SNP. Statistical 
power was appropriate for the more frequent polymorphisms (GR-9β, BclI). Our genetic 
association study suffers, like all such studies, several other possible fallacies. One of 
them is the risk on finding false positive or false negative results. In genetic studies, 
depending on SNP frequency in healthy populations, high numbers of participants are 
needed (58). To decrease the risk of having such false positive findings, we corrected 
all analyses for multiple testing. Nevertheless, it remains uncertain whether the finding 
in chapter 3, regarding lower number of hypomanic and manic episodes in carriers of 
the 9β polymorphism in patients with BD, is a false positive finding.  After including 
more patients  in the cohort, the strength of the association diminished to sub threshold 
significance level. Replication is needed in another independent cohort. Furthermore, 
besides false positive findings, and the importance of reliable phenotyping; other 
fallacies in genetic associations include influence of racial heterogeneity, and differences 
in gender and age (58). In our study, the cohort consisted of 95 % Caucasian people 
from Dutch ascend  which could be regarded an asset of this study. Furthermore, 
patients were matched on age and gender with blood bank donors in this study (1). 
Notwithstanding these limitations these genetic studies merit continuation, as studies 
focusing on medication targeting the HPA-axis are promising and underline the relevance 
of the GR and MR function in mood disorders and cognition. 
Fourth, the assay for cortisol assessment in scalp hair has only recently been developed. 
Although in the past years clinical data are rapidly accumulating that this is a reliable 
marker of long-term mean systemic cortisol levels, in this stage application in psychiatry 
as well as in other specialisms, is new. There are several issues that need to be addressed 
regarding this technique (60) : 1) the exact mechanism of how (through blood, sweat, 
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or sebum; probably most important through blood) and where (hair cortex or medulla) 
cortisol is incorporated in hair shafts, need to be further clarified; however, for our 
findings this is of no direct relevance, but in interpreting cortisol levels in relation with 
other HPA-axis assessments, this would be of relevance; 2) the grow speed of hairs is 
important in creating timelines of cortisol levels and therefore more research on possible 
interracial differences is important.
 Fifth, hair cortisol analysis needs further embedding in clinical practice of mood 
disorders. Cortisol in hair can be regarded as a trait feature; however, severe stress, 
caused for instance by mood disorders, may lead to increased mean cortisol levels. Thus, 
the relation between life events and mood, but also between therapeutic success and 
mood, can be focus of research in the future. In our sample, numbers of patients with 
severe mood episodes were too low to be useful for analysis in this study.  Our findings 
warrant further study of the use of hair cortisol in relation to BD. 
Conclusive remarks
In this thesis several potential candidates are identified as risk factors influencing clinical 
course of BD. At the genotypic level, several GR gene polymorphisms changing cortisol 
exposure by sensitivity, associate with seasonal patterns of mood episodes, especially 
hypomania. In particular, the 9β polymorphism seems to associate with clinical 
characteristics of BD. At the endophenotypic level, higher cortisol exposure assessed 
by hair analysis is associated with more psychiatric co-morbidity and an older age of 
onset of the disease. However, due to our finding that no difference is found between 
the total group of patients with the broad phenotype BD and healthy controls, we would 
recommend to focus in future analyses with long-term cortisol on more defined and 
unambiguous long-term parameters like mood episodes in preceding months, anxiety 
symptoms, life events, and cognition, all in preceding months. 
Cognitive function, as second endophenotype, is related to the number and types of 
medication used. It should be noted that while lithium had no effect on cognition, 
antipsychotics significantly did. In the analyses performed in this thesis regarding 
cognition, the main conclusion is that the rate impact of medication use on cognitive 
performance is still under debate. With these results in mind, the next phase in the 
analysis of this study is to investigate cognition as an endophenotype, in relation to e.g. 
GR and MR polymorphisms, cortisol in hair, and clinical course of BD. 
Summarizing, cortisol exposure as determined by cortisol sensitivity at the genetic level 
and by measuring long-term cortisol levels using hair extracts, is associated with several 








cognitive functioning as second endophenotype, appears to relate to (number of 
different types of) medication.
Future perspectives
First, as already noted, it would be very interesting to relate our data to the longitudinal 
course of BD.  In box 1, the current findings are summarized in the light of the Bipolar 
Stress Study.
Box 1: findings and future directions with this thesis as part of the 
Bipolar Stress Study;



































Future directions: The longitudinal part of the study will be investigated (life chart data):  
a. What is the influence of genetic variations of the cortisol receptor on mood as measured by life chart? 
Is indeed the GR 9β and MRI180V protective? Can we confirm the relation to vulnerability for seasonal 
patterns?  
b. How is the relationship between cortisol in hairs, environmental  factors and course of mood, for 
example with sub analyses to patients with and without co-morbid panic disorder? 
c. What is the influence of current mood as “state-factor” on cognitive performance? 
d. What is the relation of cognitive performance to prospective course of the disease? 
e. What is the influence of childhood trauma on endophenotypic as well as phenotypic level? 
f. How is the relation between cognition as endophenotype and the life chart data in the following 24 
months, after adjustment for number of types of medication? 
 
Current status:  
 In this figure knowledge is added on  
1) the relation of GR and MR 
polymorphisms to clinical 
characteristics of BD;  
2) on the relation of endophenotype of 
the HPA axis to clinical 
characteristics of BD;  
3) on influences like medication use on 
cognition to establish confounders in 




Second, it would be very interesting to study immunological and inflammatory parameters 
in relation to the HPA-axis in BD and subsequent phenotypic data. The intertwining 
nature of both systems requires an integral vision to interpret the data in a meaningful 
way. Chronic stress is usually accompanied with raised pro-inflammatory cytokines 
(61), leading to higher risk of daily life infections and prolonged wound healing (62). In 
BD inflammatory changes are shown by a higher prevalence of organ auto-immunity 
(20) and pro-inflammatory activity in monocytes and anti-inflammatory  activity in T 
cells (63), showing an imbalance in interleukin levels, which is normalized with Lithium 
treatment (19). An altered gene expression of inflammatory genes, found as a mRNA 
gene signature, was found in patients with BD (64), with a clear pro-inflammatory state 
of genes in monocytes (65). However, replication and meaning of those findings need 
further research. Possibly, these genes are also influenced by factors like altered GR 
sensitivity or medication use.
Third, a range of medical problems has been associated with BD (66). The most frequently 
described conditions are cardiovascular diseases, diabetes, and obesity (66). These are 
all related to what is referred to as the Metabolic Syndrome (MetS) (67), defined by 
the criteria from the National Cholesterol Education Program (NCEP) Adult Treatment 
Program III (ATP III)(68) these risk factors comprise three or more of the following five 
criteria: 1) an increased abdominal circumference (> 102 cm for men and > 88 cm for 
women), 2) hypertriglyceridemia (> 150 mg/dl), 3) a low level of high-density lipoprotein 
cholesterol (< 40 mg/dl for men and < 50 mg/dl for women), 4) hypertension (> 130/80 
mmHg), and 5) a high fasting glucose level (> 100 mg/dl). Although several definitions of 
the MetS have been developed (69-71) the NCEP/ATPIII criteria are the most widely used 
in studies investigating the MetS.  Taken into account the recent insights in metabolic 
changes due to for example atypical antipsychotics (commonly used in treatment of BD), 
it is urgently needed to understand shared mechanisms in psychopathology and hence 
be able to assess individual risks. The metabolic syndrome is highly prevalent in the 
general population (around 25% in the US (72) and around 15% in a Dutch population 
aged 28-59(73) to almost 20% in the healthy control cohort of the Netherlands Study to 
Anxiety and Depression (NESDA) (74). A relation with severity of depressive symptoms 
was predominantly found with abdominal obesity and dyslipidemia. MetS seems even 
more prevalent in bipolar patients (30% in the US study of Fagiolini (72) and 25.3% 
in an Italian sample (75)). In our sample almost 33% fulfilled the criteria of metabolic 
syndrome (unpublished analyses). The metabolic syndrome is repeatedly associated 
with increased sensitivity for glucocorticoids and with a pro-inflammatory state (76). 
Thus, physical health is important to evaluate in studies with attention for possible 








And fourth, as a consequence of the above, the influence of medication has to be 
studied separately in longitudinal studies with respect to biological changes. It would 
be very relevant to study the consequences of different types of medication use on 
endophenotypes such as cortisol sensitivity and cognitive performance, but also on 
clinical phenotype with respect to number and severity of mood episodes. Iatrogenic 
damage due to antipsychotics or anti-epileptics in high risk patients should be avoided 
or minimalized.
As a final conclusive remark, the influence of the HPA-axis in relation with other biological 
systems, should be noticed to understand the clinical course of BD. Mood disorders are 
not limited to the brain, but involves wide bodily processes through hormones, cytokines 
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Bipolar disorder (BD) is a common mood disorder, with an estimated prevalence of 2.4 % 
in the Netherlands. Worldwide, BD is estimated to stay in the top ten causes of Years Lived 
with Disability (YLDs), accounting for 2.5% of total global YLDs. BD was once considered 
as an episodic illness with a relatively favorable outcome, but nowadays more attention 
is given to the variant with a more chronic course of the disease with cognitive deficits in 
between episodes, residual mood symptoms and impaired functioning in daily life roles. 
The core pathophysiological underpinnings of BD have to be elucidated to be able to 
understand the underlying processes leading to the clinical manifestations of the disease. 
One of the possible strategies in identifying biological underpinnings is the introduction 
of endophenotypes as alternative leads to find genetic vulnerability markers instead of 
the complex, phenotypical, disease  symptoms and syndromes. Endophenotypes are 
known as subclinical quantifiable traits that exist in affected and unaffected relatives 
independent of the clinical manifestation of the disorder. The traits can be for example, 
neurophysiological, biochemical, endocrine, neuro-anatomical, or cognitive in nature. 
In this dissertation the focus will be on the role of cortisol exposure and cognitive 
performance as two possible endophenotypes influencing clinical course of BD.
Study aims
In order to identify risk factors, that have impact on the clinical course of BD and 
treatment of patients suffering from BD, we started the Bipolar Stress Study (BiSS). In this 
study three levels and their interactions with the environment (stressful life events and 
social support) were distinguished: clinical functioning (phenotype), genetic variations 
and vulnerability (genotype) and endophenotypes, specifically cortisol exposure and 
cognitive functioning.
In this dissertation, part of the results of this study is presented. The emphasis was on the 
role of genotypes of the cortisol receptors, and the endophenotypes, cortisol exposure 
and cognitive functioning. The results of the BiSS may help to develop clinically relevant 
diagnostic and treatment interventions to improve the course of BD and subsequently 
the quality of life of patients with BD. 
Patients and Methods
The BiSS consisted of a cross sectional, and a prospective, longitudinal part. For the cross 
sectional study, data of 366 patients were collected with respect to genotype, phenotype 
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and endophenotype. In the 24 month longitudinal study, of these 366 patients, 189 
patients participated. In this thesis, the cross-sectional data at baseline are analyzed. 
Genetic data were associated with clinical characteristics and retrospectively collected 
data on clinical course of BD. In a subpopulation of the 189 patients hair cortisol was 
analyzed in relation to clinical characteristics of BD at  baseline.
In the longitudinal study, we first assessed cognitive performance of the 189 patients at 
the first visit of the longitudinal part. Cognitive functioning is regarded as endophenotype 
with trait-like characteristics. Additionally, it is known to be influenced by other, more 
state-like factors as well. In order to be able to properly investigate the role of cognitive 
performance as an endophenotype, it was necessary to first elucidate the influence of 
“state-factors”, like medication use on the results of the cognitive tests. In this thesis, the 
influence of medication use on cognitive performance was analyzed with data of the first 
visit of the longitudinal part.
Results 
1. Literature review (Chapter 1 and 2)
As a first step in approaching the relation between cortisol exposure and mood, the 
literature has been reviewed, regarding 1) glucocorticoid sensitivity and mood (chapter 
1), and, 2) genetic variations, or polymorphisms, in the Glucocorticoid Receptor (GR) and 
Mineralocorticoid Receptor (MR) genes in relation to glucocorticoid sensitivity, mood 
and cognition (chapter 2). 
Our main findings are:
Chapter 1: 
· Hyperactivity of the HPA-axis occurs in 80% of the acutely depressed patients (either 
bipolar or unipolar) as measured by the Dexamethasone/ Corticotropin Releasing 
Hormone (DEX/CRH)-test, with higher cortisol levels after DEX/CRH administration. 
· A long-term pattern of mild resistance for negative feedback signaling of 
glucocorticoids has been found, worsening during depressive episodes (not 
exclusively bipolar depression). 
· Single nucleotide polymorphisms in the genes encoding the GR as well as the MR, 
influence the set-point and regulation of the HPA axis, both measured through 
the Dexamethasone Suppression Test (DST) with the use of a very low dose 
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Dexamethasone of 0.25 mg. This dosage is known to detect subtle changes in 
feedback response to cortisol elevation. 
· The GR polymorphisms ER22/23EK (rs6189/rs6190) and 9β (rs6198) and the MR 
polymorphism MRI180V (rs5522) show a relative resistance for cortisol suppression 
after the DST. The GR polymorphisms BclI (rs41423247), N363S (rs6195) and the 
MR polymorphism -2G/C (rs2070951) show a relative hypersensitivity for cortisol 
suppression after the DST. 
· In utero stress and early trauma are important (dys)regulators of this set-point, 
probably through epigenetic changes leading to different functional gene expression 
and subsequent protein synthesis.
Chapter 2: 
· By looking at different polymorphisms in the GR gene and the relation with cognitive 
endophenotypic and phenotypic characteristics, it has been shown that the BclI 
(rs41423247) and ER22/23EK (rs6189/rs6190) polymorphisms are associated with 
risk on developing depression in several studies. 
· The polymorphism ER22/23EK (rs6189/rs6190) associates with a decreased risk of 
dementia in healthy individuals. 
· During a depressive episode, carriers of this ER22/23EK (rs6189/rs6190) variant 
demonstrated a tendency towards better cognition compared with non-carriers, as 
measured by divided attention tests. 
Concluding, the above described polymorphisms in the GR and MR gene, are associated 
with phenotypic characteristics in mood and endophenotypic features in cognition, 
revealing a possible mediating mechanism through changing the HPA-axis set point. 
Mainly the BclI (rs41423247) and the ER22/23EK (rs6189/rs6190) are associated with 
higher risk for depressive episodes. 
2. GR /MR polymorphisms and clinical course (chapter 3 and 4)
Due to findings in BD research that the HPA-axis is dysregulated, we investigated the GR 
and MR as important receptors in the regulation of the feedback loop in the HPA-axis 
on pituitary level. Hereby, we focused on genetic variations of the GR and MR gene in 
relation to clinical characteristics of BD. The results of the cross sectional study show 
that the GR and MR gene polymorphisms associate with clinical characteristics and 




· In the first analysis (n= 245) no differences in frequencies of polymorphisms were 
found in bipolar patients compared to healthy controls. 
· The 9β (rs6198) polymorphism in the GR gene is less frequent in bipolar patients 
with a history of more than a median number of 5 (hypo)manic episodes.
Chapter 4
· In the extended cohort (n=326, in 40 patients genotype failed), an association is 
found between the haplotype consisting of the 9β (rs6198) polymorphism in 
combination with the TthIIII (rs10052957) polymorphism in the GR gene and a 
higher risk on seasonal patterns of hypomania. 
· For the BclI (rs41423247) haplotype, we observed a similar trend for higher risk of 
seasonal hypomania. 
· Carriers of the ER22/23EK (rs6189/rs6190) polymorphism have an almost 8 years 
earlier onset of their first (hypo)manic episode than non carriers.
· No relation between MR gene polymorphisms and characteristics of BD was found.
Our findings indicate that 9β (rs6198), BclI (rs41423247), and ER22/23EK (rs6189/rs6190) 
influence clinical features of BD. This relationship of GR-polymorphisms with the course 
and characteristics of BD can be added to a growing number of studies, in which the 
regulation and functioning of the GR has been shown to be related to clinically relevant 
aspects of mood disorders. However, we found a non-linear relationship between GR 
polymorphisms and sensitivity of the central feedback on cortisol production. The 
idea is that the HPA-axis has an optimum set point in a U-shaped curve with regard to 
cortisol exposure at pituitary level. This is illustrated by the fact that some SNPs lead to 
relative resistance while others are involved in relative hypersensitivity in response to 
GCs: both can be involved in dysregulation of mood. Moreover, with the influence of 
GR polymorphisms, specifically 9β(rs6198) or BclI (rs41423247), on HPA-axis regulation, 
other factors, like seasonal induced changes in cortisol sensitivity, can further deregulate 
the system, leading to proneness for seasonal episodes as shown in chapter 4. 
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3. Cortisol levels in saliva and hair, and the relationship with clinical 
course of BD (chapter 5)
As first in the world, we applied a new technique for assessing cortisol levels in scalp hair 
in patients with BD. This could give us the opportunity to get insight in the influence of 
e.g. life events, mood episodes and effects of treatment on the long-term functioning of 
the HPA-axis. In chapter 5 we showed the following results:
· Compared to healthy controls, bipolar patients have similar cortisol levels in scalp 
hair.
· There is no association between hair and saliva cortisol levels assessed in the BD 
group.
· Within the BD patients with higher cortisol levels as measured in hair, we found an 
association with an older age at onset (>30 years). 
· In addition, a higher rate of psychiatric co-morbidity with the exception of panic 
disorder was found in patients with higher cortisol levels. 
· Remarkably, patients with co-morbid panic disorder reveal lower cortisol levels in 
hair, even when compared to healthy controls, whereas saliva cortisol was non-
significantly increased.
Our findings raise the question whether changes in HPA-axis functioning might be limited 
to subgroups of patients or whether changes in HPA-axis functioning might be limited 
to the stress response itself and not to long-term mean cortisol levels. Additionally, the 
findings that saliva and hair cortisol did not correlate supports the concept that both 
analyses for cortisol indeed differ in what aspect of the HPA-axis functioning is assessed. 
Cortisol in hair reflects long-term free cortisol levels, whereas saliva reflects short-term 
free cortisol levels which are influenced by acute stress responses, diurnal variation, as 
well as pulsatility of cortisol secretion. Finally, several clinical characteristics correlate 
with hair cortisol levels; although results might be complex to interpret properly, our 
findings gives impetus to further research to the relationship of hair cortisol levels and 
retrospective clinical aspects of BD.
4. Associations of cognitive functioning with medication use in BD 
(chapter 6)
Currently, it has been convincingly found that cognitive deficits regarding attention, 
working memory and executive functioning, can have a negative impact on social 
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functioning and the clinical course of BD. Biologically seen, HPA-axis dysregulation 
can cause impairment of  cognitive functioning. Before using cognitive functioning as 
endophenotype in relation to cortisol exposure and to clinical characteristics, we decided 
to first investigate the “state-like” effects on cognition. We started with analyzing the 
influence of medication use on cognitive performance, and continued with analyzing the 
influence of current mood on cognitive performance. Therefore, the Test for Attentional 
Performance (TAP) was explored in relation to medication use and clinical parameters. 
Our main findings in chapter 6 comprise:
· A significant association between use of multiple types of medication and poor 
cognitive performance regarding executive functioning. 
· Attention and working memory showed a similar, however non-significant trend. 
· Particularly the use of antipsychotics is associated with impaired executive 
functioning.
· Lithium use is not associated with diminished cognitive performance. 
The question remains whether medication use, specifically use of multiple types of 
medication (polypharmacy), is causing cognitive impairments or is an expression of 
the severity of the disease. In other words, it might be possible that patients with a 
more severe form of BD need more medication. However, we adjusted the analyses 
with inclusion of disease severity, which did not alter the results, indicating that the 
medication use might be an independent factor. However, other study designs, like 
Randomized Controlled Trials, could investigate this important topic in more depth. 
Conclusion
In this dissertation, several factors are identified as risk factors influencing clinical course 
of BD. At the genetic level, several GR gene polymorphisms altering cortisol sensitivity, 
associate with seasonal patterns of mood episodes, especially hypomania. In particular 
the 9β polymorphism (rs6198) seems to associate with clinical characteristics of BD. One 
hypothetical explanation could be the link with increased anti-inflammatory activity. 
These findings give further biological background to the importance of sensitivity of 
cortisol feedback response in relation to mood disorders. 
At the endophenotypic level, higher cortisol exposure assessed by hair analysis is 
associated with more psychiatric co morbidity in BD patients, and an older age at onset 
of the disease. However, no difference is found between the total group of BD patients 
and healthy controls, indicating that long-term cortisol in scalp hairs is not changed 
Summary
205
when comparing with a broad phenotypic entity like BD. This is underlining the need of 
precise defined and unambiguous long-term phenotypic parameters like mood episodes, 
anxiety symptoms, life events, and cognition, all in preceding months. This thesis gives 
impetus to further research with this technique, in order to identify consequences of 
chronic stress and chronic stress hormone elevations. 
Cognitive function is another endophenotypic marker. Before using cognitive 
performance as endophenotype, we first investigated the influences of medication as 
potential confounder. We found that cognitive performance is related to the number 
and types of medication used. It should be noted that while lithium had no effect on 
cognition, the use of antipsychotics significantly did. With this result in mind, the next 
phase in the analysis of the Bipolar Stress Study will be to first investigate the influence 
of current mood on cognitive functioning as second potential confounder. Thereafter, we 
will study the relationship between cognition and GR and MR polymorphisms, as well as 
cognition as potential endophenotypic risk factor influencing course of BD. 
Summarizing, cortisol exposure and cognition are both associated with several clinically 
relevant phenomena defining course of BD, thereby giving ground to further investigation 
of the consequences on the long-term effects of differences in cortisol exposure in BD 







Bipolaire stoornis,ook bekend als manisch depressieve stoornis, komt bij ongeveer 2% 
van de bevolking voor. De ziekte begint bij de meeste patiënten tussen het 20ste en 30ste 
levensjaar, en kan veel lijdensdruk geven en grote gevolgen hebben voor het functioneren 
op allerlei gebied. Onderzoek naar oorzaken, beloop, behandeling en gevolgen van de 
ziekte, zijn daarom van groot belang. 
Bipolaire stoornis wordt gekenmerkt wordt door periodes van depressie afgewisseld met 
manie of hypomanie. Het ziektebeloop kan sterk verschillen tussen patiënten. Tussen 
de episodes door kunnen mensen volledig herstellen, en vaak met medicatiegebruik 
stabiel blijven. Ongeveer de helft van de patiënten is niet volledig klachtenvrij 
tussen episoden. Dit kan bijvoorbeeld betekenen dat ze lichte depressieve klachten 
houden, of veel stemmingswisselingen kennen. Sommige patiënten hebben last van 
cognitieve beperkingen ten gevolge van doorgemaakte episodes. Dit kan zich uiten in 
concentratieproblemen, vergeetachtigheid en moeite met complexere cognitieve taken, 
zoals plannen en overzicht houden. Dit kan in wisselende mate invloed hebben op het 
functioneren in de maatschappij en in de thuissituatie.
Tot nu toe is het niet mogelijk om in een vroeg stadium een voorspelling te doen over 
het verdere klinische beloop van de bipolaire stoornis. De biologische achtergrond en de 
genetische oorzaken zijn vooralsnog onvoldoende duidelijk om goed te kunnen begrijpen 
wat er gebeurt als een patiënt manisch of depressief wordt. Met andere woorden, de 
vraag is wat er eigenlijk gebeurt in het lichaam, inclusief de hersenen, als de stemming 
ontregelt. 
Naast het kijken naar klinische verschijnselen en beloop (fenotype) kan gekeken 
worden naar endofenotypes. Endofenotypes kunnen een eenduidiger link geven naar 
genetische oorzaken, en bewegen zich als scharnier tussen genetica enerzijds en het 
heterogene klinische beloop anderzijds. Eén van de kenmerken van een endofenotype 
is dat het meetbaar is, en dat het relatief onafhankelijk van de fase van de ziekte is. In 
dit onderzoek zijn twee endofenotypes centraal gesteld, waarvan bekend is dat ze bij de 
bipolaire stoornis een rol spelen. Ten eerste is dat de gevoeligheid van de Hypothalamus-
Hypofyse- Bijnier as (HPA-as) voor stresshormoon cortisol. Ten tweede is dat het cognitief 




Doel en opzet studie
In dit proefschrift wordt een deel van het onderzoeksproject “The Bipolar Stress Study” 
gepresenteerd. Dat onderzoek kent een cross-sectioneel gedeelte en een prospectief 
longitudinale deel, waarbij de relatie tussen bovengenoemde endofenotypes en het 
ziektebeloop nader onderzocht wordt. In dit proefschrift ligt de nadruk op het eerste 
cross-sectionele gedeelte.
In dit gedeelte hebben we gekeken naar de mogelijke invloed van de verschillen in 
gevoeligheid van de HPA-as en van cognitief functioneren, op het beloop van de bipolaire 
stoornis. We zijn daartoe in 2005 begonnen met de “Bipolar Stress Study”, waarbij we 
gegevens verzameld hebben van in totaal 366 patiënten met een bipolaire stoornis 
die behandeld worden binnen het team Bipolaire Stoornissen van PsyQ Den Haag. De 
gevoeligheid van de HPA-as wordt bepaald door onder andere de genetische codering 
voor receptoren die zorgen voor de effecten van het stresshormoon cortisol,  de cortisol 
receptoren. Verschillen in codering kunnen leiden tot een verhoogde gevoeligheid of 
juist resistentie (verminderde gevoeligheid) voor het cortisol signaal. We hebben de 
twee cortisol receptoren onderzocht, namelijk de Glucocorticoid Receptor (GR) en de 
Mineralocorticoid Receptor (MR). De GR is vooral actief als het cortisol niveau hoog is, 
dus tijdens de stress reactie. Het reguleert deze reactie door de aanmaak van cortisol 
af te remmen. In het brein is het betrokken bij de vorming van herinnering rond de 
gebeurtenis. De MR is actief als er lage cortisol niveaus zijn, dus in rust. In het brein heeft 
de MR een rol bij het behouden van stabiliteit, en het beïnvloeden van gedrag.
 Daarnaast hebben we de hoeveelheid cortisol in hoofdhaar per tijdseenheid gemeten; 
dit als reflectie voor het lange termijn functioneren van de HPA-as. Tot slot hebben 
we gekeken naar het cognitief functioneren en de invloed van type en hoeveelheid 
medicatie gebruik door de patiënt.
Het doel van het onderzoek is om te kijken of verschillen tussen patiënten op het gebied 
van de stressrespons en van de cognitieve functie, van invloed zijn op het klinische 
beloop van de bipolaire stoornis.  In dit proefschrift wordt een deel van deze vraagstelling 
beantwoord, namelijk: 
a.  Wat is de associatie tussen de genetisch variaties in de genen die coderen voor de 
MR en de GR, en de klinische kenmerken van bipolaire stoornis?
b.  Wat is het verband tussen de lange-termijn cortisol niveaus en enkele belangrijke 
klinische kenmerken van bipolaire stoornis?





In hoofdstuk 1 en hoofdstuk 2 is de literatuur samengevat op het gebied van de 
biologische stressrespons. De gevoeligheid van de stressrespons wordt vooral bepaald 
door de gevoeligheid voor het stresshormoon cortisol. Het hormoon cortisol wordt 
in de bijnier geproduceerd en remt de eigen aanmaak, doordat het de productie van 
cortisol-stimulerende hormonen door de hersenen en de hypofyse remt. Dit wordt 
negatieve feedback genoemd. De acute stressrespons wordt dus ook weer actief 
beëindigd, wat een belangrijke, functionele actie is. Vermindering van de negatieve 
feedback leidt tot een chronische activatie van de stressrespons met als mogelijke 
negatieve gevolgen stemmingsklachten en cognitieve klachten, maar ook bijvoorbeeld 
vermoeidheid, suikerziekte en hoge bloeddruk. Om te begrijpen hoe het kan dat dit 
feedback mechanisme verminderd functioneert, is het van belang om te weten dat 
cortisol alleen werkt na binding met de cortisol receptor. Na binding met de cortisol 
receptor kan het cortisol door de celwand heen naar de celkern toe, en heeft dan direct 
effect op de activiteit van verschillende genen. Er zijn 2 verschillende cortisol receptoren, 
de mineralocorticoid receptor (MR) en de glucocorticoid receptor (GR). De MR bindt 
het makkelijkst met cortisol, met als gevolg dat bij lage cortisolconcentraties vooral de 
MR actief is. De MR in het brein is vooral gelokaliseerd in de hippocampus (belangrijke 
rol bij geheugenfuncties), de amygdala (centraal in de regulering van angst en emoties) 
en de prefrontale cortex (PFC; van belang bij hogere cognitieve functies). De GR is 
wijdverbreid in het brein, maar heeft eveneens een grotere aanwezigheid in onder meer 
de hippocampus en de PFC. De MR speelt een grote rol in het behouden van stabiliteit, 
met onder meer ook beoordelen van informatie, en selectie van gedrag. De GR is actief 
tijdens de stressrespons, als de cortisol niveaus fors stijgen, en heeft naast de negatieve 
feedback, een belangrijke functie bij het vormen van herinnering aan de stressor en de 
bijbehorende gedragsaanpassing in die situatie.
Er zijn als gevolg van een aantal bekende variaties in de genen die coderen voor de 
cortisolreceptor, kleine veranderingen in de receptor die kunnen leiden tot subtiele 
verschillen in de sterkte van de negatieve feedback. Deze subtiele verschillen kunnen 
echter op de lange termijn gevolgen hebben voor de lichamelijke en geestelijke 
gezondheid. Sommige genetische variaties, ofwel polymorfismen, in het gen dat 
codeert voor de GR kunnen leiden tot milde hypersensitiviteit (BclI), andere juist tot 
resistentie voor cortisol (9β, ER22/23EK). Ook de MR kent zowel een variatie die tot 
hypersensitiviteit leidt (-2G/C) als een die tot resistentie leidt (I180V). Zowel resistentie 
als hypersensitiviteit kan verband houden met depressieve episodes. De genoemde 
polymorfismen zijn allen in verband gebracht met verhoogd risico op depressie, met 
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uitzondering van MR -2G/C, die bij vrouwen juist associeert met optimisme en minder 
hopeloosheid.
In de hoofdstukken 3 en 4 beschrijven we dat een aantal GR polymorfismen (BclI en 9β) 
associëren met een hoger risico op seizoensgebonden hypomanie. Daarnaast vonden 
we dat ER22/23EK dragers gemiddeld 8 jaar jonger waren bij eerste symptomen van de 
bipolaire stoornis. 
Deze bevindingen laten zien dat kleine veranderingen in de genetische codering van de 
GR klinische invloed hebben op het verloop van de bipolaire stoornis. We vonden dit 
verband voor de meest voorkomende polymorfismen, en dan met  name bij hypomanieën 
in de lente en zomer.  De stress gevoeligheid is verschillend per seizoen; in de winter is 
er sprake van een milde resistentie voor het stresshormoon, en in de zomer juist een 
actievere respons bij stijging van het stresshormoon. Het kan zijn dat deze wisselingen 
van cortisol gevoeligheid in seizoenen versterkt wordt door klinische relevante GR 
polymorfismen. Het feit dat zowel grotere gevoeligheid als resistentie (respectievelijk 
BclI en 9β) voor cortisol leidt tot kwetsbaarheid voor het seizoensgebonden patroon van 
hypomanie, wijst erop dat de stressrespons een optimale+ balans kent. 
De ER22/23EK is een apart polymorfisme, dat minder vaak voorkomt in de Westerse 
bevolking. Dit polymorfisme is zowel geassocieerd met een betere metabole status (dus 
smallere tailleomtrek, hogere botdichtheid, minder risico op diabetes) alswel met een 
verhoogd risico op depressie. De fors jongere leeftijd waarop dragers van ER22/23EK 
eerste symptomen kregen, zou overeenkomen met het idee dat de stemming 
kwetsbaarder is voor ontregeling bij deze mensen.
In hoofdstuk 5 hebben we als eerste in de wereld een nieuwe methode toegepast voor 
bepaling van lange termijn cortisol niveaus bij patiënten met een bipolaire stoornis. In 
het hoofdhaar van patiënten is de hoeveelheid cortisol bepaald per 3 cm. Het haar groeit 
gemiddeld 1 cm per maand,wat betekent dat 3 cm een retrospectieve kalender verschaft 
van de gemiddelde cortisolwaarden van de afgelopen 3 maanden. In dit hoofdstuk 
laten we zien dat de hoeveelheid cortisol in haar bij patiënten met een bipolaire 
stoornis vergelijkbaar is met gezonde controles. Dit doet de vraag rijzen, of de in de 
literatuur gevonden ontregeling van de HPA-as wellicht beperkt is tot een subgroep van 
patiënten. We vonden inderdaad wel verschillen tussen bijvoorbeeld mensen met een 
bipolaire stoornis die wel of niet een paniekstoornis hadden. De groep patiënten met 
een paniekstoornis had een beduidend lagere hoeveelheid cortisol in het haar dan de 
patiënten zonder paniekstoornis.  Patiënten echter met een andere co-morbide stoornis 
(dus niet paniekstoornis) naast de bipolaire stoornis, hadden juist een verhoogd cortisol 
vergeleken met de patiënten zonder co-morbide psychiatrische diagnose. Dit duidt erop 
dat de ziekere mensen een verhoogd cortisol hadden. Tot slot vonden we een verband 
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met de leeftijd waarop eerste symptomen van de bipolaire stoornis zich manifesteerden, 
en de hoogte van cortisol. Patiënten die ouder waren dan 30 jaar tijdens de eerste 
manifestaties van de ziekte, hadden een beduidend hoger cortisol, terwijl mensen die 
jonger waren dan 30 jaar bij eerste symptomen een met gezonde controles vergelijkbaar 
cortisol niveau hadden. Ons onderzoek geeft aanleiding om deze nieuwe methode van 
haarcortisol metingen verder te onderzoeken op betekenis en bruikbaarheid in dit veld. 
Tot slot hebben we in hoofdstuk 6 gekeken naar de resultaten van een test om cognitieve 
functies te meten: de Test for Attentional Performance. In het vervolg op dit promotie 
traject gaan we de relatie tussen de testresultaten en het klinische beloop van de 
bipolaire stoornis onderzoeken. Ten behoeve daarvan hebben we alvast gekeken naar de 
mogelijke invloeden van klinische factoren en medicatie op de testresultaten. Met deze 
test worden cognitieve functies gemeten, zoals concentratievermogen, geheugen en 
executieve functies (hogere complexe functies als bijvoorbeeld het vermogen te plannen, 
prikkels te verwerken en informatie te integreren; van groot belang bij allerlei dagelijkse 
processen). In dit hoofdstuk laten we zien dat vooral medicatiegebruik van invloed lijkt 
te zijn op executieve functies. Gebruik van antipsychotica blijkt vooral van invloed, en 
daarnaast ook het aantal verschillende soorten medicijnen die mensen gebruiken lijkt 
de executieve functies negatief te beïnvloeden. Hoewel we zo aanwijzingen hebben 
dat medicatie van invloed is op cognitieve functies, ook na correctie voor ernst van de 
ziekte, kan het verband ook andersom liggen: de ziekste mensen gebruiken gemiddeld 
meer verschillende soorten medicijnen en hebben meer cognitieve beperkingen. Om 
precies zicht te krijgen op de gevolgen van gebruik van verschillende soorten medicatie 
op cognitief functioneren, zou een andere onderzoeksopzet nodig zijn.
Conclusies uit dit proefschrift
De bevindingen in dit proefschrift wijzen op de betrokkenheid van de HPA-as bij de 
regulatie van de stemming van patiënten met een bipolaire stoornis. De volgende 
conclusies kunnen op basis van dit proefschrift getrokken worden:
1. Genetische variaties in het gen dat codeert voor de GR houden verband met 
klinische kenmerken van de bipolaire stoornis. Dragers van de BclI of de 9β variant 
hebben vaker last van seizoensgebonden patronen van hypomanie. De ER22/23EK 
dragers hebben een 8 jaar eerder ontstaan van symptomen. Deze bevindingen 
ondersteunen eerder onderzoek, en maken duidelijk dat genetische variaties op 




2. Op endofenotypisch niveau is een voorzichtige conclusie te trekken dat een aantal 
subgroepen van patiënten met een bipolaire stoornis een verhoogd lange termijn 
cortisol (gemeten in hoofdhaar) hebben. Dit betreft patiënten die ouder dan 30 
jaar waren bij de aanvang van stemmingsklachten en patiënten bij wie meerdere 
psychiatrische diagnoses gesteld zijn. Patiënten met een paniekstoornis naast de 
bipolaire stoornis hadden juist een verlaagd cortisol. Dit zijn wereldwijd de eerste 
bevindingen met deze techniek bij patiënten met een bipolaire stoornis, ze moeten 
daarom wel bevestigd worden in ander, onafhankelijk onderzoek. Wel maken deze 
resultaten duidelijk dat cortisol niveaus niet bij alle patiënten verhoogd zijn, maar 
een indicatie kunnen geven van een subgroep die mogelijk een ander beloop kent 
van de ziekte.  Dit zou gevolgen kunnen hebben op de keuze van behandeling.
3. Cognitief functioneren is een belangrijk domein bij bipolaire stoornissen. Medicatie 
gebruik, waaronder ook de hoeveelheid verschillende soorten medicijnen, moet 
in toekomstig onderzoek zeker als co-variaat meegenomen worden. Lithium bleek 
geen verband te houden met cognitieve dysfunctie.
De twee endofenotypes, HPA-as regulering en cognitief functioneren, gaan we in de 
toekomst verder onderzoeken in relatie tot beloop en ernst van de bipolaire stoornis. De 
lange termijn gegevens die we verzameld hebben, zullen we hierbij gebruiken om te zien 
of de voorgaande conclusies stand houden. In dit kader willen we bijvoorbeeld kijken of 
er subpopulaties van patiënten zijn bij wie de stemming ontregelt in samenhang met een 
ontregeling van de HPA-as. Kortom, het beter kunnen voorspellen van het ziektebeloop 
van deze ziekte, die zich meestal zo vroeg in het volwassen leven openbaart en waarbij 
een groot risico bestaat op blijvende klachten, is van groot belang. Dit zou op termijn 
mogelijkheden kunnen geven om de behandeling hierop aan te passen en te verbeteren. 
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Cortisol exposure, cognition and clinical course of bipolar disorder 
 
1) De polymorfismen 9  en BclI van het gen coderend voor de glucocorticoid receptor 
(GR) kunnen leiden tot een verhoogde kans op hypomanie in het voorjaar (dit 
proefschrift).  
 
2) Hoewel het polymorfisme ER22/23EK van het GR gen associeert met gezondere 
metabole status (Van Rossum et al; JCEM,2004, 89(8): 4004-9), hebben dragers van deze 
variant wel een groter risico op depressie (Van Rossum et al; 2006, Biol Psych, 59(8): 
681-8), en een duidelijk eerdere aanvang van klachten van een bipolaire stoornis (dit 
proefschrift).  
 
3) Cortisol bepaling in hoofdhaar geeft wezenlijk andere informatie over het 
functioneren van de Hypothalamus Hypofyse Bijnier- as dan alle eerder gebruikte 
cortisol testen (Manenschijn et al, Steroids. 2011,76(10-11):1032-6). Haar cortisol 
waarden reflecteren de systemische cortisol waarden van de maanden voorafgaande 
aan de haarafname en is daarmee een veelbelovende maat voor toekomstig 
onderzoek (dit proefschrift). 
 
4) Het cortisol in hoofdhaar is hoger bij mensen die ouder dan 30 jaar waren bij eerste 
klachten van bipolaire stoornis; mensen die jonger waren dan 30 jaar hadden een 
cortisol wat vergelijkbaar is met gezonde controles. Dit wijst op het bestaan van een  
subgroep patiënten bij wie de Hypothalamus- Hypofyse- Bijnier- as functie een rol 
speelt (dit proefschrift). 
 
5) Executieve functies, van belang bij planning en ordening van taken, zijn verminderd 
wanneer patiënten met een bipolaire stoornis meerdere psychofarmaca tegelijkertijd 
gebruiken. Vooral bij gebruik van antipsychotica speelt dit een rol (dit proefschrift). 
 
6) Genetische variaties in het GR gen kunnen leiden tot hypersensitiviteit dan wel 
resistentie voor cortisol effecten (Van Rossum et al,Recent Prog Horm Res. 2004, 59: 333-
57). Van beide soorten polymorfismen is een relatie met stemmingsstoornissen 
aangetoond. Dit is suggestief voor het belang van een optimale balans voor cortisol 
gevoeligheid met betrekking tot het functioneren van de stress respons (Van Rossum 
et al; 2006, Biol Psych, 59(8): 681-8).  
 
7) De nieuwe huisartsenrichtlijn voor depressie en depressieve klachten waarin initieel 
leefstijlinterventies en stressreductie centraal staan (NHG standaard Depressie, 2012), 
zou breder getrokken kunnen worden door het ontwikkelen van een algemene 
medische richtlijn “Gezond leven voor lichaam en geest”, ofwel “Mens sana in 
corpore sano” (Juvenalis- Satire X).  
 
8) De vraag of psychofarmaca ook een rol zouden kunnen spelen bij het induceren  van 
een chronisch verloop van psychiatrische ziekten moet serieus genomen moeten 
worden (R. Withaker - The anatomy of an epidemic). Zie het toegenomen risico op een 
chronisch beloop van de bipolaire depressie bij gebruik van antidepressiva (S. Nassir 
Ghaemi; Am J Psychiatry, 2008; 165:300-302). 
 
9) Door de onvermijdelijke toename van online communicatie met patiënten, verandert 
de communicatie qua vorm (zien, bellen, mailen, chatfora, etc) maar vereist ook 
andere vaardigheden van de behandelaar. Dit verdient  een kritische verkenning van 
grenzen, mogelijkheden maar ook aanpassing in het opleiding curriculum. 
 
10) Het is stellig gemakkelijker zichzelf te veranderen dan anderen om te vormen 
(Uitspraak van Zeno; Italo Svevo- Bekentenissen van Zeno).  
 
11) Hoewel het als onbeleefd ervaren kan worden door medeweggebruikers, is het wel 
rationeel om op de weg volledig gebruik te maken van de invoegstrook; zo wordt de 
weg optimaal benut (Tom Vanderbilt - Traffic).  
 
12) Verwende kinderen kunnen in het volwassen leven te maken krijgen met Vrouw 
Holle, die egocentrisme beloont met pek en veren (sprookje Vrouw Holle).  
 
 
